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ABSTRACT 
 
Ketoprofen is a potent non-steroidal anti-inflammatory drug which is used for the treatment 
of rheumatoid arthritis.  The oral administration of ketoprofen can cause gastric irritation and 
adverse renal effects.  Transdermal delivery of the drug can bypass gastrointestinal 
disturbances and provide relatively consistent drug concentrations at the site of 
administration. 
 
The release of ketoprofen from proprietary gel products from three different countries was 
evaluated by comparing the in vitro release profiles.  Twenty extemporaneously prepared 
ketoprofen gel formulations using Carbopol® polymers were manufactured.  The effect of 
polymer, drug concentration, pH and solvent systems on the in vitro release of ketoprofen 
from these formulations were investigated.  The gels were evaluated for drug content and pH.  
The release of the drug from all the formulations obeyed the Higuchi principle. 
 
Two static FDA approved diffusion cells, namely the modified Franz diffusion cell and the 
European Pharmacopoeia diffusion cell, were compared by measuring the in vitro release rate 
of ketoprofen from all the gel formulations through a synthetic silicone membrane. 
 
High-performance liquid chromatography and ultraviolet spectrophotometric analytical 
techniques were both used for the analysis of ketoprofen.  The validated methods were 
employed for the determination of ketoprofen in the sample solutions taken from the receptor 
fluid. 
 
Two of the three proprietary products registered under the same manufacturing license 
exhibited similar results whereas the third product differed significantly.  Among the 
variables investigated, the vehicle pH and solvent composition were found have the most 
significant effect on the in vitro release of ketoprofen from Carbopol® polymers.  The 
different grades of Carbopol® polymers showed statistically significantly different release 
kinetics with respect to lag time. 
 
When evaluating the proprietary products, both the modified Franz diffusion cell and the 
European Pharmacopoeia diffusion cell were deemed adequate although higher profiles were 
generally obtained from the European Pharmacopoeia diffusion cells. 
iii 
Smoother diffusion profiles were obtained from samples analysed by high-performance liquid 
chromatography than by ultraviolet spectrophotometry in both diffusion cells.  Sample 
solutions taken from Franz diffusion cells and analysed by ultraviolet spectrophotometry also 
produced smooth diffusion profiles.  Erratic and higher diffusion profiles were observed with 
samples taken from the European Pharmacopoeia diffusion cell and analysed by ultraviolet 
spectrophotometry. 
 
The choice of diffusion cells and analytical procedure in product development must be 
weighed against the relatively poor reproducibility as observed with the European 
Pharmacopoeia diffusion cell. 
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STUDY OBJECTIVES 
 
Ketoprofen is a non-steroidal anti-inflammatory, analgesic and antipyretic drug used for the 
treatment of rheumatoid osteoarthritis, ankylosing spondylitis and gout.  It is more potent 
than the other non-steroidal anti-inflammatory drugs (NSAIDs) with respect to some effects 
such as anti-inflammatory and analgesic activities. 
 
Although ketoprofen is rapidly absorbed, metabolized and excreted, it causes some 
gastrointestinal complaints such as nausea, dyspepsia, diarrhoea, constipation and some renal 
side effects like other NSAIDs.  Therefore, there is a great interest in developing topical 
dosage forms of these NSAIDs to avoid the oral side effects and provide relatively consistent 
drug concentrations at the application site for prolonged periods. 
 
The objectives of this study were: 
 
1. To develop and validate a suitable high-performance liquid chromatographic method 
for the determination of ketoprofen from topical gel formulations. 
2. To develop and validate a suitable ultraviolet spectrophotometric method for the 
determination of ketoprofen from topical gel formulations. 
3. To extemporaneously manufacture topical gel formulations using Carbopol® polymers 
and study the effect of polymer type, pH, loading concentration and solvent 
composition on the in vitro release of ketoprofen.  
4. To compare and contrast the in vitro release rates of ketoprofen from proprietary gel 
products and extemporaneously prepared topical gel formulations using the Franz 
diffusion cell and the European Pharmacopoeia diffusion cell. 
5. To compare and contrast the in vitro release rates of different proprietary gel products 
and extemporaneously prepared topical gel formulations using ultraviolet 
spectrophotometry and high-performance liquid chromatography utilizing both the 
Franz diffusion cell and the European Pharmacopoeia diffusion cell. 
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CHAPTER ONE 
TRANSDERMAL DRUG DELIVERY 
 
1.1 PAST PROGRESS, CURRENT STATUS AND FUTURE PROSPECTS OF 
TRANSDERMAL DRUG DELIVERY 
 
1.1.1 Introduction 
Human beings have been placing salves, lotions and potions on their skin from ancient times 
(1) and the concept of delivering drugs through the skin is a practice which dates as far back 
as the 16th century BC (2).  The Ebers Papyrus, the oldest preserved medical document, 
recommended that the husk of the castor oil plant be crushed in water and placed on an 
aching head and ‘the head will be cured at once, as though it had never ached’ (2).  In the late 
seventies transdermal drug delivery (TDD) was heralded as a methodology that could provide 
blood drug concentrations controlled by a device and there was an expectation that it could 
therefore develop into a universal strategy for the administration of medicines (3). 
 
The transdermal route of controlled drug delivery is often dismissed as a relatively minor 
player in modern pharmaceutical sciences.  One commonly hears that the skin is too good a 
barrier to permit the delivery of all but a few compounds and that transdermal transport is not 
even worth the consideration for new drugs of the biotechnology industry (4).  This has 
however been disputed as today TDD is a well-accepted means of delivering many drugs to 
the systemic circulation (2) in order to achieve a desired pharmacological outcome.  
Traditional preparations used include ointments, gels, creams and medicinal plasters 
containing natural herbs and compounds.  The development of the first pharmaceutical 
transdermal patch of scopolamine for motion sickness in the early 1980s heralded acceptance 
of the benefits and applicability of this method of administration of modern commercial 
products (4 - 6).  The success of this approach is evidenced by the fact that there are currently 
more than 35 TDD products approved in the USA for the treatment of conditions including 
hypertension, angina, female menopause, severe pain states, nicotine dependence, male 
hypogonadism, local pain control and more recently, contraception and urinary incontinence 
(2 - 8, 55).  Several products are in late-stage development that will further expand TDD 
usage into new therapeutic areas, including Parkinson’s disease, attention deficit and 
hyperactivity disorder and female dysfunction (5, 6).  New and improved TDD products are 
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also under development that will expand the number of therapeutic options in pain 
management, osteoporosis and hormone replacement (6).  The current USA market for 
transdermal patches is over $3 billion annually and for testosterone gel is approximately $225 
million (7, 8, 55) and represents the most successful non-oral systemic drug delivery system 
(27). 
 
Clearly, the clinical benefits, industrial interest, strong market and regulatory precedence 
show why TDD has become a successful and viable dosage form (6). 
 
1.1.2 Rationale for transdermal drug delivery 
Given that the skin offers such an excellent barrier to molecular transport, the rationale for 
this delivery strategy needs to be carefully identified.  There are several instances in which 
the most convenient of drug intake methods (the oral route) is not feasible therefore 
alternative routes must be sought.  Although intravenous introduction of the medicament 
avoids many of these shortfalls (such as gastrointestinal tract (GIT) and hepatic metabolism), 
its invasive nature (particularly for chronic administration) has encouraged the search for 
alternative strategies and few anatomical orifices have not been investigated for their 
potential as optional drug delivery routes.  The implementation of TDD technology must be 
therapeutically justified.  Drugs with high oral bioavailability and infrequent dosing regimens 
that are well accepted by patients do not warrant such measures.  Similarly, transdermal 
administration is not a means to achieve rapid bolus-type drug inputs, rather it is usually 
designed to offer slow, sustained drug delivery over substantial periods of time and, as such, 
tolerance-inducing drugs or those (e.g., hormones) requiring chronopharmacological 
management are, at least to date, not suitable.  Nevertheless, there remains a large pool of 
drugs for which TDD is desirable but presently unfeasible.  The nature of the stratum 
corneum (SC) is, in essence, the key to this problem.  The excellent diffusional resistance 
offered by the membrane means that the daily drug dose that can be systematically delivered 
through a reasonable ‘patch-size’ area remains in the < 10 mg range (27).  The structure and 
barrier property of the SC are discussed in sections 1.2.2.1 and 1.2.4 respectively. 
 
1.1.3 Advantages and drawbacks of transdermal drug delivery 
The skin offers several advantages as a route for drug delivery and most of these have been 
well documented (2 - 8, 27).  In most cases, although the skin itself controls drug input into 
 3 
the systemic circulation, drug delivery can be controlled predictably and over a long period of 
time, from simple matrix-type transdermal patches (3).  Transdermal drug systems provide 
constant concentrations in the plasma for drugs with a narrow therapeutic window, thus 
minimising the risk of toxic side effects or lack of efficacy associated with conventional oral 
dosing (2).  This is of great value particularly for drugs with short half-lives to be 
administered at most once a day and which can result in improved patient compliance (2, 5).  
In clinical drug therapies, topical application allows localized drug delivery to the site of 
interest.  This enhances the therapeutic effect of the drug while minimising systemic side 
effects (11).  The problems associated with first-pass metabolism in the GIT and the liver are 
avoided with TDD and this allows drugs with poor oral bioavailability to be administered at 
most once a day and this can also result in improved patient compliance (2, 3, 12, 37).  
Transdermal administration avoids the vagaries of the GIT milieu and does not shunt the drug 
directly through the liver (1).  How much of a problem exists is very dependant on the 
properties of the medicinal agent, but it should be remembered that the skin is capable of 
metabolising some permeants (3, 38).  The deeper layers of the skin are metabolically more 
active than the SC.  Although the SC is considered to be a dead layer, it has been established 
that microflora present on the skin surface are capable of metabolising drugs (9, 38).  The 
GIT tract presents a fairly hostile environment to a drug molecule.  The low gastric pH or 
enzymes may degrade a drug molecule, or the interaction with food, drinks and/or other drugs 
in the stomach may prevent the drug from permeating through the GIT wall (1).  The 
circumvention of the drug from the hostile environment of the GIT minimises possible gastric 
irritation and chemical degradation or systemic deactivation of the drug (2, 11, 37).  Unlike 
parenteral, subcutaneous and intramuscular formulations, a transdermal product does not 
have the stigma associated with needles nor does it require professional supervision for 
administration (1, 2, 27).  This increases patient acceptance (1, 3) and allows ambulatory 
patients to leave the hospital while on medication.  In the case of an adverse reaction or 
overdose, the patient can simply remove the transdermal device without undergoing the harsh 
antidote treatment of having the stomach pumped (1, 12, 37).  An additional benefit that has 
been noted in hospitals is the ability of the nurse or physician to tell that the patient is on a 
particular drug, since the transdermal is worn on the person and can be identified by its label 
(1) although this does not hold if the dosage form is a semi-solid.  Further benefits of TDD 
systems have emerged over the past few years as technologies have evolved.  These include 
the potential for sustained release and controlled input kinetics which are particularly useful 
for drugs with narrow therapeutic indices (27).  Transdermal applications are suitable for 
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patients who are unconscious or vomiting (2).  Despite all these advantages, a timely warning 
to formulators was also issued in 1987 (2), ‘TDD is not a subject which can be approached 
simplistically without a thorough understanding of the physicochemical and biological 
parameters of percutaneous absorption.  Researchers who attempt TDD without appreciating 
this fact do so at their peril.’ 
 
As with the other routes of drug delivery, transport across the skin is also associated with 
several disadvantages, the main drawback being that not all compounds are suitable 
candidates (94).  Since the inception of TDD there has only been a very limited number of 
products launched onto the market (3) and the considerable research and development 
expense in the transdermal product development and skin research field to bring more TDD 
products to the market has been slow (37).  There are various reasons for this but the most 
likely is the rate-limiting factor of the skin (1).  The rate-limiting resistance resides in the SC 
(26).  The skin is a very effective barrier to the ingress of materials, allowing only small 
quantities of a drug to penetrate over a period of a day (3, 9).  A typical drug that is 
incorporated into a dermal drug delivery system will exhibit a bioavailability of only a few 
percent and therefore the active has to have a very high potency.  For transdermal delivery, as 
a rule of thumb, the maximum daily dose that can permeate the skin is of the order of a few 
milligrams.  This further underscores the need for high potency drugs (3).  As evidence of 
this, all of the drugs presently administered across the skin share constraining characteristics 
such as low molecular mass (< 500 Da), high lipophilicity ( Plog  in the range of 1 to 3), low 
melting point (< 200°C) and high potency (dose is less than 50 mg per day) (1, 2, 4, 6, 8, 10, 
55).  The smallest drug molecule presently formulated in a patch is nicotine (162 Da) and the 
largest is oxybutinin (359 Da).  Opening the transdermal route to large hydrophilic drugs is 
one of the major challenges in the field of TDD (8).  The required high potency can also 
mean that the drug has a high potential to be toxic to the skin causing irritation and/or 
sensitisation (1, 3, 7).  If the barrier function of the skin is compromised in any way, some of 
the matrix-type delivery devices can deliver more of the active than necessary and the 
transdermal equivalent of ‘dose dumping’ can occur (3).  Elevated drug concentrations can be 
attained if a transdermal system is repeatedly placed on the old site and this can lead to the 
possibility of enhanced skin toxicity.  Other difficulties encountered with TDD are the 
variability in percutaneous absorption, the precision of dosing, the reservoir capacity of the 
skin, heterogeneity and inducibility of the skin in turnover and metabolism, inadequate 
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definition of bioequivalence criteria and an incomplete understanding of technologies that 
may be used to facilitate or retard percutaneous absorption (5, 12, 20). 
 
1.1.4 Innovations in transdermal drug delivery 
TDD has been the subject of extensive research (11).  The introduction of new transdermal 
technologies such as chemical penetration enhancement (2 - 6, 9, 11, 12, 18, 28, 34, 35), 
iontophoresis (2 - 6, 7, 11, 18, 19, 28, 34), sonophoresis (2 - 7, 10 - 12, 17, 18, 34), 
transferosomes (12), thermal energy (6, 8), magnetic energy (6), microneedle applications (6, 
8), electroporation (3, 4, 7, 11, 12, 34) and high velocity jet injectors (8) challenge the 
paradigm that there are only a few drug candidates for TDD.  Despite difficult issues related 
to skin tolerability and regulatory approval, most attention, at least until recently, has been 
directed at the use of chemical penetration enhancers.  However, this focus is now shifting 
towards the development of novel vehicles comprising accepted excipients (including lipid 
vesicular-based systems, supersaturated formulations and microemulsions) and to the use of 
physical methods to overcome the barrier.  In the latter category, iontophoresis is the 
dominant player and is by far the method furthest along the evaluatory path.  Applications of 
electroporation, ultrasound and high pressure, etc., remain at the research and feasibility stage 
of development.  Interestingly, the level of endeavour devoted to either removal or 
perforation of the SC (e.g., by laser ablation, or the use of microneedle arrays) has increased 
sharply, with these so-called ‘minimally invasive’ techniques essentially dispensing with the 
challenge of the barrier function of the skin (29).  Physical methods have the advantage of 
decreased skin irritant/allergic responses, as well as no interaction with the drugs being 
delivered (11).  The extent to which these are translated into practise will be defined by time 
(12).  TDD is therefore a thriving area of research and product development, with many new 
diverse technology offerings both within and beyond traditional passive transdermal 
technologies (6). 
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1.2 PERCUTANEOUS ABSORPTION 
 
1.2.1 Introduction 
Although the skin is the most accessible organ of the body to superficial investigations, the 
direct measurement of penetrating substances has long posed major hurdles for detailed 
mechanistic studies.  In recent decades many investigators have studied the mechanisms, 
routes and time curves by which drugs and toxic compounds may penetrate the skin, which is 
of particular importance for many areas of medicine, pharmacy, toxicity assessment and the 
cosmetic industry (22).  The introduction of chemicals into the body through the skin occurs 
by passive contact with the environment and direct application of chemicals on the body for 
the purposes of medical therapy in the management of skin diseases and in use in TDD 
devices and as cosmetics (40).  Percutaneous absorption is a complex physicochemical and 
biological process.  In addition to partition and diffusion processes, there are other potential 
fates for drug entities entering the skin which include irreversible binding to cutaneous 
proteins such as keratin, degradation by cutaneous enzymes and partition into subcutaneous 
fat (36, 39).  Many in vitro and in vivo experimental methods for determining transdermal 
absorption have been used to understand and/or predict the delivery of drugs from the skin 
surface into the body of living animals or humans (36).  The skin acts as a barrier to maintain 
the internal milieu, however, it is not a total barrier and many chemicals have been shown to 
penetrate into and through the skin (30).  The release of a therapeutic agent from a 
formulation applied to the skin surface and its transport to the systemic circulation involves: 
i. dissolution within and release from the formulation, 
ii. partitioning into the outermost layer of the skin, SC, 
iii. diffusion through the SC, 
iv. partitioning from the SC into the aqueous viable epidermis, 
v. diffusion through the viable epidermis and into the upper dermis and 
vi. uptake into the local capillary network and eventually the systemic circulation (31). 
 
In order to rationally design formulations for cosmetic or pharmaceutical purposes, a detailed 
knowledge of the human skin and its barrier function is imperative (28). 
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1.2.2 Human skin 
1.2.2.1 Structure and functions of skin 
The skin is the largest organ of the body, accounting for more than 10% of body mass and the 
one that enables the body to interact most intimately with its environment (12, 32).  It is one 
of the most extensive, readily accessible organs and is the heaviest single organ of the body 
which combines with the mucosal linings of the respiratory, digestive and urogenital tracts to 
form a capsule which separates the internal body structures from the external environment 
(14).  It covers around 2 m2 of an adult average body and receives approximately one-third of 
all blood circulating through the body (13, 82).  A typical square centimetre of skin 
comprises 10 hair follicles, 12 nerves, 15 sebaceous glands, 100 sweat glands, 3 blood vessels 
with 92 cm total length, 360 cm of nerves and 3 x 106 cells (14).  Many of the functions of 
the skin can be classified as essential to the survival of animals in a relatively hostile 
environment (12).  In terms of the number of functions performed, the skin outweighs any 
other organ.  Its primary function is protection, which covers physical, chemical, immune, 
pathogen, uv radiation and free radical defences.  It is also a major participant in 
thermoregulation, functions as a sensory organ, performs endocrine functions (vitamin D 
synthesis, peripheral conversion of prohormones), significant in reproduction (secondary 
sexual characteristics, pheromone production) and perpetuation of the species, human non-
verbal communications (verbal signalling, emotions expressed), as well as a factor in 
xenophobia and bias against fellow humans that has shaped the destiny of humanity (12, 15, 
16).  The skin also serves as a barrier against the penetration of water-soluble substances and 
to reduce transepidermal water loss (TEWL) (23) and is also the basis of several billion-
dollar industries such as the personal care, cosmetic and fashion industries.  For 
pharmaceuticals, it is both a challenge (barrier) and an opportunity (large surface area) for 
delivering drugs (15).  The skin is a multilayered organ composed of many histological layers 
(13).  In essence, the skin consists of four layers namely the SC (non-viable epidermis), the 
remaining layers of the epidermis (viable epidermis), dermis and subcutaneous tissues (41).  
There are also several associated appendages such as hair follicles, sweat ducts, apocrine 
glands and nails (12). 
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Figure 1.1 Components of the epidermis and dermis of human skin (12) 
 
1.2.2.2 The epidermis 
The epidermis is divided into four anatomical layers namely stratum basale (SB), stratum 
spinosum (SS), stratum granulosum (SG) and SC (13, 15, 21) as shown in Figure 1.1.  The 
SC is the heterogeneous outermost layer of the epidermis and is approximately 10 - 20 µm 
thick.  It is non-viable epidermis and consists of 15 - 25 flattened, stacked, hexagonal and 
cornified cells embedded in a mortar of intercellular lipid.  Each cell is approximately 40 µm 
in diameter and 0.5 µm thick (12, 28, 39).  The thickness varies and may be a magnitude of 
order larger in areas such as the palms of the hands and soles of the feet.  These are areas of 
the body associated with frequent direct and substantial physical interaction with the physical 
environment.  Not surprisingly, absorption is slower through these regions than through the 
skin of other parts of the body (12).  The cells of the SC, keratinocytes, originate in the viable 
epidermis and undergo many morphological changes before desquamation.  The 
keratinocytes are metabolically active and capable of mitotic division (39) and therefore the 
epidermis consists of several cell strata at varying levels of differentiation (Figure 1.2).   
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Figure 1.2 Epidermal differentiation: major events include extrusion of lamellar bodies, loss of 
nucleus and increasing amount of keratin in the stratum corneum (12) 
 
The origins of the cells of the epidermis lie in the basal lamina between the dermis and viable 
epidermis (12).  In the basal layer of the epidermis there is continuous renewal of cells.  
These cells are subsequently transported to the upper layers of the epidermis.  The 
composition of lipids changes markedly during apical migration through successive 
epidermal layers.  When the differentiation process is accomplished (i.e., in the SC), lipid 
composition changes markedly, phospholipids are degraded enzymatically into glycerol and 
free fatty acids and glucosylceramides into ceramides.  The main constituents of the SC lipids 
are cholesterol, free fatty acids and ceramides (26, 28).  At physiological temperature, which 
is below the gel-to-liquid crystalline phase transition temperature, the lipids are highly 
ordered (26).  The SC is a composite of corneocytes (terminally differentiated keratinocytes) 
and secreted contents of the lamellar bodies (elaborated by the keratinocytes), that give it a 
‘bricks-and-mortar’ structure (15, 18, 42).  This arrangement creates a tortuous path through 
which substances have to traverse in order to cross the SC.  The classic ‘bricks-and-mortar’ 
structure is still the most simplistic organizational description.  The protein-enriched 
corneocytes (bricks) impart a high degree of tortuosity to the path of water or any other 
molecule that traverses the SC, while the hydrophobic lipids, organised into tight lamellar 
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structures (mortar) provide a water-tight barrier property to the already tortuous route of 
permeation in the interfollicular domains (15). 
 
1.2.2.3 The viable epidermis 
The viable epidermis consists of multiple layers of keratinocytes at various stages of 
differentiation.  The basal layer contains actively dividing cells, which migrate upwards to 
successively form the spinous, granular and clear layers.  As part of this process, the cells 
gradually lose their nuclei and undergo changes in composition as shown in Figure 1.2.  The 
role of the viable epidermis in skin barrier function is mainly related to the intercellular lipid 
channels and to several partitioning phenomena.  Depending on their solubility, drugs can 
partition from layer to layer after diffusing through the SC.  Several other cells (e.g., 
melanocytes, Langerhans cells, dendritic T cells, epidermotropic lymphocyes and Merkel 
cells) are also scattered throughout the viable epidermis, which contain a variety of active 
catabolic enzymes (e.g., esterases, phosphatates, proteases, nucleotidases and lipases) (24, 
41). 
 
1.2.2.4 The dermis 
The dermis (or corium), at 3 to 5 mm thick, is much wider than the overlying epidermis 
which it supports and thus makes up the bulk of the skin (14).  The dermis, which provides 
the elasticity of the skin, contains immune cells and has the vascular network that supplies the 
epidermis with nutrients that can carry absorbed substances into the body (30, 39).  The 
dermis consists of a matrix of connective tissue woven from fibrous proteins (collagen 75%, 
elastin 4% and reticulin 0.4%) which is embedded in mucopolysaccharide providing about 
2% of the mass.  Blood vessels, nerves and lymphatic vessels cross this matrix and skin 
appendages (endocrine sweat glands, apocrine glands and pilosebaceous units) penetrate it.  
In man, the dermis divides into a superficial, thin image of the ridged lower surface of the 
epidermis and a thick underlying reticular layer made of wide collagen fibres (14).  It also 
plays a role in temperature, pressure and pain regulation (12). 
 
1.2.3 Routes of drug permeation across the skin 
For transdermal delivery to be effective, drugs have to enter into the viable skin in sufficient 
quantities to produce a therapeutic effect (11).  The route through which permeation occurs is 
largely dependent on the physicochemical properties of the penetrant, the most important 
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being the relative ability to partition into each skin phase (18).  Three possible pathways for 
TDD (Figure 1.3) have been reported (11, 24 - 26, 82, 84, 94).  They are transport through 
appendages such as hair follicles, transcellular transport through the corneocytes and 
intercellular transport via the extracellular matrix. 
 
1.2.3.1 Transcellular pathway 
It was originally believed that transcellular diffusion mechanisms dominated over the 
intercellular and transappendageal routes during the passage of solutes through the SC (94).  
The permeant crosses the SC by the most direct route and repeatedly partitions between and 
diffuses through the cornified cells, the extracellular lipid bilayers (26), viable epidermis and 
papillary layer of the dermis, with the microcirculation usually providing an infinite sink 
(21).  Although the transcellular route appears most favoured on geometric grounds, there has 
been no direct evidence presented to provide support for its participation in the SC 
penetration process.  However the so-called ‘protein domain’ of the SC may represent a 
region into which topically applied molecules may partition and therefore act as a reservoir.  
Additionally, certain penetration enhancers (e.g., anionic surfactants and alkyl sulphoxides) 
have been shown to interact with keratin and induce protein conformational changes.  The 
presence of these materials could increase the likelihood that permeates access the 
transcellular route (26). 
 
1.2.3.2 Intercellular pathway 
The intracellular SC spaces were initially dismissed as a potentially significant diffusion 
pathway because of the small volume they occupy.  However, the physical structure of the 
intracellular lipids was thought to be a significant factor in the barrier properties of the skin 
(94).   The solute remains in the lipid domains and permeates via a tortuous pathway.  Within 
this lipid domain, the drug has to cross repetitively complete lipid bilayers (26).  Available 
evidence has shown (26) that there is a preponderance of support for the intercellular pathway 
and it has been identified as the major route of transport across the SC.  The intracellular 
route is usually regarded as a pathway for polar (hydrophilic) molecules, since cellular 
components are predominantly aqueous in nature.  Here the pathway is directly across the 
SC, the rate-limiting barrier being the multiple bilayered lipids that must also be crossed (39). 
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1.2.3.3 Appendageal pathway 
The penetrant transverses the SC via a ‘shunt’ pathway: e.g., a hair follicle or a sweat gland.  
These shunts are known to be important at short times prior to steady state diffusion.  The 
available diffusional area of the shunt route is approximately 0.1% of the total skin area and 
therefore the contribution to drug permeation compared to the former is significantly less (21, 
24, 26, 33, 82).  Despite their small fractional area, the skin appendages may provide the 
main portal of entry into the subepidermal layers of the skin for ions and large polar 
molecules (21, 24, 26, 33).  The appendageal pathway has been reported (26) to be the major 
contributor to the initial phase of SC permeation. 
 
 
Figure 1.3 Schematic diagram of the potential routes of drug penetration through the stratum 
corneum I = intercellular T = transcellular A = appendegeal (26) 
 
The precise mechanisms by which drugs permeate the SC are still under debate but there is 
substantial evidence that the route of permeation is a tortuous one following the intercellular 
channels (3, 9, 32).  The transcellular pathway requires the substrates to travel through the 
corneocytes while the intercellular pathway is via the extracellular matrix between the 
corneocytes.  For intercellular skin transport, hydrophilic substrates are rate limited by the 
lipid environment of the intercellular matrix of the SC.  On the other hand, lipophilic 
substrates partition into the intercellular lipids of the SC.  However the rate-limiting step is 
the partition into the epidermis, which is practically an aqueous environment.  Molecular 
transport through the skin has been described by a solubility-diffusion model and a transfer 
free energy model (11).  Hydrophilic substances prefer the transcellular route through the 
protein-enriched corneocytes.  In general, molecules with amphoteric chemical properties are 
thought to be able to penetrate best.  Additionally, the stereochemical characteristics and the 
molecular weight of a compound are of major interest (22).  Although the intracellular route 
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has been identified as the major contributor to percutaneous permeation, it must be 
emphasised that the other pathways also contribute.  The three pathways are not mutually 
exclusive and most molecules will pass through the SC by a combination of these routes (39).  
The existence of these pathways for permeation across skin has significant implications in the 
design, development and use of penetration enhancers.  It is unlikely that an enhancer that 
acts primarily on one pathway, e.g., by increasing the fluidity of the extracellular lipid, will 
have any great effect on the permeability rate of a compound whose route is primarily 
transcellular.  Furthermore, it is entirely feasible that the presence of an enhancer will alter 
the thermodynamic activity of a penetrant in a formulation resulting in changes in 
partitioning tendencies (18). 
 
1.2.4 Barrier function of the skin 
The natural function of the skin is the protection of the body against the loss of endogenous 
substances such as water and undesired influences from the environment caused by 
exogenous substances (28, 39).  This implies that the skin acts as a barrier against diffusion of 
substances through the underlying tissue (28).  The diffusional resistance of the SC is a 
challenge that has been accepted by the pharmaceutical scientist and considerable activity has 
been directed towards percutaneous penetration enhancement technologies (4).  Overcoming 
this natural barrier is the main challenge in dermal or transdermal delivery of drugs (28).   
 
The barrier function of the skin is accomplished by the outermost few microns of the skin, the 
SC, a compositionally and morphologically unique membrane (27, 28, 39, 47).  This 
extremely thin, least permeable layer of skin is the ultimate stage in the epidermal 
differentiation process, forming a laminate of compressed keratin-filled corneocytes 
(terminally differentiated keratinocytes) anchored in a lipophilic matrix (27).  The lipids of 
this extracellular matrix are distinctive in many respects.  They provide the only continuous 
phase (and diffusion pathway) from the skin surface to the base of the SC, the composition 
(ceramides, free fatty acids and cholesterol) is unique among biomembranes and particularly 
noteworthy is the absence of phospholipids.  Despite the deficit of polar bilayer-forming 
lipids, the SC lipids exist as multilamellar sheets and the predominantly saturated, long-chain 
hydrocarbon tails facilitate a highly ordered, interdigitated configuration and the formation of 
gel-phase membrane domains as opposed to the more usual (and more fluid and permeable) 
liquid crystalline membrane systems (18, 20, 22, 23, 27).  However, the unusual lipid matrix 
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alone cannot entirely explain the outstanding resistivity of the membrane and the SC 
architecture as a whole has been proposed to play an instrumental role in the barrier function 
of the membrane (27).  The staggered corneocyte arrangement in a lipid continuum (similar 
to the brick and mortar assembly) is suggested to bestow a highly tortuous lipoidal diffusion 
pathway rendering the membrane one thousand times less permeable to water relative to most 
other biomembranes.  The transport role of this sinuous pathway is further supported by 
visualization studies localizing several permeants in the intercellular channels by kinetic 
analysis of the in vivo skin penetration rates of model compounds and by the evidence from 
thermotropic biophysical studies of lipid domains (27, 31).  The impermeability is a 
considerable problem in the delivery of medicines both to and through the skin.  It has been 
estimated that only a small percentage of the active material reaches its target site when it is 
delivered topically (82). 
 
1.2.5 Enhancing transdermal drug delivery 
To produce a systemic effect, TDD requires that suitable quantities of drug be transported 
through the skin (11, 41).  A disadvantage of this route for drug delivery is that a relatively 
high dose is required to deliver therapeutic amounts across the skin and therefore evaluation 
of the potential for enhancement of skin penetration is of great practical importance (43).  
This has proved to be a challenge and has led to the development of a large repertoire of 
penetration enhancer compounds and physical techniques that, to different degrees, facilitate 
drug penetration across the skin (41).  Traditionally, enhanced TDD has been achieved with 
patch devices that occlude the skin.  Occlusion traps the natural transepidermal moisture of 
the skin which increases the water content of the horny layer and swells the membranes, 
therefore compromising its barrier function.  Prolonged occlusion of this nature can cause a 
10 to 100-fold increase in drug permeability.  However the tradeoff with these occlusive 
delivery systems is their propensity to cause local skin irritation (2). 
 
1.2.5.1 Chemical approach 
Much effort has been directed towards the search for specific chemicals, or combinations of 
chemicals, that can act as penetration enhancers (2, 4, 5) also known as accelerants or 
sorption promoters (24, 44).  These chemicals interact with skin constituents to promote drug 
flux (44) by reversibly compromising the barrier function of the skin and consequently 
allowing the entry of otherwise poorly penetrating molecules into the membrane and through 
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to the systemic circulation (27).  Diffusion of drugs across the skin is a passive process and 
compounds with low solubility and affinity for the hydrophilic and lipophilic components of 
the SC will partition at a slow rate.  These difficulties may be overcome by addition of a 
chemical adjunct to the delivery system that would promote drug partitioning into the SC 
(35).  The trend in recent years has been to identify substances that are categorized as 
‘generally recognised as safe’ (GRAS), rather than the more difficult path of seeking 
regulatory approval for a newly synthesized enhancer (i.e., a new chemical entity) (4, 82).  
However with limited success, attempts have been made to synthesize novel penetration 
enhancers e.g., lauracapram (Azone) and 2-n-nonyl-1,3-dioxolane (SEPA) which are being 
evaluated for clinical applications (55).  The ideal candidate would provide a reversible 
reduction in the barrier properties of the skin without long term damage to the viable cells 
(5).  An expanded list of desirable attributes is as follows (45): 
i. The material should be pharmacologically inert and it should possess no action of 
itself at receptor sites in the skin or in the body generally.  In fact, the most widely 
studied penetration enhancer, dimethyl sulfoxide (DMSO), is clinically active in many 
disease states. 
ii. The material should not be toxic, irritating or allergenic. 
iii. On application, the onset of penetration-enhancing action should be immediate; the 
duration of the effect should be predictable and should be suitable. 
iv. When the material is removed from the skin, the tissue should recover its normal 
barrier property. 
v. The barrier function of the skin should reduce in one direction only, so as to promote 
penetration into the skin.  Body fluids, electrolytes or other endogenous materials 
should not be lost to the atmosphere. 
vi. The enhancer should be chemically and physically compatible with a wide range of 
drugs and pharmaceutical adjuvants. 
vii. The substance should be an excellent solvent for drugs. 
viii. The material should spread well on the skin and it should possess a suitable skin feel. 
ix. The chemical should formulate into lotions, suspensions, ointments, creams, gels, 
aerosols and skin adhesives. 
x. It should be inexpensive, odourless, tasteless and colourless so as to be cosmetically 
acceptable. 
It is unlikely that any single material would possess such a formidable array of desirable 
properties (45) and compromises will have to be made with appropriate benefit to risk 
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calculations (46).  However, some substances do possess several of these attributes and they 
have been investigated clinically or in the laboratory (45).   
 
1.2.5.1.1 Chemical penetration enhancers (CPE) 
The mechanisms by which CPE act have their basis in the underlying physical chemistry that 
controls percutaneous absorption (82).  Permeation enhancers fall into two major categories: 
those that impact on diffusion across the SC and those that alter partitioning into the SC (5, 
6).  The former class generally comprises a long alkyl chain capable of interacting with long 
chains of the intercellular lipids, in addition to a polar head group that is capable of 
interacting with the lipid polar head groups (5).  This serves to disrupt the ordered nature of 
the skin lipids (5) and renders the SC more fluid thereby increasing the diffusion co-efficient 
of the permeant (46).  Substances reported to the render the SC more permeable include 
alcohols, polyalcohols, pyrrolidones, amines, amides, fatty acids, sulphoxides, esters, 
terpenes, alkanes, surfactants and phospholipids (27, 35, 46, 87 - 90).  Water is perhaps the 
ideal enhancer, since hydrated skin is generally more permeable (47), however, it is not 
applicable to all permeants (46).  The latter class of CPE modify skin permeability by shifting 
the solubility parameter of the skin in the direction of that of the permeant.  The solubility of 
the permeant in the outer layers of the skin will be increased and this, in turn, improves the 
flux.  Simple solvent type molecules, such as propylene glycol, ethanol, Transcutol®, and N-
methyl pyrollidone are thought to act in this way (46).  It is possible that both mechanisms 
may operate simultaneously, therefore an additive effect on the overall rate of drug delivery 
may then be expected.  Other mechanisms of CPE have been reported (49).  CPE may 
increase skin/vehicle partitioning of the drug and they may increase solvent transport into or 
across the skin.  The results of increased penetration may include increased drug solubility in 
the skin and increased skin penetration of the drug if the drug has a high affinity for the 
solvent (49).  If an enhancer, or combination of enhancers, affects both the solubility of the 
diffusant in the SC and reduces the rigidity of the lipid matrix, then the overall increase in the 
flux rate theoretically should approximate the product of the increases afforded by either 
enhancement method alone (48).  Despite the extensive studies performed, few compounds 
have been successfully incorporated into marketed products, partly because of the difficulty 
in predicting in vivo behaviour under conditions of use from the in vitro permeation tests that 
are normally used as screens for enhancement.  It has also proved a difficult task to balance 
the formulation characteristics to ensure that the drug retains its tendency to partition from 
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the vehicle in the presence of the CPE (5).  Numerous articles in this field have been 
published in recent years.  Sridevi et al. (50) discussed optimizing transdermal delivery of 
ketoprofen using pH and hydroxypropyl-β-cyclodextrin as co-enhancers.  Mura et al. (51) 
reviewed the evaluation of Transcutol® as a clonazepam transdermal permeation enhancer 
from hydrophilic gel formulations.  Ghafourian et al. (52) reviewed the effect of penetration 
enhancers on the drug delivery through skin.  Godwin et al. (53) discussed the influence of 
Transcutol® CG on the skin accumulation and transdermal permeation of ultraviolet 
absorbers.  Fang et al. (54) studied the effect of enhancers and retarders on percutaneous 
absorption of flurbiprofen from hydrogels among others.  Although individual chemical 
enhancers have had limited success, combinations offer new opportunities in transdermal 
formulations.  However, the rational design of enhancer combinations is limited by the lack 
of mechanistic information on the interactions between individual chemical enhancers and 
the SC (55).  Synergistic interactions between CPE, ultrasound, iontophoresis and 
electroporation have been reported (25). 
 
1.2.5.2 Physical approach 
The passive delivery of most compounds across the skin is limited due to the barrier 
properties of the epidermis (86).  An interesting area of research over the past 10 to 15 years 
has been focussed on developing transdermal technologies that utilise mechanical energy to 
increase the drug flux across the skin by either altering the skin barrier or increasing the 
energy of the drug molecules (6).  The reason for such research is due to the newly emerging 
biotechnology drugs such as peptides, proteins and oligonucleotides.  These drugs, although 
highly specific and potent, are usually large, polar and/or charged - characteristics that 
normally preclude TDD.  Recent advances in physical enhancement technologies directly 
respond to these challenges and offer exciting and powerful strategies to resolve these 
delivery issues (27). 
 
1.2.5.2.1 Iontophoresis 
Iontophoresis has been the primary electrical approach studied and has been shown to 
provide enhanced transport for some low molecular weight molecules such as pain 
medications and even decapeptides (7).  This technique has been known for many years with 
some of the pioneering studies conducted in the nineteenth century (3) due to the emergence 
of a large number of peptide drugs (60).  Drugs in the ionic form, contained in some 
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reservoir, can be ‘phoresed’ out with a small current and driven into the body through the 
skin (62).  It involves the use of an electric field to move both charged and uncharged species 
across the skin (55, 85).  The electric field imposes a force on the ion which adds to and often 
dominates the ‘diffusion force’ or concentration gradient.  This additional force then drives 
the ion through the membrane far more efficiently than in the case of pure diffusion or 
‘passive’ TDD (58).  Charged species are repelled into and through the skin as a result of an 
electrical potential across the membrane.  The amount of compound delivered is directly 
proportional to the quantity of charge passed and is dependent on the applied current, the 
duration of current application and the area of the skin surface in contact with the active 
electrode compartment (59).   
 
 
 
Figure 1.4 Basic principle of iontophoresis.  A current passed between the active electrode and the 
indifferent electrode repelling drug away from the active electrode and into the skin (63) 
 
Three main mechanisms enhance molecular transport (25, 33, 56): 
i. charged species are driven, primarily by electrical repulsion, from the driving 
electrode, 
ii. the flow of electric current may increase the permeability of skin, 
iii. electroosmosis may affect uncharged molecules and large polar peptides. 
 
The efficiency of this process is dependent on the polarity, valency and ionic mobility of the 
permeant as well as on the composition of the delivery formulation and the current profile 
(27).  A particular advantage of the technique is that the rate of drug delivery may potentially 
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be regulated by controlling the current through the device.  Furthermore, iontophoresis may 
serve to reduce the intra- and inter-subject variability in the rates of the drug delivery through 
the skin (56, 57).   
 
1.2.5.2.2 Electroporation 
Electroporation or electropermeabilization is the transitory structural perturbation of lipid 
bilayer membranes due to the application of high voltage pulses (67, 72) and is also described 
as the simultaneous creation of a transient, high permeability state and electrically driven 
transport in bilayer membranes by the application of high voltage for a short period of time 
(61).  It is best known as a physical transfection method in which cells are exposed to a brief 
electrical pulse, thereby opening pores in the cell membrane, allowing DNA or other 
macromolecules to enter the cell.  The technique of electroporation is normally used on the 
unilamellar phospholipid bilayers of cell membranes.  However, it has been demonstrated 
that electroporation of skin is feasible, even though the SC contains multilamellar, 
intercellular lipid bilayers with few phospholipids and no living cells (66).  Cell membrane 
electroporation is widely used to manipulate cells in vitro, usually for the introduction of 
genetic material (70). 
 
 
Figure 1.5 Basic principle of electroporation.  High voltage current is applied to the skin producing 
hydrophilic pores in the intercellular bilayers via momentary realignment of lipids (63) 
 
The application of high voltage pulses to skin induces the creation of new and/or the 
enlargement of existing aqueous pathways in the SC through which molecular transport 
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occurs (67 - 74).  These pores allow the passage of macromolecules due to a combination of 
diffusion, electrophoresis and electroosmosis (63, 67).  Permeability and electrical 
conductance of lipid bilayers can be rapidly and reversibly increased by many orders of 
magnitude.  Electroporation occurs when the transmembrane voltage reaches a few hundred 
millivolts for electric field pulses, typically of 10 µs to 100 ms duration (63, 68, 69).  Despite 
a high current density within a pore while a high electric field is present, electroporation is 
theoretically described as a non-thermic phenomenon (71). 
 
1.2.5.2.3 Phonophoresis 
Phonophoresis (or sonophoresis) uses ultrasound energy in order to enhance the skin 
penetration of active substances (63).  It is the movement of drugs through living intact skin 
and into soft tissue under the influence of an ultrasonic perturbation (83).  When skin is 
exposed to ultrasound, the waves propagate to a certain level and cause several effects that 
assist skin penetration (63).  The propagation of an ultrasonic wave within the skin has two 
main physical consequences, namely heating and cavitation.  These mechanisms may be 
linked as cavitation may cause heating (76).  Although considerable attention has been given 
to the investigation of sonophoresis in the past years, its mechanisms are not clearly 
understood, reflecting the fact that several phenomena may occur in the skin upon ultrasound 
exposure (61). 
 
 
Figure 1.6 Basic principle of phonophoresis.  Ultrasound pulses are passed through the probe into 
the skin fluidizing the lipid bilayers by the formation of bubbles caused by cavitation (63) 
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These include thermal effects due to absorption of ultrasound by the skin, acoustic streaming 
caused by development of time-independent fluid velocities in the skin due to ultrasound, 
cavitational effects due to the formation, oscillation and possible collapse of air bubbles in or 
next to the skin (17, 27, 55) and mechanical effects due to the occurrence of stresses from 
pressure variation induced by ultrasound (27, 61, 80).  Among these, cavitation was found to 
be primarily responsible for sonophoresis (55, 61, 75, 78 - 80).  Although literature supports 
the observation that increasing temperature leads to enhanced skin permeability (61, 75, 76, 
81), recent studies indicate that thermal effects play an insignificant role in promoting 
transdermal drug transport that is effected using low-frequency (20 - 100 kHz) ultrasound and 
therefore the observed skin permeability is related to the non-thermal effect of ultrasound 
(79).  The overall consequence is increased skin permeability due to increased fluidity of 
intercellular lipids by heating or mechanical stress and/or by enlarging intercellular space, or 
by creating permeant or transient holes through corneocytes and keratinocytes as a 
consequence of cavitation and/or by driving the drug and the vehicle through the 
permeabilized skin by convection (76, 77).  The interest in ultrasound-mediated molecule 
delivery is based on two factors (10): 
i. the capacity to enhance the efficacy of existing transdermal formulations 
(e.g., anaesthetic and non-steroidal anti-inflammatory drugs) by improving the topical 
action of the drug and 
ii. the potential of sonophoresis for the improvement of patient compliance in 
therapeutic domains such as diabetes and psychiatry and also in the delivery of 
vaccines. 
Low frequency ultrasound has shown an enhancing effect on the transdermal delivery of 
various molecules, both in vitro and in vivo.  These methods include in vitro and in vivo 
delivery of insulin, mannitol, glucose and heparin (17, 80).  Phonophoresis may have an 
additional advantage in the transcutaneous permeation of non-polar agents due to the 
utilization of mechanical rather than electromotive force.  Differential scanning calorimetry 
(DSC) and attenuated total reflectance-Fourier transform infrared (ATR-FTIR) studies 
suggested that there were no irreversible morphological changes in the SC due to ultrasound 
exposure (83). 
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1.2.5.2.4 Microneedle 
Recently, several attempts have been made to enhance the transport of substances across the 
skin barrier using minimally invasive techniques.  The proper function of an appropriate 
system requires that the SC has to be breached.  More recent developments focus on the 
concepts of microneedles (63).  Microneedles are needles that are 10 to 200 µm in length and 
10 to 50 µm in width.  They are solid or hollow and are connected to a reservoir which 
contains the active principle.  Microneedle arrays are applied to the skin surface so that they 
pierce the upper epidermis far enough to increase skin permeability and allow drug delivery, 
but too short to cause any pain to the receptors in the dermis (5, 55, 63, 65). 
 
 
Figure 1.7 Basic design of microneedle delivery system devices.  Needles with or without hollow 
centre channels are placed onto the skin surface so that they penetrate the SC and epidermis without 
reaching the nerve endings present in the upper epidermis (63) 
 
Human studies have shown that microneedles are reported as painless when inserted into the 
skin of human subjects (55).  Microneedles create larger transport pathways of micron 
dimensions.  These pathways are orders of magnitude bigger than molecular dimension and 
therefore should readily permit transport of macromolecules as well as possibly 
supramolecular complexes and microparticles (34).  Solid microneedles have increased skin 
permeability in vitro by up to four orders of magnitude for compounds ranging from small 
molecules to proteins to polystyrene nanospheres (55, 64).  Therefore there is no limitation 
concerning polarity and molecular weight of the delivered molecules.  The fabrication of such 
small structures became possible with the advent of micromachining technology which is an 
essential technology for the microelectronic industry (63). 
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Table 1.1 Comparison of methods to enhance transdermal delivery 
Delivery method Increased 
transport 
Sustained 
delivery 
No pain/ 
irritation 
Low cost/ 
complexity 
Hypodermic needle Good Moderate Limited Good 
Chemical enhancers Limited Good Moderate Good 
Iontophoresis Moderate Good Good Limited 
Electroporation Moderate Good Moderate Limited 
Ultrasound Moderate Good Good Limited 
Microneedles Moderate Good Good Limited 
Jet injection Good Limited Limited Limited 
Thermal poration Moderate Good Good Limited 
 
1.2.5.2.5 Pressure waves 
Pressure waves (high amplitude pressure transients) generated by lasers is, perhaps, one of 
the latest platforms for drug delivery (11).  They were described by Ogura et al. (84) as laser-
induced stress waves (LISW).  The LISW generated by high-power pulsed lasers are 
characterised by broadband, unipolar and compressive waves.  The LISW interacts with 
tissues in ways that are different from those of ultrasound.  Whereas the action of ultrasound 
is primarily mediated by heat and cavitation which is induced by a negative pressure, the 
effects of the LISW are caused by positive mechanical forces (11, 84).  Currently the 
mechanism of permeabilization of the SC by applying a LISW is not well understood.  
Electron microscopy of the human SC exposed to a LISW showed that there was an 
expanded lacuna system with the SC although high peak pressures were needed to obtain 
deep penetration of the drug into the skin.  However, increases in the peak pressure and the 
pulse width of the LISW result in mechanical damage in the tissue (84). 
 
1.2.5.2.6 Other approaches 
Similar to microneedles that pierce the holes into the surface of the skin, thermal methods 
have also been used to locally heat and ablate holes in the SC, thereby increasing skin 
permeability.  This thermal poration approach has been used to deliver conventional drugs 
and DNA vaccines to animals and to extract interstitial fluid glucose from human subjects.   
 
After a rise and fall in popularity in the mid-twentieth century, high-velocity jet injectors are 
receiving increased attention.  The focus now is on improved device designs for controlled, 
needle-free injection of drug solutions across the skin and into deeper tissues.  Insulin is 
delivered clinically by jet injection and jet injectors for other drugs are under development 
(55).  There have been problems with bruising and particles bouncing off skin surfaces.  
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Regulatory authorities will need convincing that high velocity particles passing through the 
SC do no damage and they do not carry contaminants such as bacteria into viable skin layers 
(24).   
 
Limited work probed the ability of magnetic fields (magnetophoresis) to move diamagnetic 
material through skin (24) although Murthy et al. (91, 92) has demonstrated the efficacy of a 
magnetic field to act as permeation enhancer. 
 
1.2.5.2.7 Synergistic effect of enhancers 
Although the various penetration enhancement methods discussed above have individually 
been shown to enhance transdermal drug transport, their combinations are often more 
effective.  During the past ten years, several studies have supported this hypothesis, specially 
addressing combinations of chemicals and iontophoresis, chemicals and electroporation, 
chemicals and ultrasound, iontophoresis and ultrasound, electroporation and iontophoresis 
and electroporation and ultrasound.  In addition to increasing transdermal transport in a 
possibly synergistic manner, a combination of enhancers can also reduce the required dose of 
each enhancer.  In this way, combinations of enhancers could increase safety and efficacy.  
Although combinations offer opportunities, most commercial efforts have emphasized single 
enhancers, probably due to the complexity of combining multiple technologies (55). 
 
1.2.6 Selection of drug candidates for transdermal drug delivery 
One important goal for the pharmaceutical industry is the identification of molecules with the 
potential for becoming approved drugs (96).  The drug development process selects for 
molecules having the optimal pharmacological activity in the biological assay of choice (26).  
Although it may appear to be a simple task to select lead compounds for pharmaceutical 
product development based on therapeutic rationale and compound safety and efficacy, the 
practicalities of this procedure are somewhat more complex.  For the most part, therapeutic 
efficacy is dependent on the ability of a compound to cross biological barriers, travel to the 
target site and interact with the receptors.  However, it is often more appropriate in 
dermatological therapy to select compounds based on their inability to breach relevant 
biological barriers (93).  Transport across the SC is largely a passive process and thus the 
physicochemical properties of a permeant are an important determinant of its ability to 
penetrate and diffuse across the membrane (94). 
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1.2.6.1 Biological properties of the drug 
1.2.6.1.1  Potency 
The skin is a very efficient barrier to the ingress of materials, allowing only small quantities 
of a drug to penetrate over a period of a day.  Realistically, a transdermal delivery system 
should not cover an area much larger than 50 cm2.  Drugs such as nitroglycerin, which 
penetrate skin relatively rapid, do so at fluxes in the 10 - 15 µg/cm2/h range from saturated 
aqueous solution.  Hence the total amount of nitroglycerin which can be delivered across the 
skin from a 50 cm2 system in one day is approximately 15 mg.  In general, therefore, TDD is 
suitable only for drugs for which the daily dose is of the order of a few milligrams (9). 
 
1.2.6.1.2  Half-life 
The biological half-life of the active is a factor that is often ignored in the selection and 
design of sustained and controlled drug delivery systems.  It is pointless, for example, to 
produce a transdermal system for a drug which has a very long biological half-life (9). 
 
1.2.6.1.3  Toxicity 
Skin toxicity is another biological property that should be considered.  If a pharmacologically 
active material is to be presented to the skin under an occlusive patch system over an 
extended period, the likelihood of an irritant or allergic response is significant.  Limits will 
have to be determined for the acceptability of this undesired effect (9). 
 
1.2.7 Physicochemical properties of the drug 
1.2.7.1 Oil-water partition co-efficient 
It is generally accepted that the oil-water partitioning characteristics of a chemical are crucial 
to its ability to penetrate the skin (26) and can be used to predict the partition behaviour 
within the skin (5).  Essentially, the SC barrier is lipophilic, with the intercellular lipid 
lamellae forming a conduit through which drugs must diffuse in order to reach the underlying 
vascular infrastructure and to ultimately access the systemic circulation.  For this reason, 
lipophilic molecules are better accepted by the SC.  A molecule must first be liberated from 
the formulation and partition into the uppermost SC layer, before diffusing through the entire 
thickness, and must then repartition into the more aqueous viable epidermis beneath (27).  In 
general, the more lipophilic chemicals are absorbed more readily and hydrophilic chemicals 
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may penetrate only very slowly (30).  There is often a parabolic relationship between the 
octanol-water partition co-efficient as expressed by Plog  and the penetration rate.  
Compounds with low Plog  exhibit low permeability because there is little partitioning into 
the skin lipids.  However, compounds with high Plog  also give low permeability due to their 
inability to partition out of the SC (5).  Thomas et al. (5) reported the accepted range of 
Plog  for maximum permeation between 1 and 3.  Hadgraft et al. (148) in previous work 
showed that there was maximum percutaneous absorption for a series of NSAIDs and 
salicylates where the Plog  was between 2 and 3.  
 
1.2.7.2 Solubility and molecular dimensions 
The chemical structure of the drug also influences the diffusivity, due to interactions between 
the polar head groups of the intercellular lipids with hydrogen-bond-forming functional 
groups present in the drug structure.  As a general rule, the number of hydrogen bonding 
groups in the permeant should not exceed two.  Suitable candidates for transdermal 
permeation are small molecules with good water and lipid solubility.  These solubility 
characteristics are often also indicated by the possession of a low melting point, typically less 
than 200°C (5).  Mathematical models have been described to predict the permeability of the 
SC to hydrophobic drugs (55).  Potts et al. (97) developed an equation that correlates skin 
permeability to a drug in aqueous solution with solute molecular mass and octanol-water 
partition co-efficient. 
 
1.2.7.3 Polarity and charge 
Polar and non-polar substances may diffuse through the skin by different mechanisms.  The 
more polar substances may follow cellular surfaces or follicular pathways whereas the more 
non-polar substances may pass through the lipid matrix of the skin (30).  Many permeants are 
weak acids or bases.  Permeation will depend on the degree of ionisation and how ionisation 
influences the solubility in the applied phase and its partition into the skin.  One of the 
problems involved in interpreting permeation data of ionised compounds is that the species 
that permeate will be a composite of free acid (or base) of the ionised material and ion pairs 
that can exist with counter ions present either in the formulation or in the skin (32). 
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1.3 MATHEMATICAL PRINCIPLES IN TRANSMEMBRANE DIFFUSION 
 
1.3.1 Introduction 
A number of mathematical models have been used to describe percutaneous absorption 
kinetics.  In general, most of these models use either diffusion-based or compartmental 
equations which suffer from being too complex to be practically useful (98) however sound 
knowledge of the underlying mathematical principles of membrane transport is essential if we 
are to expand our understanding of how membrane barriers fulfil their function and how we 
can alter their properties to our advantage.  Much of the early mathematics relating to 
transmembrane diffusion had its origin in the theoretical description of heat transfer and 
conductance.  Indeed, the most basic of the diffusion equations, Fick’s first law, has its roots 
here (99). 
 
1.3.2 Fickian model 
1.3.2.1 Fick’s first law of diffusion 
In transport, the flow (or flux, Ji in mol cm-2 s-1) is related to the velocity of molecular 
movement (υ in cm s-1) and the concentration (Ci in mol cm-3) of the molecules in motion in 
equation 1.1. 
 
υii CJ =  (1.1) 
 
A fundamental principle of irreversible thermodynamics is that the flow, at any point in the 
system, at any instant, is proportional to the appropriate potential gradient.  It can be 
expressed mathematically for a species i  as shown in equation 1.2 where ii x∂∂μ  is the 
gradient and Li is the proportionality constant. 
 
⎟⎠
⎞⎜⎝
⎛
∂
∂−=
x
LJ iii μ  (1.2) 
 
Equation 1.2 is the general form of Fick’s first law of diffusion.  If constant temperature and 
pressure is assumed equation 1.2 can be expressed as equation 1.3 where iD  is the diffusion 
co-efficient. 
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1.3.2.2 Fick’s second law of diffusion 
Fick’s second law relates the rate of change in concentration with time at a given point in a 
system to the rate of change in concentration gradient at that point.  It is expressed in 
equation 1.4 where x  is the diffusion distance in the direction of the concentration gradient. 
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Fick’s laws are more applicable if certain parameters or boundaries are specified.  In this 
laboratory, the mathematical boundary conditions imposed are those of a well-designed 
diffusion experiment when the permeant is at a high, fixed activity on one side of an inert 
homogenous membrane through which it diffuses into a sink on the other side and before the 
start of the experiment the membrane is entirely devoid of permeant (99).   
 
This implies that the diffusive flow begins at the high-concentration side (the donor side) of 
the membrane where 0CC =  and hx =  at all time intervals, t .  There is no diffusant 
material within the membrane before ingress of the permeant being modelled, implying that 
at 0=t  we have 0=C for all values of x .  Diffusion occurs in the direction of decreasing x  
toward the opposite side of the membrane where 0=x  and 0=C  (sink receptor phase) for 
all time intervals, t .  The cumulative mass Q , of permeant that passes through a unit area of 
a membrane in a time t  is shown in equation 1.5 where C0 is the concentration of diffusant in 
the membrane lamina juxtaposed to the donor vehicle, and h is the thickness of the membrane 
(99). 
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As ∞→t , the exponential term tends to zero and Fick’s second law has been expanded to 
become equation 1.6. 
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This equation is applicable to typical cumulative mass versus time diffusion plots that have 
an initial non-linear lag time followed by a linear steady state plot (100).  From equation 1.6, 
we can solve for t  and this yields the lag time ( lagt ) as described by equation 1.7 which 
relates inversely to the diffusion co-efficient and directly to the diffusional pathlength. 
 
D
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When equation 1.6 is differentiated relative to time we obtain equation 1.8, possibly the most 
well-known form of Fick’s law of diffusion that describes the flux J , at steady state. 
 
h
DCJ
dt
dQ o==  (1.8) 
 
It is often impractical to use the forms of equations 1.6 and 1.8 as shown because they 
include a term oC  (the concentration of permeant in the outer layer of the membrane), that is 
extremely difficult to measure.  The value oC  is replaced with a term that links it to the 
concentration in the vehicle vC  through the partition co-efficient K , which rearranges to give 
equation 1.9. 
 
h
DKCJ
dt
dQ v==  (1.9) 
 
The product of the partition co-efficient and the donor vehicle concentration will yield the 
diffusant concentration in the membrane lamina.  Therefore the main variables influencing 
the rate of diffusion are D , K , vC and h  (100).  Frequently, particularly in biological 
membranes, there is a practical difficulty in measuring the diffusional pathlength and that the 
information concerning the individual effects of changes in K  and D  is often not required, a 
composite parameter is usually used to replace these values in equation 1.9.  The permeability 
co-efficient P , is thus defined as hKDP = , and this simplifies equation 1.9 to further give 
equation 1.10. 
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vPCJ =  (1.10) 
 
Equation 1.10 is perhaps the most basic and frequently used expression in the routine 
assessment of membrane permeability.  However the principles upon which this equation is 
based stipulate that the donor concentration is constant and that the diffusion has reached 
steady state (99). 
 
1.3.3 Higuchi model 
Higuchi (101) describes drug release as a diffusion process based on Fick’s law, square root 
time dependant.  This relation can be used to describe the drug dissolution from several types 
of modified release pharmaceutical dosage forms, as in the case of some transdermal systems 
and matrix tablets with water soluble drugs (102).  For drug release from an ointment in 
which the drug is initially uniformly dissolved is governed by equation 1.11 and 1.12 where 
Q  is the amount of drug released per unit area of application, h  is the thickness of layer, oC  
is the initial concentration of the drug in the ointment, D  is the diffusion co-efficient of drug 
in the ointment, t  is the time after application and R is the percent of drug released (101, 
104). 
 
2
1
2 ⎟⎠
⎞⎜⎝
⎛= π
DtCQ o   (1.11) 
 
2
1
2200 ⎟⎠
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h
DtR π  (1.12) 
 
If the rate of drug release obeys this law, the amount of drug released is a linear function of 
t½, and D  can be calculated from the slope.  The assumptions in this treatment are that the 
drug is the only component diffusing out of the vehicle, that sink conditions are maintained in 
the receptor phase and that D  is constant with respect to time and position in the vehicle 
(101, 103).  Permeation of this nature has a characteristic curved profile, exhibiting relatively 
high flux at early contact times which decreases as the diffusant front regresses into the bulk 
vehicle, away from the membrane.  The path is progressively more tortuous and it takes 
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longer for drug molecules to diffuse from the region of high concentration in the vehicle to 
replenish the drug molecules at the membrane interface that have partitioned into the 
membrane, therefore the flux rate decreases with time (100). 
 
Equations 1.1 - 1.12 describe drug diffusion through a homogenous membrane with a 
constant activity difference and a constant diffusion co-efficient and these mathematical 
functions have been employed in the analysis of data in this laboratory. 
 
It is evident that from sections 1.2 - 1.3 that the transport of drugs though the skin depends on 
a number of factors such as the characteristics of the permeant, condition and type of skin, 
other chemicals present in the topical formulation (e.g., enhancers) and external conditions 
(e.g., temperature).  The factor with perhaps the greatest influence is the physicochemical 
character of the permeant.  According to Fick’s first law (section 2.3.2.1), the permeation of a 
drug through the SC depends on the permeability co-efficient and the concentration gradient 
of the permeant across the SC.  The permeability co-efficient is the product of the partition 
and the diffusion co-efficient, divided by the length of the pathway through the SC.  These 
factors, in turn, depend on variables such as molecular weight, size and structure and degree 
of ionization of the permeant (95). 
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1.4 METHODS FOR STUDYING PERCUTANEOUS ABSORPTION 
 
1.4.1 Introduction 
There is an increasing demand for data describing the rate, degree and route of penetration of 
compounds across human skin.  First, there is a requirement to optimise the delivery of 
dermatological drugs into various skin strata for maximum therapeutic effect.  Second, the 
transdermal and topical routes have become popular alternatives to more traditional methods 
of drug delivery.  A third stimulus has been the toxicological and risk assessment 
implications of the everyday use of a wide range of potentially harmful materials in the 
agrochemical, chemical, cosmetic, household and pharmaceutical sectors.  This has been 
driven largely by regulatory and safety bodies and a perceived need for improved data on the 
permeability of the skin to xenobiotics (111).  A key aspect of any new drug product is its 
safety and efficacy as demonstrated in controlled clinical trials.  However the time and 
expense associated with such trials make them unsuitable as routine quality control methods 
to re-establish comparability in quality and performance following a change in formulation or 
method of manufacture.  Therefore, in vitro and in vivo surrogate tests are often used to 
assure that product quality and performance are maintained over time in the presence or 
absence of change (107).  At present, U. S. Food and Drug Administration (FDA) approval 
for transdermal dosage forms requires in vivo and where appropriate, in vitro data.  In vivo 
studies include clinical safety and efficacy, local irritation, systemic toxicity and 
bioavailability.  In vitro studies, on the other hand, include quality control procedures such as 
assay, content uniformity and drug release characteristics (112). 
 
1.4.2 Diffusion cell design 
Numerous designs of apparatus for studying diffusion of active ingredients from semisolids 
have appeared in the literature (103 - 120).  In general, these systems consist of a donor cell 
which holds the semisolid material and a receptor cell or compartment which holds the 
chosen receptor medium and from which samples are withdrawn at regular intervals.  The 
system may or may not include a membrane separating the two phases and means of stirring 
and controlling the temperature of the receptor medium (116).   
 
The in vitro diffusion cells should be made from inert, non-reactive materials (such as glass, 
stainless steel, Teflon).  Inertness (lack of absorption) to all components of the cell, including 
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flow-through lines and the collection chambers themselves, should be demonstrated by the 
experiment.  It should also be shown that there is no loss of drug through its volatility during 
the permeation procedure.  If volatility is a problem, a quantitative accounting of this must be 
made.  The receptor medium should provide an effective sink for the penetrant.  Ideally, it 
should, at the same time, contain a minimum volume to facilitate analysis because, in general, 
the more concentrated the drug in the collection medium, the easier the assay procedure.  The 
cell design should allow the receptor fluid to be well mixed and temperature controlled (116).  
In vitro systems range in complexity from a simple two-compartment static diffusion cell to 
multijacketed flow-through cells (111).  Although numerous studies using modifications of 
the various systems described above have been reported (103 - 120), two design types have 
shown the highest potential for use as standardised, compendial methods.  They are the 
vertical diffusion cells for measurement of percutaneous absorption (i.e., Franz and modified 
Franz), which require the use of a membrane when measuring drug release and immersion 
cells for use with the standard USP dissolution apparatus (i.e., the European Pharmacopoeia 
diffusion cell), which may be used with or without a membrane (116). 
 
1.4.2.1 Franz and modified Franz diffusion cell 
Most of the published work on in vitro release from semisolids used vertical Franz-type cells 
(115).  Finite dose techniques and the design of a static one-chambered diffusion cell were 
described by Franz (121, 122).  Shortcomings of the original Franz cells were identified and 
modifications were proposed to improve adequate solution hydrodynamics, mixing efficiency 
and temperature control (271).  These modifications were employed in this study.  The cell 
body consists of a jacketed glass receptor chamber, 12.5 ml in volume (modified cells exist 
with slightly different receptor volumes) and a glass sampling port.  The membrane is placed 
horizontally over the receptor chamber, the cell cap is applied over that, and the components 
are held together with a metal clamp.  The test formulation can then be applied to the surface 
of the membrane through the top of the cell cap, which is open to the atmosphere unless 
sealed by the user.  A study in this laboratory by Pefile et al. (123) showed that the inability 
to control the evaporation process of the volatile components from the vehicle resulted in 
erratic drug release from the unoccluded bases with marked variability in drug release rates.  
Therefore the top of the cell cap was sealed during the diffusion run.  A micro-magnetic 
stirrer is placed at the bottom of the receptor chamber. 
 
 34 
 
Figure 1.8 Modified Franz diffusion cell (116) 
 
The temperature in the bulk of the receptor medium is maintained by circulating water 
through a water jacket that surrounds the receptor compartment (223).  The entire cell is 
positioned in a multiple-cell drive unit which drives the magnetic stirrer to agitate the 
receptor medium at a controlled rate of 100 rpm.  The jacketed portions of multiple cells are 
connected in series with tubing to a circulating temperature-controlled water bath (116). 
 
1.4.2.2 European Pharmacopoeia diffusion cell 
An alternate to the Franz diffusion cell is the use of an immersion cell with a standard USP 
dissolution apparatus.  The European Pharmacopoeia diffusion cell, although similar in 
design and operation to the VanKel enhancer cell and to the Hanson ointment cell (116), has 
some notable differences.  The European Pharmacopoeia diffusion cell is described in detail 
in the European Pharmacopoeia (124).  The diffusion cell consists of a support, a cover and a 
membrane.  The support contains a central depression which acts as the reservoir for the 
transdermal dosage form.  The depth of the central reservoir is 2.6 mm and the diameter  
38 mm.  The cover has a central aperture with a diameter of 32 mm and a corresponding 
surface area of 8.03 cm2 through which the topical formulations diffuses.  The cover is held 
firmly in place above the support by four screws extending into the support base. 
 
The diffusion cell is assembled and placed into a cylindrical vessel with the diffusion surface 
facing upwards and parallel to the horizontal plane.  The cylindrical vessel is made from 
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borosilicate glass or other suitable transparent material, with a hemispherical bottom and a 
nominal capacity of 1000 ml.  The vessel has a flanged upper rim and is fitted with a lid that 
has a number of openings, one of which is central.  The USP dissolution apparatus is 
equipped with a motor with a speed regulator capable of maintaining the speed of rotation of 
the paddle within ± 4% of 100 rpm.  The motor is fitted with a stirring element which 
consists of a drive shaft and a paddle.  The paddle is lowered to a depth corresponding to  
10 ± 2 mm above the diffusion cell surface.  The temperature of the receptor fluid is 
maintained at 32 ± 5 °C.  Evaporation is prevented by the fitted lid.  Samples are taken from 
the cylindrical vessel at suitable time intervals (124). 
 
Figure 1.9 European Pharmacopoeia diffusion cell (125) 
 
The diffusion cell is easy to load and most laboratories have a USP dissolution apparatus 
(115) and it does not have the serious drawback due to the presence of air bubbles at the 
membrane/liquid interface as commonly observed with the Franz diffusion cells (110).  
Fares et al. (115), Liebenberg et al. (105) and Sanghvi et al. (125) compared the rate of drug 
release from both the Franz cells and the enhancer cells and concluded that once the data is 
corrected for differing surface area, drug release is nearly superimposable. 
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CHAPTER TWO 
KETOPROFEN MONOGRAPH 
 
2.1 PHYSICOCHEMICAL PROPERTIES OF KETOPROFEN 
 
2.1.1 Introduction 
Ketoprofen is an anionic non-steroidal anti-inflammatory drug (NSAID).  It is a derivative of 
propionic acid and widely used in the management and treatment of patients with rheumatic 
disease (131).  It has been described chemically in a number of ways: 
i. (2RS)-2-(3-benzoylphenyl) propanoic acid (132) 
ii. 2-(3-benzoylphenyl) propionic acid (133, 134, 135, 138) 
iii. 2-(benzoyl-3-phenyl) propionic acid (135) 
iv. 3-benzoyl-α-methylbenzeneacetic acid (134, 138) 
v. α-(benzoylphenyl) propionic acid (135) 
vi. α-(3-benzoylphenyl) propionic acid (135) 
vii. m-benzoylhydratropic acid (135, 138, 139) 
viii. (RS)-2-(3-benzoylphenyl) propionic acid (131, 140). 
 
O
CH3H
CO2H
 
C16H14O3  MM 254.3 g/mol 
Figure 2.1 Structure of ketoprofen 
 
2.1.2 Description 
Ketoprofen is a white or almost white, crystalline odourless powder with a sharp bitter taste 
(131-134, 140).  It is prepared by chemical synthesis as a racemate (131) and contains not 
less than 99.0% and not more than the equivalent of 100.5% of (2RS)-2-(3-benzoylphenyl) 
propanoic acid, calculated with reference to the dried substance (132). 
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2.1.3 Stereochemistry 
The presence of at least one asymmetric carbon atom in a chemical entity results in the 
existence of stereoisomers.  Ketoprofen has one asymmetric carbon, also referred to as a 
chiral centre, which gives rise to two enantiomers (140).  Both enantiomers possess different 
biological activities (142).  The (S)-enantiomer reduces inflammation and relieves pain, 
whereas the (R)-enantiomer can be used as a toothpaste additive to prevent periodontal 
disease.  The majority of synthetic chiral drugs are now marketed as racemates, but this 
situation is rapidly changing due to Food and Drug Administration (FDA) regulations and 
recent advances in biocatalytic methods (143, 144). 
 
CH3
CO2H
O
H
HO2C
H
O
H3C
 
               (R) - enantiomer                                                                    (S) - enantiomer  
Figure 2.2 Stereochemistry of ketoprofen 
 
2.1.4 Melting point 
Ketoprofen has been reported to melt in the range of 94°C to 97°C (132, 140), 93°C to 95°C,  
94°C, 96°C, 92°C, 91°C (135) and 93°C to 96°C (134). 
 
2.1.5 Solubility 
Ketoprofen is practically insoluble in water, freely soluble in acetone, ethanol and methylene 
chloride (132).  It is also soluble in chloroform, ether and benzene (134).  In ethanol, 
ketoprofen has a solubility of about 1 in 5 and in water < 1 in 10 000 (131).  Adjusting the pH 
to a higher value can solubilize ketoprofen, as solubility increases at pH values above its pKa 
(141). 
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2.1.6 Dissociation constant 
Ketoprofen is a weak monocarboxylic acid (141, 145) and has reported dissociation constant 
values, pKa, of 4.23 (147), 4.55 (131), 4.45 (134, 146), 4.60 (141, 145, 149) in water and 
5.02 in aqueous solutions of pH 1.5 (148).  The pKa will be an important determinant in 
ionisation and hence permeation (150).  
 
2.1.7 Maximum flux ( maxJ ) 
The maximum flux through the skin is obtained by taking the permeability co-efficient and 
multiplying it by the aqueous solubility.  The maxJ  is reported as 0.75 µg/cm2/h (147, 150). 
 
2.1.8 Partition co-efficient and permeability co-efficient 
There is a linear free energy relationship between lipophilicity and biological activity.  As a 
suitable measure of lipophilicity, the partition co-efficient, P , between 1-octanol and water 
was determined.  The value of P  varies slightly with temperature and concentration of solute 
(151).  The octanol-water partition co-efficient ( Plog ) has been reported as 3.12 (147, 150).  
Previous work by Hadgraft et al. (147) showed that there was maximum percutaneous 
absorption for a series of NSAIDs and salicylates where the Plog  was between 2 and 3.  At 
low Plog , the permeability co-efficient is low but the aqueous solubility is high and at high 
Plog , the permeability co-efficient is high but the aqueous solubility is low.  The reported 
permeability co-efficient is 5.01 x 10-3 (cm/h)2 (147, 150).  NSAIDs tend to have low 
solubilities and high permeabilities at low pH, but high solubilities and reduced effective 
permeabilities at higher pH (149). 
 
2.1.9 Optical rotation 
Ketoprofen is a racemic mixture of (±) α-(3-benzoylphenyl) propionic acid.  Both 
enantiomers show Cotton Effects at 223 nm.  The (+)-enantiomer shows a positive Cotton 
Effect indicating an S-absolute configuration and interacts more strongly with human serum 
albumin as well as with biotransformation enzymes than the (-)-enantiomer (135). 
(+)-enantiomer [ α ]D 2 3 + 57.1 o (C = 0.76 in CH2Cl2 ) 
(-)-enantiomer  [ α ]D 2 3  - 57.4 o  (C = 0.88 in CH2Cl2 ) 
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2.1.10 Synthesis 
Ketoprofen was synthesised by Rhône-Poulenc Research Laboratories, Paris in 1967 and was 
first approved for clinical use in France and the United Kingdom in 1973 (136, 137).  Several 
methods for the synthesis of ketoprofen have been reported in the literature.  Figures 2.3 - 2.5 
show the synthesis starting from (3-carboxyl-phenyl)-2-propionitrile,  
2-(4-aminophenyl)-propionic acid and (3-benzoylphenyl)-acetonitrile respectively. 
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CH CN
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CH CN
CH3
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O
CH CN
CH3
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CH COOH
CH3
Friedel-Craft
Hydrolysis
 
 
Figure 2.3 Synthesis of ketoprofen starting from (3-carboxy-phenyl)-2-propionitrile (135) 
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Figure 2.4 Synthesis of ketoprofen starting from 2-(4-aminophenyl)-propionic acid (135) 
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Figure 2.5 Synthesis of ketoprofen starting from (3-benzoylphenyl)-acetonitrile (135) 
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2.1.11 Stability 
Ketoprofen must be protected from light and moisture (135).  Exposure of aqueous solutions 
of ketoprofen (as the sodium salt) to ultraviolet radiation at 254 nm or daylight, for one hour 
at room temperature, was reported (134) to yield (3-benzoylphenyl) ethane which was 
subsequently converted to (3-benzoylphenyl) ethanol and (3-benzoylphenyl) ethanone 
(analysis by thin layer chromatography and high-performance liquid chromatography).  
Samples that were protected from light showed negligible decomposition over 24 months. 
 
Figure 2.6 Ketoprofen impurities and photodegradation products (132) 
O
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CH3
and enantiomer
and enantiomer
 
 
 
1-(3-benzoylphenyl) ethanone 
 
 
 
R = H, R1 = C6H5:  
(3-benzoylphenyl) acetic acid 
R = CH3, R1 = OH:  
(2RS)-2-(3-carboxyphenyl) propanoic acid 
 
R = CO2H, R1 = CH3: 
(2RS)-2-[3-(4-methylbenzoyl) phenyl] 
propanoic acid 
R = CO-NH2, R1 = H: 
(2RS)-2-(3-benzoylphenyl) propanamide 
R = CN, R1 = H: 
(2RS)-2-(3-benzoylphenyl) propanenitrile 
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2.1.12 Ultraviolet absorption 
The ultraviolet (uv) spectrum of ketoprofen in 0.2 M phosphate buffer at pH 6.8 is depicted in 
Figure 2.7.  The maxλ  is 260 nm.  The spectrum was obtained using a double beam GBC 
UV/Vis 916 Spectrophotometer from GBC Scientific Equipment Pty Ltd (Victoria, 
Australia).  The solvent also affects the maxλ .  In acetonitrile the maxλ  is 254 nm.  The maxλ  
reported in alcohol is 255 nm (132, 135). 
 
2.1.13 Infrared spectrum 
The major band assignments of ketoprofen are given in Table 2.1. 
 
Table 2.1 Major infrared band assignments of ketoprofen (135) 
Band position (cm-1) Assignment 
3200 - 2500 O - H stretching 
3020 C - H stretching of aromatic groups 
2970, 2930 C - H stretching of CH3 group (asymmetric) 
2880 C - H stretching of CH3 group (symmetrical) 
1695 C = O stretching of the acid 
1655 C = O stretching of the ketone 
1595, 1580, 1455 C = C stretching of the aromatic ring 
1440 C – H deformation of CH3 (asymmetrical) 
1370 C – H deformation of CH3 (symmetrical) 
860 - 690 C – H deformation of aromatic rings 
 
2.1.14 Nuclear magnetic resonance spectrum 
The H1-NMR spectrum of ketoprofen in CDCl3 on an EM-360 6 MHz NMR 
spectrophotometer is shown in Figure 2.9.  Table 2.2 compares published values for 
ketoprofen. 
 
Table 2.2 Published ketoprofen H1-NMR spectrum values (135) 
Instrument used Values 
Varian EM-360 1.53 (d, 3 H, J = 7 Hz), 3.80 (q, 1 H, J = 7 Hz), 7.20 – 7.90 (m, 9 H), 
11.50 (s, 1 H) 
Varian T60 & A60 1.52 (d, 3 H, J = 7 Hz), 3.76 (q, 1 H, J = 7 Hz), 7.2 – 7.8 (m, 9 H), 11.8 
(s, 1 H) 
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Figure 2.7 Ultraviolet spectrum of ketoprofen standard in aqueous solution 
 
 
Figure 2.8 Infrared spectrum of ketoprofen (135) 
 
 
Figure 2.9 Nuclear magnetic resonance spectrum of ketoprofen (135) 
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2.2 CLINICAL PHARMACOLOGY OF KETOPROFEN 
 
Ketoprofen is an effective anti-inflammatory and analgesic drug in clinical practice and is 
used in the treatment of rheumatoid arthritis and osteoarthritis.  It is as effective in clinical 
trials as other NSAIDs such as naproxen from both the efficacy and side effect point of view 
(131).  Like most NSAIDs, ketoprofen is advantageous because it lacks addictive potential 
and does not result in sedation or respiratory depression.  In addition ketoprofen also exerts 
analgesic and antipyretic pharmacological properties (152). 
 
2.2.1 Anti-inflammatory effects 
In several animal models (rats, mice, rabbits, guinea pigs and pigeons) ketoprofen displayed 
potent activity against acute inflammation (increased vascular permeability, oedema and 
erythema), sub acute inflammation (pleurisy, abscess and granuloma formation), and chronic 
inflammation (experimental arthritis and synovitis) (136).  Its anti-inflammatory activity is 20 
times more potent than ibuprofen, 80 times more potent than phenylbutazone and 160 times 
more potent than aspirin (131, 136). 
 
2.2.2 Analgesic and antipyretic effects 
Ketoprofen was shown to be a potent, peripherally acting analgesic in two classical animal 
models of pain.  It was also shown to be equivalent to indomethacin, slightly more potent 
than naproxen and 30 times more potent than aspirin in pain management.  Like other 
NSAIDs, ketoprofen is inactive in assays measuring centrally mediated analgesia.  It did not 
reduce basal temperature but decreased antigen-induced hyperthermia in rats and rabbits to a 
greater extent than any other NSAID tested, including indomethacin, naproxen, ibuprofen and 
phenylbutazone (136). 
 
2.2.3 Mechanism of action 
As with all NSAIDs, the physiological basis of the pharmacodynamic activities of ketoprofen 
is presumed to be interference with arachidonic acid metabolism (136).  Arachidonic acid is 
the most abundant and probably the most important of the precursors of the eicosanoids.  It is 
a 20-carbon fatty acid that contains four double bonds beginning at the omega-6 position to 
yield 5, 8, 11, 14-eicosatetraenoic acid (153).  Free release of arachidonic acid from 
membrane phospholipids is catalysed by the enzymatic activation of phospholipid A2.  It is 
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then converted to various forms of prostaglandins, including thromboxane A2 (TXA2), 
prostaglandin D2 (PGD2), prostaglandin E2 (PGE2), prostaglandin F2α (PGF2α) and 
prostaglandin I2 (PGI2) by the cyclooxygenase activity of the COX enzyme.  Prostaglandins 
have overlapping roles but co-ordinately regulate smooth muscle contractility, mediation of 
pain and fever, regulation of blood pressure and platelet aggregation (154, 174). 
 
Cyclooxygenase (COX), a prostaglandin-endoperoxide synthase (PTGS), catalyses the 
formation of prostaglandins from arachidonic acid (155).  COX is a dual function enzyme, 
incorporating both a cyclooxygenase and a peroxidase activity (174).  There are principally 
two isozymes of COX, COX-1 (constitutive isozyme) and COX-2 (inducible isozyme) (152-
156).  Although a COX-3 isozyme has recently been identified (154, 157), its existence with 
respect to activity has been challenged (154, 158).  These isozymes have diverse physiologic 
and pathophysiologic roles and exhibit pharmacologically important differences in structure 
and profiles of inhibition (156).  The COX-1 isozyme is essential for the maintenance of 
normal physiologic states in many tissues including the kidneys, gastrointestinal tract and 
platelets.  The COX-2 isozyme is induced by various inflammatory stimuli including 
cytokines, endotoxins and growth factors (155, 171, 174). 
 
Ketoprofen is one of the most powerful inhibitors of cyclooxygenase at concentrations well 
within the range of therapeutic plasma concentrations (EC50 2 μg/l) (136).  It produces 
reversible COX inhibition by competing with the substrate, arachidonic acid, for the active 
site of the enzyme (174).  This inhibition results in a reduction in the tissue production of 
prostaglandins such as PGE2 and PGF2α  (131).  In addition to its effects on cyclooxygenase, 
ketoprofen inhibits the lipoxygenase pathway of the arachidonic acid cascade.  This pathway 
produces non-cyclized monohydroxyl acids (HETE) and leukotrienes.  Of these, only 
leukotrienes (B4, C4, and D4) are thought to increase vascular permeability, however, both 
HETE and leukotrienes synthesised within leukocytes are active in promoting leukocyte 
migration and activation.  It has been suggested that lipoxygenase inhibitors may attenuate 
cell-mediated inflammation and thus retard the progression of tissue destruction in inflamed 
joints.  Ketoprofen is also a powerful inhibitor of bradykinin, an important chemical mediator 
of pain and inflammation.  It also stabilises lysosomal membranes against osmotic damage 
and prevents the release of lysosomal enzymes that mediate tissue destruction in 
inflammatory reactions (131, 136, 137, 159, 168). 
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2.2.4 Therapeutic use 
2.2.4.1 Indications 
Ketoprofen is used for musculoskeletal and joint disorders such as ankylosing spondylitis, 
osteoarthritis, and rheumatoid arthritis, and in peri-articular disorders such as bursitis and 
tendinitis.  It is also used for postoperative pain, painful and inflammatory conditions such as 
acute gout or soft tissue disorders and to reduce fever (131, 140, 148, 152).  It is also 
indicated for the management of acute painful shoulder syndrome and juvenile rheumatoid 
arthritis (136).  Ketoprofen can also be used in the following instances. 
i. For prophylaxis and treatment of migraine headaches. 
ii. In surgical and traumatic situations where analgesic action is required for sports 
injuries, orthopaedic manipulations, dental extraction.  
iii. In infectious diseases which require analgesic, anti-inflammatory and anti-pyretic 
effects. 
iv. In gynaecological conditions which involve the management of dysmenorrhoea 
following intra-uterine device (IUD) insertion and for uterine relaxation and analgesia 
in post-partum, non-nursing women (131). 
 
2.2.4.2 Contraindications 
Ketoprofen is contraindicated in the following medical conditions. 
i. Bronchospasm 
Patients with rhinitis, nasal polyps and asthma associated with aspirin use may show 
cross-sensitivity with other non-steroidal anti-inflammatory drugs including 
ketoprofen (131).  NSAIDs can affect the lungs through inhibition of prostaglandins 
and increased concentrations of leukotrienes, leading to asthma exacerbation in 
susceptible  patients (152). 
ii. Peptic ulceration 
Ketoprofen should not be administered to patients with active peptic ulceration or 
with a history of recurrent peptic ulceration or chronic dyspepsia (131).  NSAIDs 
damage the gastrointestinal tract (GIT) through both local and systemic effects.  At 
the superficial mucosal level, NSAIDs act as weak acids and because of the highly 
acidic milieu of the stomach, they remain in the non-ionised form that favours 
migration across cell membranes and into superficial epithelium.  Once there, they are 
metabolised into their ionised form where they trap hydrogen ions.  NSAIDs can also 
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attenuate the protective effects of the gastric mucosa, leading to epithelial damage.  
Although it has been theoretically possible to reduce upper GIT damage at the local 
level, systemic effects are responsible for injury via inhibition of protective 
prostaglandins (152). 
iii. Severe renal insufficiency 
Since prostaglandins synthesised in the kidneys are potent vasodilators that balance 
the effects of vasoconstrictive stimuli (norepinephrine, angiotensin II and renin) on 
renal blood flow, preventing their production will affect renal function in some 
situations.  As expected, the presence of underlying pathologic conditions that cause 
renal ischaemia, such as congestive heart failure, high renal state, cirrhosis and renal 
disease predispose the patients to adverse renal effects during NSAID treatment (136, 
152).  Any patient with these risks is highly dependent on prostaglandins for renal 
flow.  Renal functional changes induced by NSAIDs, whether asymptomatic or 
accompanied by oedema, are reversible on withdrawal of the drug (136). 
 
2.2.5 Adverse reactions 
NSAIDs are very widely prescribed but they have a poor tolerability profile, with a range of 
potential adverse effects.  NSAIDs that are used in topical formulations have been developed 
in the past 15 years and their use is increasing.  The purpose is to achieve a high local 
concentration of the active ingredient at the effected site, with as low plasma concentration as 
possible to minimise possible systemic adverse effects (169). 
 
The unwanted side effects of ketoprofen are due to inhibition of COX-1, while their 
therapeutic effects are due to inhibition of COX-2 (156, 160).  Most of the ketoprofen 
adverse drug reactions (ADRs) are mild upper gastrointestinal complaints such as nausea, 
dyspepsia or epigastric discomfort.  Less frequent are subjective nervous system symptoms 
(headache, drowsiness and dizziness) and complaints referable to the lower GIT (diarrhoea, 
constipation and flatulence) (131, 136, 137).  The central nervous system (CNS) related side 
effects include headache, vertigo, dizziness, nervousness, tinnitus, depression, drowsiness 
and insomnia.  Hypersensitivity reactions may occur occasionally and include fever, angio-
oedema, bronchospasm and rashes (160, 162).  Some patients may experience visual 
disturbance (160).  Haematological adverse effects of ketoprofen include anaemias, 
thrombocytopenia, neutropenia, eosinophilia and agranulocytosis.  Ketoprofen has been 
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associated with nephrotoxicity such as interstitial nephritis and nephrotic syndrome.  NSAIDs 
may provoke renal failure especially in patients with pre-existing renal impairment.  Fluid 
retention may occur, rarely precipitating heart failure in elderly patients (131, 160, 162, 169, 
170).  Similar to other NSAIDs, ketoprofen can produce increases in blood urea nitrogen and 
serum creatinine concentrations, mostly transient and asymptomatic (137).  Other adverse 
effects include photosensitivity, alveolitis, pulmonary eosinophilia, pancreatitis, Stevens-
Johnson syndrome and toxic epidermal necrolysis.  Induction or exacerbation of colitis has 
also been reported (131, 140, 159, 160).  Deaths caused by ketoprofen are rare and are 
probably mainly due to idiosyncrasy such as anaphylaxis rather than to the pharmacological 
effects of the drug, though occasionally gastrointestinal haemorrhage may have a fatal 
outcome (131). 
 
For topical preparations, delayed hypersensitivity dermatitis may occur at the site of the 
application, but this is uncommon (162, 169).  Cases of contact erythema and photocontact 
dermatitis have also been reported (170).  It is advised that they should not be used on broken 
or inflamed skin (169).  The skin reactions are reversible on discontinuation of therapy (168).  
Cross-sensitisation of topical ketoprofen and other propionic NSAIDs has been reported 
(162). 
 
2.2.6 Toxicology 
Acute studies have been performed in mice, rats, guinea pigs and dogs and oral chronic 
studies in rats, dogs and monkeys.  Rats exhibited toxic effects in the gastrointestinal and 
renal systems, a spectrum consistent with the typical NSAID profile (136).  Dogs were also 
susceptible to ulceration however baboons had only minimal irritation of the gastrointestinal 
tract.  There was no evidence of carcinogenicity or mutagenicity in standard screening assays, 
and the drug appears to have no effect on proteins, or on DNA or RNA synthesis.  No 
embryotoxic or teratogenic effects have been demonstrated for ketoprofen and the drug has 
not been shown to affect foetal or postpartum development (131, 136).  As with other 
NSAIDs, its use during pregnancy should be avoided since increased maternal toxicity and 
dystocic effects have been observed in rats (131, 136, 160). 
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2.2.7 Drug interactions 
i. Aspirin 
Concomitant use of more than one NSAID should be avoided because of increased 
risk of adverse effects (160). 
ii. Warfarin, sulphonylureas and hydantoins 
Ketoprofen is highly protein-bound about 95% (131) 99% (136, 137, 140).  In theory, 
interaction is possible following concomitant use of other protein-bound drugs, for 
example oral anti-diabetic agents, anticoagulants and hydantoins.  In practice, such 
interactions seem extremely rare and there is just a single report of prolongation of the 
prothrombin time and gastrointestinal bleeding occurring in a patient taking several 
drugs following concomitant use of ketoprofen (131, 136). 
iii. Methotrexate, lithium and cardiac glycosides 
Ketoprofen reduced the clearance of methotrexate, lithium and cardiac glycosides 
leading to increased plasma concentrations (131, 136, 160). 
iv. Furosemide and angiotensin converting enzyme (ACE) inhibitors 
Like other NSAIDs, ketoprofen slightly inhibits the sodium diuresis induced by 
furosemide and other diuretics.  It may increase the risk of hyperkalaemia with 
potassium-sparing diuretics and ACE inhibitors (131, 160, 161). 
v. β-blockers 
Ketoprofen may reduce the antihypertensive effect of β-blockers (131). 
vi. Probenecid 
The effects of probenecid on ketoprofen pharmacokinetics were investigated.  
Increases in the concentration of ketoprofen and its conjugates were observed (131). 
vii. Zidovudine 
There may be increased risk of haematotoxicity during concomitant use of zidovudine 
(160, 161). 
The risk of gastrointestinal bleeding and ulceration associated with NSAIDs is increased 
when used with corticosteroids, the antiplatelets clopidogrel and ticlopidine, alcohol, 
bisphosphonate and oxpentifylline (160, 161). 
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2.2.8 Pharmaceutics 
Ketoprofen is currently marketed throughout the world in a variety of forms: capsules, 
tablets, injectable solutions, suppositories and gels (136).  South Africa is the only country 
that markets ketoprofen in tablet dosage forms. 
 
Table 2.3 Ketoprofen formulations 
Route Dosage form Strength 
Oral Tablets 50 mg 
 Enteric coated 100 mg 
 Capsules 50 mg 
  75 mg 
  100 mg 
 Extended (Controlled) Release 100 mg 
  200 mg 
Parenteral Intramuscular 100 mg/2 ml 
Rectal Suppository 100 mg 
Topical Gel 2.5 g/100 g 
 
In the treatment of rheumatic disorders a usual daily dose of ketoprofen by mouth is 100 to 
200 mg in 2 to 4 divided doses, modified-release formulations taken once daily may also be 
used.  In the USA some manufacturers suggest initial oral doses of 75 mg three times daily or 
50 mg four times daily increased as needed to a maximum of 300 mg daily in divided doses. 
Ketoprofen may also be administered rectally as suppositories in a dose of 100 mg at night.  
In the UK it is recommended that the total daily combined dose by mouth and by rectum 
should not exceed 200 mg.  Ketoprofen may be given by deep intramuscular injection into the 
gluteal muscle for acute exacerbation of musculoskeletal, joint, peri-articular and soft tissue 
disorders and in the management of pain following orthopaedic surgery.  Doses of 50 to    
100 mg may be given every 4 hours, up to a maximum dose of 200 mg in 24 hours, for up to 
3 days.  Ketoprofen may be applied as a 2.5% m/m gel for local pain relief.  Doses vary 
slightly between preparations; a typical regimen is application 2 or 3 times daily for up to 10 
days (140).  Gel preparations should not be diluted (134). 
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2.3 PHARMACOKINETICS OF TOPICAL KETOPROFEN 
 
The introduction of a transdermal formulation for an NSAID raises the distinct possibility of 
achieving therapeutic benefit, without the risk of gastrointestinal or other side effects suffered 
by the oral route.  To establish the validity of this hypothesis requires that:  
i. percutaneous absorption occurs in sufficient amounts to achieve therapeutic 
concentrations in the target tissues,  
ii. clinical efficacy is demonstrable in suitably controlled clinical trials,   
iii. the safety profile of the topical agent is superior to that of the oral agent, particularly 
with regard to gastrointestinal side effects and   
iv. the topical agents are cost-effective (162). 
 
The pharmacokinetics of ketoprofen in man after repeated percutaneous administration has 
been investigated and compared to the results obtained after oral administration of ketoprofen 
(163).  In this study, a 2.5% ketoprofen gel formulation was used and was applied over an 
area of 750 cm2 for a period of 15 days.  An average quantity of 375 mg was applied, and 
from the third day onward, the dose was divided into two applications for 10 consecutive 
days and for the remaining two days, only one of the divided doses was administered.  Ten 
subjects (5 men and 5 women) with a mean age of 23.2  ± 2.5 years, a mean weight of  
60.7 ± 9.5 kg and a mean height of 1.70 ± 0.09 m participated in the study.  The peak plasma 
concentrations ( maxC ) obtained were 144 ± 91 ng/ml.  The apparent absorption and 
elimination half-lives calculated respectively were 3.2 ± 2.4 h and 27.7 ± 18.0 h.  The 
apparent total body clearance was 76.5 ± 39.9 l/h and the total quantities of ketoprofen 
eliminated in the urine were 9.7 ± 3.2 mg, representing about 2.6% of the dose applied.  
Although the inter-subject variability of the peak plasma concentration of ketoprofen after 
administration of the gel appears to be equivalent to that observed after oral administration, 
the extreme values for maxC  in this study differed by a factor of 1 to 5 as compared with 1 to 
2.5 or 4 with the oral route.  It reaches maxC  in the first hour of administration if taken orally 
and after six hours if applied topically (135).  The area under the curves were much more 
widely scattered for the gel than for the oral route.  Following cutaneous application of 
ketoprofen gel (375 mg of ketoprofen), the peak plasma concentration was about 100 times 
lower than that observed after administration of an oral dose of 150 mg.  The apparent plasma 
elimination half-life was very much longer than that observed after oral administration (t½ of 
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about 2 h).  This apparent half-life was evaluated more accurately after stopping treatment 
(17.1 ± 9.1 h) than after the first administration (27.7 ± 18.0 h), as reflected by the values 
calculated from both the plasma data and the urinary data (17.2 ± 4.2 h).  In contrast the 
apparent absorption half-life (t½a = 3.2 ± 2.4 h) was similar to the values usually recorded for 
elimination half-life after oral administration.  Comparison of the values for these two 
parameters suggests that percutaneous administration corresponds to a flip-flop phenomenon.  
This phenomenon is observed when the absorption constant is very much smaller than the 
elimination constant, either in the case of very rapidly eliminated drugs or in the case of 
pharmaceutical formulations with very slow release according to the first order process.  In 
this study (163), the dermis may be considered a reservoir from which the absorption of 
ketoprofen would be extremely slow and continuous.  The ketoprofen value of the apparent 
elimination constant is 0.052 ± 0.029 h-1.  The quantity of ketoprofen eliminated in the urine 
in the 48 hours after the first dose only accounted for 2.9% of the dose administered, whereas 
urinary elimination over the same time period accounts for 60% of an oral or intramuscular 
dose.  The relation between these percentages suggests that the bioavailability of the drug in 
gel form would be of the order of 5%. 
 
Another study (164) compared the concentration of ketoprofen in intra-articular adipose 
tissue, capsular tissue and synovial fluid after topical administration in man.  It showed that 
ketoprofen was detected from the second hour and reached its maximum in six hours.  The 
concentration of ketoprofen in the tissues was about one hundred times higher than that found 
in the plasma and the concentration of ketoprofen in the synovial fluid is one hundred times 
higher than in the plasma (164, 168, 173).  Ballerini et al. (164) and Rolf et al. (172) showed 
high concentrations of ketoprofen in intra-articular adipose tissues and in capsular tissue after 
gel and plaster applications respectively. 
 
Pharmacokinetic data has demonstrated that, following percutaneous administration of 
ketoprofen gel, the anti-inflammatory agent penetrates into the general circulation slowly  
(163, 164) and reaches underlying tissues including the synovial fluid (168).  This low 
systemic diffusion, combined with good local tolerance, would ensure an improved systemic 
tolerance for the local treatment of rheumatic conditions (163 - 170).  However, it has been 
suggested that the gel formulation containing 2.5% ketoprofen should be evaluated further 
(166). 
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Ketoprofen is extensively metabolised in the liver.  Only 1% of the dose is excreted 
unchanged in the urine.  The main pathway of metabolism is glucuronic acid conjugation, 
with hydroxylation as a minor pathway (131, 135, 140, 168).  The metabolites are excreted 
mainly in the urine with 80% of the dose as the glucuronide.  10 - 20% of the dose is excreted 
in the bile.  Some enterohepatic circulation is probable.  The metabolic products of 
ketoprofen appear to be pharmacologically inert (131).  Figure 2.10 shows the metabolic 
products of ketoprofen.  
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Figure 2.10 Metabolism of ketoprofen (135)
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CHAPTER THREE 
IN VITRO ANALYSIS OF KETOPROFEN 
 
3.1 DEVELOPMENT AND VALIDATION OF AN HIGH-PERFORMANCE 
LIQUID CHROMATOGRAPHIC METHOD FOR THE DETERMINATION 
OF KETOPROFEN 
 
3.1.1 Method development 
3.1.1.1 Introduction 
 
High-performance liquid chromatography (hplc) is a separation technique based on a solid 
stationary phase and a liquid mobile phase.  Separations are achieved by partition, adsorption, 
or ion-exchange processes depending upon the type of stationary phase used.  Hplc has 
distinct advantages over gas chromatography for the analysis of organic compounds.  
Compounds to be analysed are dissolved in a suitable solvent and most separations take place 
at room temperature.  Thus most drugs, being non-volatile or thermally unstable compounds, 
can be chromatographed without decomposition or the necessity of making volatile 
derivatives (175). 
 
Numerous chromatographic methods have been published for the quantification of ketoprofen 
in different media, serum (178), urine (179), plasma (179), and also in pharmaceuticals (185).  
The amount of drug in these samples was determined using double beam ultraviolet 
spectrophotometry (144, 183, 184, 187), thin-layer chromatography (181), capillary 
electrophoresis (178), gas chromatography (181), electrospray ionization mass spectrometry 
(180) and hplc (141 - 143, 145, 148, 182, 183, 186, 188, 189, 191, 192).  Published analytical 
procedures for determining ketoprofen in topical preparations also include FT-near infrared 
spectroscopy (177) and a solid-phase extraction spectrophotometry (176).  In general, hplc 
has been the most commonly employed method for the measurement of ketoprofen, although 
some published methods present insufficient sensitivity, inadequate reproducibility or 
chromatographic interferences and are not sufficiently sensitive for the determination of 
ketoprofen in topical preparations in the presence of other excipients and also in the presence 
of potential degradation products (190). 
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A simple, rapid and sensitive method with a relatively simple and robust sample preparation 
was required to analyse dissolution, stability and content uniformity of batches.  Previously 
published methods shown in Table 3.1 were used as initial studies for the development of a 
rapid and specific hplc method for the analysis of ketoprofen. 
 
3.1.1.2 Experimental 
3.1.1.2.1 Reagents 
All reagents used were of analytical grade.  Ketoprofen (K1751) was donated by Sigma-
Aldrich (Atlasville, South Africa).  Acetonitrile 200 far uv ROMIL-SpS™ Super Purity 
Solvent and Methanol 215 ROMIL-SpS™ Super Purity Solvent were purchased from 
ROMIL Ltd. (Cambridge, United Kingdom).  Acetic acid glacial, sodium hydrogen pellets, 
potassium dihydrogen orthophosphate and ortho-phosphoric acid 85% v/v were obtained 
from MERCK (Wadeville, South Africa). 
 
Hplc grade water was obtained from a Milli-Q® Academic A10 water purification system 
(Millipore, Molsheim, France) that consists of a Quantum™ EX ultrapure organex cartridge 
and a Q-Gard™ purification pack.  The water was filtered through a 0.22 μm Millipak stack 
filter prior to use. 
 
3.1.1.2.2 Instrumentation 
The apparatus consisted of a binary pump solvent delivery system (SpECTRASERIES P100), 
an ultraviolet-visible (UV-Vis) variable wavelength detector (Spectra 100) and an integrator 
(SP 4290) all from Spectra-Physics Inc. (California, USA).  Samples were introduced into a 
Rheodyne 7120 20 μl fixed-loop injector from Catati (California, USA) with a 100 μl glass 
syringe (710 NR) from Hamilton Bonaduz AG (Bonaduz, Switzerland).  Chromatographic 
separation was performed on a partition 5 μm pore size, 4.0 mm x 250 mm Waters 
Spherisorb® C18 stainless steel analytical column from Waters Corporation (Massachusetts, 
USA) fitted with a 5 μm pore size, 4.6 mm x 30 mm Spheri-5 RP-18 guard column from 
Perkin Elmer Instruments (Norwalk, USA). 
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Table 3.1 Initial hplc studies employed in the method development for the analysis of ketoprofen 
Stationary Phase Mobile Phase Wavelength 
(nm) 
Flow rate 
(ml/min) 
Retention time 
(mins) 
Internal 
Standard 
Reference 
Shim-Pack C18 
(250 x 4.5 mm, 5 µm) 
Methanol: 100 mM acetic acid 
(80:20) 
255 1.5 3.2  141 
Silica gel C18 Methanol: Water (85:15) 254 0.8   142 
Reverse-phase C18 Acetonitrile: Water (80:20) with 
50 µl phosphoric acid 
254 1.0   143 
Eurospher C8  
(250 x 4 mm, 5 µm) 
Acetonitrile: phosphate buffer  pH 
7.5 (15:85) 
262    145 
Kromasil 100 C18 
(250 x 4 mm, 5 µm) 
Acetonitrile: 10 mM phosphate 
buffer pH 1.5 with orthophosphoric 
acid (60:40) 
260 1.0  Ibuprofen 148 
Phenomenex Luna C18 (250 x 
4.6 mm, 5 µm) 
Acetonitrile: Methanol: Water 
(36:54:10)  
265 1.2 2.3 Propylparaben 182 
Zorbax ODS 
(150 x 4.6 mm) 
Acetonitrile: 50 mM phosphate 
buffer pH 2.5 with glacial acetic acid 
(45:55) 
265 1.2 5.5 Flurbiprofen 182 
Microsorb-MV C18 
(150 x 4.6 mm, 5 μm)  
Acetonitrile: 5 mM phosphate buffer 
pH 3.0 with glacial acetic acid 
(60:40) 
254 1.0 4.5 Ibuprofen 183 
Phenomenex Kingsorb C18 
(250 x 4.6 mm, 5 µm) 
Acetonitrile: 20 mM phosphate 
buffer pH 3 (45:55) 
258 1.0 6.8  186 
Alltech Alltima C18 
(150 x 4.6 mm, 3 μm) 
Acetonitrile: 20 mM pH 4 acetate 
buffer (55:45) 
256 1.0 5.2  188 
Lichrosorb RP-18 
(150 x 4.6 mm) 
Acetonitrile: 20 mM phosphate 
buffer pH 3.0 (35: 65) 
256 1.0   189 
Nucleosil 100-5C18 
(250 x 4 mm, 5 μm) 
Acetonitrile: phosphate buffer  pH 
5.0 (40:60) 
260 1.0   191 
Shim-Pack C18 
(150 x 4.6 mm, 5 μm) 
Acetonitrile: 10 mM phosphate 
buffer pH 7.0 (24:76) 
258 1.0 7.7 Naproxen 192 
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3.1.1.2.3 Ultraviolet detection 
Detection by ultraviolet (uv) absorption is a convenient and effective technique that is readily 
combined with hplc.  Uv spectrophotometers have a high sensitivity for many solutes but 
samples must absorb in the uv or visible region (190 - 600 nm) to be detected.  It is the most 
commonly described method of detection for the analysis of ketoprofen in the literature (141 
- 143, 145, 148, 182, 183, 186, 188, 189, 191, 192).  There are essentially three types of uv 
detectors available that can be used with hplc namely fixed, multi-wavelength and variable 
wavelength detectors (175).   A variable wavelength detector was employed in this laboratory 
for the analysis of ketoprofen.  This type of detector permits a wavelength to be chosen where 
the solute absorbance is maximal and little interference is observed from additional solutes or 
the mobile phase.  The absorption maximum of ketoprofen was measured at 255 nm.  
Published methods for the analysis of ketoprofen vary considerably, utilising wavelengths 
from 254 to 265 nm, but many of these methods are not only optimised for the detection of 
ketoprofen but for the presence of other excipients such as preservatives.  The ability of the 
uv source to generate the required wavelength is important, particularly if impurities related 
to the solute are present and any error in wavelength may not be consistent over the range of 
the detector (193). 
 
3.1.1.2.4 Column selection 
The column is the heart of hplc separation processes.  The availability of a stable, high-
performance column is essential in developing a rugged, reproducible method.  Commercial 
columns differ widely between suppliers and even between supposedly identical columns 
from a single source.  Such differences can have a serious impact on developing the desired 
hplc method.  Specifically, different columns can vary in plate number, band symmetry, 
retention, band spacing and lifetime (194). 
 
Most column packings used for hplc separations make use of a silica particle or support 
although there are columns that can be packed with porous-polymer supports.  Totally porous 
microspheres are most commonly used because of the favourable compromise of desired 
properties such as efficiency, sample loading, durability, convenience and availability.  
Micropellicular particles have a solid core with a very thin outer skin of interactive stationary 
phase.  These silica- or polymer-based particles, usually available in 1.5 to 2.5 μm sizes, 
display outstanding efficiency for macromolecules because of fast mass transfer kinetics but 
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have limited sample load characteristics because of low surface areas and thus are best suited 
for analysis only.  They are also very useful in guard columns.  Perfusion particles contain 
very large pores (e.g., 4000 to 8000 Å) throughout the support and also include a network of 
smaller interconnecting pores (e.g., 300 to 1000 Å) between these large throughpores.  
Experiences with these particles are still limited, however applications appear to be best 
suited for the preparative isolation of macromolecules such as proteins.  Particle size is very 
important in hplc.  Particle diameters of about 5 μm represent a good compromise for 
analytical columns in terms of column efficiency, backpressure and lifetime.  It is worth 
noting that smaller diameters such as 3 μm are available for faster separations and 1.5 μm for 
extremely rapid separations of macromolecules such as proteins (194). 
 
Bonded phase columns are the most commonly used and these can be polar or non-polar.  
Non-polar bonded phases are used for partition hplc with polar solvents such as water, 
buffers, methanol and acetonitrile, while polar bonded phases are used in adsorption hplc 
usually with non-polar mobile phases.  Non-polar bonded silica is frequently used as it is 
extremely stable and octadecasilane (Si(CH2)17CH3) is the most common bonded phase.  
Partition chromatography is similar to the extraction of different molecules from water into 
an organic solvent such as octanol, where more hydrophobic (non-polar) compounds 
preferentially extract into the non-polar octanol phase.  The column (typically a silica support 
modified with a C8 or C18 bonded support) is less polar than the water-organic mobile phase.  
Molecules partition between the polar mobile phase and non-polar C8 or C18 stationary phase 
and more hydrophobic (non-polar) compounds are retained more strongly (195). 
 
The choice of the bonded phase will depend on the properties of the solute.  As the 
separations obtained in hplc depend on the interactions between the solute, the bonded phase 
and the mobile phase, then the polarity of all three must be considered.  Polar compounds are 
readily analysed by partition hplc and their retention time will depend on the degree to which 
they interact with the bonded phase which is influenced by molecular weight, ionisable 
groups and solubility of the solute.  The most commonly used columns reported for the 
analysis of ketoprofen are octadecasilyl C18 (141 - 143, 148, 182, 183, 186, 188, 189, 192) 
and octylsilane C8 (145). 
  
To prolong the life of analytical columns, guard columns can be inserted between the sample 
valve and the analytical column.  The guard column captures the strongly retained sample 
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components and prevents them from contaminating the analytical column.  Guard columns 
are usually relatively short (5 - 10 cm) and contain a stationary phase equivalent to that in the 
analytical column.  These guard columns are replaced at required intervals to ensure constant 
performance of the more expensive analytical column (194). 
 
3.1.1.2.5 Mobile phase selection 
The design of a successful hplc separation depends on matching the right mobile phase to a 
given column and sample.  Solvents used should be readily available, compatible with the 
detector, safe to use, pure and relatively unreactive.  The solvent should be able to dissolve 
the sample.  In cases where a photometric detector is used for detection, it is important to 
know the lowest wavelength at which the solvent transmits significant energy.  Acetonitrile 
and methanol, the two commonly used solvents, have ultraviolet cut-off wavelength values of 
190 and 205 nm respectively when highly purified.  Many solvents are ruled out for most 
applications because of their tendency to react with the sample, or undergo polymerization in 
the presence of certain stationary phases.  It is usually preferable that solvents boil at  
20 - 50°C above the temperature of the column.  Lower boiling solvents are difficult to use 
with reciprocating pumps, since they tend to form bubbles in the piston chamber, which 
adversely affect pumping precision and in extreme cases, lead to loss of pumping prime.  
Furthermore, the composition of mixtures of such solvents can readily change due to 
evaporation.  Higher boiling solvents are usually excessively viscous, which reduces 
separation efficiency and results in higher back pressure (196). 
 
The use of a mobile phase that interacts with the selected stationary phase can alter the 
properties or integrity of the stationary phase.  The pH of mobile phases should be within  
2 - 8 as hydrolysis of the bonded phase or dissolution of silica may occur.  The mobile phase 
should be degassed before use to minimise the presence of oxidative species which can react 
with the drug of interest and also to reduce possible mechanical damage in relation to the 
pumping mechanism of the hplc system. 
 
 The initial mobile phases used were based on published data as shown in Table 3.1.  The 
mobile phases used during method development and the corresponding retention times of 
ketoprofen are reported in Table 3.2 below.  Where necessary, the pH correction was 
achieved with glacial acetic acid. 
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Table 3.2 The effect of mobile phase composition on the retention time of ketoprofen 
Reference Mobile phase composition Retention time 
(mins) 
Comment 
142 Methanol: Water (85:15) 2.72 Peak tailing barely resolved 
from solvent front. 
143 Acetonitrile: Water (80:20) with  
50 µl phosphoric acid 
2.70 Sharp peak barely resolved 
front solvent front with peak 
tailing. 
182 Acetonitrile: Methanol: Water 
(36:54:10) 
2.35 No solvent front and 
excessive peak tailing. 
182 Acetonitrile: 50 mM phosphate 
buffer pH 2.5 (45:55) 
7.76 Sharp peak, well resolved 
from solvent front. 
183 Acetonitrile: 5 mM phosphate buffer 
pH 3.0 (60:40) 
4.22 Sharp peak, with peak tailing. 
186 Acetonitrile: 20 mM phosphate 
buffer pH 3 (45:55) 
8.80 Sharp peak, well resolved 
from solvent front. 
188 Acetonitrile: 20 mM phosphate 
buffer pH 4 (55:45) 
5.11 Sharp peak, well resolved 
from solvent front. 
192 Acetonitrile: 10 mM phosphate 
buffer pH 7.0 (24:76) 
5.88 Broad peak. 
 
Sharp peaks that were well resolved from the solvent front were observed with mobile phases 
comprising acetonitrile and phosphate buffer at low pH values.  The mobile phase 
composition selected for further development and validation was acetonitrile and 20 mM 
phosphate buffer at pH 4.0 in a ratio of 55:45 because it was reported to have sharp peaks 
which were well resolved from the solvent front.  It was noted that, although well resolved, 
sharp peaks were obtained from some of the mobile phases shown in Table 3.2, mobile 
phases should however be optimised to produce peaks with shorter retention times.  Mobile 
phase selection was based on peak parameters (symmetry, tailing), run time, ease of 
preparation and cost. 
 
3.1.1.2.6 Preparation of selected mobile phase 
The buffer solution was prepared by weighing accurately 1.3609 g of potassium dihydrogen 
orthophosphate into a 500 ml A-grade volumetric flask and made up to volume with hplc 
grade water.  The pH was then adjusted to 2.5 using glacial acetic acid.  A Crison GLP 21 
pH-meter from Crison Instruments, (Lasec, South Africa) was used for pH measurements.  
The buffer solution was then combined with acetonitrile in a ratio of 40:60 and filtered 
through a 0.5 µm FH filter from Millipore (Massachusetts, USA) under vacuum with an 
Eyela Aspirator A-2S from Tokyo Rikakikai Co., Ltd (Tokyo, Japan).  The mobile phase was 
prepared daily and was not recycled during use. 
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3.1.1.2.7 Preparation of stock solutions 
Stock solutions of ketoprofen were prepared by accurately weighing approximately 10 mg 
into an A-grade 100 ml volumetric flask and made up to volume with 0.2 M phosphate buffer 
at pH 6.8 prepared with hplc grade water.  Standards ranging in concentration from 0.5 - 15.0 
µg/ml were prepared by serial dilution of this stock solution using A-grade glassware. 
 
3.1.1.3 Optimisation of the chromatographic conditions 
3.1.1.3.1 Detector wavelength (λ) 
Published methods from the literature, shown in Table 3.1, used different wavelengths for the 
analysis of ketoprofen.  The wavelengths ranged from 255 nm (141), 254 nm (142, 143, 183), 
256 nm (188, 189), 258 nm (186, 192), 260 nm (148, 191), 262 nm (145) and 265 nm (182).  
It is possible that the wavelengths of some methods were adjusted to accommodate the 
presence of excipients and other actives that may be present in the formulation.  
Consequently, the effect of different wavelengths on peak area was investigated. 
 
Table 3.3 Effect of wavelength on the relative percent  peak area of ketoprofen 
Concentration (μg/ml) 254 nm 255 nm 260 nm 265 nm 
0.5025 92.05 100 88.98 89.94 
1.0050 93.19 100 83.33 98.74 
5.0250 80.08 100 85.58 96.91 
10.050 96.85 100 83.31 89.88 
20.100 79.73 100 85.83 93.25 
Average 88.38 100 85.41 93.74 
Standard Deviation 7.94 0 2.33 4.02 
% RSD 8.98 0 2.73 4.29 
 
The results, as shown in Table 3.3, indicated that concentration was optimal at 255 nm, with 
decreasing concentration through 254 nm, 260 nm and 265 nm.  Based on the results of this 
experiment, 255 nm was chosen as the wavelength of detection. 
 
3.1.1.3.2 Choice of column 
A partition 5 μm pore size, 4.0 mm x 250 mm Waters Spherisorb® C18 stainless steel 
analytical column from Waters Corporation (Massachusetts, USA) was selected for the 
analysis of ketoprofen.  Ketoprofen is a weak acid and is soluble in the aqueous-organic 
mobile phase combination, thus the retention time is expected to be short with a non-polar 
stationary phase, as ketoprofen will partition preferentially into the mobile phase.  This is 
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desirable as rapid and selective analysis of ketoprofen in single component dosage forms was 
required. 
 
3.1.1.3.3 Mobile phase composition 
Manipulation of mobile phase composition is undoubtedly the most powerful means for 
adjusting both absolute and relative retentions in chromatography, particularly partition hplc.  
Not only can the water content be adjusted, but the nature of the organic modifier such as 
methanol, acetonitrile and tetrahydrofuran can also be changed.  It is also possible to control 
the pH and ionic strength of the eluent, which has a large effect on the chromatographic 
behaviour of ionic compounds (197).  As mentioned previously the mobile phase selected for 
further development comprised acetonitrile and 20 mM phosphate buffer at pH 4.0 in a ratio 
of 55:45.  This mobile phase gave a satisfactory retention time and resolution, however 
further developments were performed to ascertain the effect of pH changes, ratio volumes 
and molarity on the retention time and nature of the peaks. 
 
It was observed that lower pH values produced sharper peaks than higher pH values which 
produced broad peaks with much longer retention times.  Changes in the pH of the mobile 
phase of partition systems will modify the retention time of weak acids and bases, as the 
unionised species is retained longer, being less polar (197).  A pH value of 2.5 of the buffer 
was chosen.  It was however noted later that the pH of the overall mobile phase was 3.9 
which was well within the range of pH values of 2.0 - 8.0 thus not compromising the stability 
of the stationary phase.  High concentrations of buffer salts are undesirable as there is a 
potential for precipitation with subsequent damage to pump heads, seals and pistons and 
blockages with consequent increases in back pressure.  No statistically significant differences 
(p > 0.05, ANOVA) on the retention times were noted when the molarity of the buffer was 
altered.  20 mM was chosen as the optimum concentration as no apparent damage to the 
binary pump was observed.  Changing the content of acetonitrile in the mobile phase 
produced significant changes in the retention time.  Increasing the volume of acetonitrile 
produced sharp peaks which eluted quickly and in some cases were barely resolved from the 
solvent front.  Ketoprofen becomes more soluble in the mobile phase with higher acetonitrile 
content and partitioned less in the stationary phase.  The optimum content of acetonitrile 
should be one that elutes the peaks within a relatively short time but well resolved from the 
solvent front so that multiple analyses can be performed as rapidly as possible especially 
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where manual injection of samples is employed.  The ratio of the final mobile phase was 
changed to 60% acetonitrile and 40% phosphate buffer at pH 2.5 to produce a well resolved 
peak with a retention time of 4.0 minutes. 
 
3.1.1.4 Chromatographic conditions 
The optimal chromatographic conditions established during the method development are 
summarised below in Table 3.4 and Figure 3.1 shows a typical chromatogram obtained from 
the analysis of a standard solution of ketoprofen using the method described above. 
 
Table 3.4 Optimal chromatographic conditions applied 
Parameter Conditions applied 
Mobile phase 60% acetonitrile: 40% 20 mM phosphate buffer at pH 2.5  
Flow rate 1.0 ml/min 
Detection wavelength 255 nm 
Sensitivity 0.2 AUFS 
Injection volume 20 μl 
Retention time 4.0 mins 
Temperature Ambient 
 
 
Figure 3.1 Typical chromatogram of a standard solution of ketoprofen at 10 µg/ml obtained using the 
chromatographic conditions specified 
 
3.1.1.5 Conclusion 
The effects of altering system variables on the elution of ketoprofen were established in these 
preliminary investigations.  By optimising the choice of mobile phase, detection wavelength 
and analytical column, an hplc method which provided well resolved symmetrical peaks, 
suitable retention times and minimal baseline noise was developed. 
 66 
3.1.2 Method validation 
3.1.2.1 Introduction 
Validation of analytical methodologies is widely accepted as pivotal before they are put into 
routine use (213, 214).  A method must be tested for effectiveness and must be appropriate 
for the particular analysis to be undertaken (198).  Method validation is defined as the process 
of proving, through scientific studies, that an analytical method is acceptable for its intended 
use (213, 199) and it instils confidence that the method can generate test data of acceptable 
quality (202). 
 
Recent guidelines for methods development and validation for new non-compendial test 
methods are provided by the FDA draft document, ‘Analytical Procedures and Method 
Validation: Chemistry, Manufacturing and Controls Documentation’ (200).  In recent years, a 
great deal of effort has been devoted to the harmonization of pharmaceutical regulatory 
requirements in the United States, Europe and Japan.  As part of this initiative, the 
International Conference on Harmonization (ICH) has issued guidelines for analytical method 
validation.  The recent FDA methods validation draft guidance document as well as the 
United States Pharmacopoeia (USP) (201) both refer to the ICH guidelines (199). 
 
The validation process may vary slightly between laboratories (215), however, a number of 
general tests are usually performed; recovery, accuracy, precision, reproducibility, linearity, 
specificity, limit of detection and quantitation and ruggedness.  Therefore method 
development is complete only when the method has been stringently tested and shown to 
demonstrate acceptable analytical performance (198).  It is important to realise that method 
validation is not a stand-alone process and is rather a part of an overall validation process, 
which includes the validation of the hardware and software being used (installation, operation 
and performance qualifications should be performed for all equipment being utilized) and the 
verification of system suitability and performance (203). 
 
3.1.2.2 Accuracy and bias 
Accuracy is the measure of exactness of an analytical method, or the closeness of agreement 
between the measured value and the value that is accepted either as a conventional, true value 
or an accepted reference value (203).  Bias assesses the influence of the analyst on the 
performance of the method.  Accuracy and bias were determined by injecting three replicate 
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measurements each of three samples of varying concentration.  According to the ICH 
guidelines, the measurements were performed in consecutive and non-consecutive sequences 
(203).  It is desirable to have an injection precision, in terms of area unit relative standard 
deviation (RSD), of less than 2.0% for each standard solution and recovery within 98% and 
102% (204). 
 
Table 3.5 Accuracy test results on blinded samples 
Concentration 
(μg/ml) 
Mean experimental 
concentration 
(μg/ml) 
Standard 
deviation 
RSD 
(%) 
Recovery 
(%) 
Bias 
(%) 
4.95 4.97 0.01 0.29 100.40 -0.40 
9.90 9.85 0.04 0.36 99.49 0.51 
14.85 14.87 0.01 0.10 100.13 -0.13 
 
The accuracy results shown in Table 3.5 were within the limits indicating that the analytical 
method was accurate for the determination of ketoprofen. 
 
3.1.2.3 Precision 
Precision quantifies the variability of an analytical result as a function of operator, method 
manipulations and day-to-day environment (205).  It is also the measure of the degree of 
repeatability of an analytical method under normal operation and is expressed as the percent 
RSD for a statistically significant number of samples (201).  Precision experiments give a 
good indication of the performance of the method and should be repeated regularly.  
Generally, any increase of the RSD above 2.0% should be investigated (198).  According to 
ICH, three types of precision can be defined and should all be assessed as described below. 
 
3.1.2.3.1 Repeatability 
Repeatability refers to the results of the method operating over a short time interval under the 
same conditions (inter-assay precision).  It expresses the degree of variation arising during 
replicate assays performed consecutively and non-consecutively but on the same day.  
Repeatability should be determined from a minimum of nine determinations covering the 
specified concentration range of the procedure (203). 
 
 68 
Table 3.6 Inter-day (repeatability) assessment on five concentrations  
Concentration  
(μg/ml) 
Mean peak area 
)3( =n  
Standard deviation % RSD 
1.025 5670.67 19.22 0.34 
2.050 11633.33 30.44 0.26 
5.125 26639.00 130.05 0.49 
10.250 52417.33 41.02 0.08 
20.500 103074.00 205.67 0.20 
 
The inter-day assay results shown in Table 3.6 were within the limits indicating that there 
was minimum variation of the analytical method with respect to the analyst and the 
equipment for the determination of ketoprofen. 
 
3.1.2.3.2 Intermediate precision (ruggedness) 
Intermediate precision refers to the results from laboratory variations due to random events 
such as differences in experimental periods, analysts and equipment (203).  Intermediate 
precision was expressed in this laboratory on three different days with respect to the analyst 
and the equipment.  Three replicates of the five standards analysed below were injected over 
a three day period and collected as the intra-day data. 
 
Table 3.7 Intra-day assessment of five concentrations 
Concentration  
(μg/ml) 
Mean peak area 
)3( =n  
Standard deviation % RSD 
1.025 5335.44 14.18 0.27 
2.050 11432.78 177.14 1.55 
5.125 25995.67 730.42 2.81 
10.250 51307.00 1542.81 3.01 
20.500 101433.56 2801.00 2.76 
 
The intra-day assay results shown in Table 3.7 produced percent RSD values greater than 
0.2% but less than 3.1%.  Although there was no evidence of official acceptance criteria or 
figures of merit found for intermediate precision these values were acceptable based on the 
literature (206 - 210). 
 
3.1.2.3.3 Reproducibility 
Reproducibility is an indication of the ability of the method to be transferred from one 
laboratory to another.  This was not assessed. 
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3.1.2.4 Specificity and selectivity 
A method is specific if it produces a response for only one single solute.  Since it is almost 
impossible to develop a chromatographic assay for a drug in a matrix that will respond to 
only the compound of interest, the term selectivity is more appropriate (214).  Selectivity 
describes the ability of an analytical method to differentiate various substances in the sample 
and is applicable to methods in which two or more components are separated and quantitated 
in a complex matrix (211).  It is a measure of degree of interference from such things as other 
active ingredients, excipients, impurities and degradation products, ensuring that a peak 
response is due only to a single component, i.e., that no co-elution exists (203).  Specificity 
was assessed by analysing a 2.5% m/m ketoprofen proprietary gel product (Fastum®, South 
Africa) and a placebo extemporaneous gel formulation in 0.2 M phosphate buffer at pH 6.8 
after exposing it to light for two hours. 
 
 
Figure 3.2 Chromatographic representation of a buffered solution of Fastum® gel formulation after 
exposure to light 
 
The chromatogram shown in Figure 3.2 indicated that the hplc method developed was 
specific for the analysis of ketoprofen (peak C) as there were no interferences with either the 
presence of other excipients (peak A and B) in the proprietary gel product or degradation 
products (peak D) in solution.  Analysis of an extemporaneous placebo gel formulation 
showed no peak at the retention time of 4.0 minutes.  The retention time of the primary peak 
in the chromatogram of the proprietary gel formulation is the same as the retention time of 
the ketoprofen peak in the standard, indicating specificity of the procedure. 
 
3.1.2.5 Limit of detection and limit of quantitation 
The USP requires that the limit of detection (LOD) and the limit of quantitation (LOQ) be 
determined for studies that involve the detection and quantitation of components at or near 
trace levels.  Such studies include purity testing of active pharmaceutical ingredients, stability 
testing of dosage forms and the analysis of manufacturing equipment cleaning validation 
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samples (212).  For many pharmaceutical applications the LOQ is generally a more useful 
parameter than the LOD (211).  The LOD is defined as the lowest concentration of a solute in 
a sample that can be detected, though not necessarily quantitated and the LOQ is defined as 
the lowest concentration of a solute in a sample that can be determined with acceptable 
precision and accuracy under the stated operational conditions of the method (203, 214).  
Four techniques have been outlined by Paino et al. (212) for the determination of LOD and 
LOQ values of an hplc method.  The lowest concentration for which RSD is less than 5% was 
the method employed in the determination of LOD and LOQ.  This method involves 
choosing the LOQ as the lowest concentration for which the RSD of multiple injections is 
less than 5% and by convention, the LOD value is taken as LOQ×3.0 . 
 
Table 3.8 Limit of quantification values assessed 
Concentration 
(μg/ml) 
Mean peak area 
)3( =n  
Standard deviation % RSD 
0.5075 2584.67 8.50 0.33 
0.4060 2048.67 6.35 0.31 
0.3045 1537.33 11.68 0.76 
0.2030 1007.33 4.16 0.41 
0.1015 502.33 29.87 5.95 
 
The LOQ was found to be 0.2 μg/ml which had a percent RSD value of 0.41% and therefore 
by convention the LOD value is taken to be 0.06 μg/ml.  It is worth noting that the LOD is 
not a very stable characteristic because of its susceptibility to minor changes in the conditions 
of the analytical method like temperature, purity of reagents, sample matrices and 
instrumental system changes.  For this reason the LOD concentration level should not be 
included in the calibration curve (214). 
 
3.1.2.6 Linearity and range 
Linearity defines the analytical response as a function of solute concentration and range 
prescribes a region over which acceptable linearity, precision and accuracy are achieved 
(205).  Linearity is generally reported as the variance of the slope of the regression line.  
Range is the interval between the upper and lower concentrations of solute that have been 
demonstrated to be determined with precision, accuracy and linearity using the method.  The 
ICH guidelines specify a minimum of five concentrations, along with certain minimum 
specified ranges (203).  A calibration curve was constructed over the concentration range  
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0.5 - 15 μg/ml by linear regression of the peak areas obtained versus the concentration. 
Three replicate determinations of each of five concentrations were used.  The calibration 
curve shown in Figure 3.3 was linear over the concentration range studied with 9999.0² =r .  
The equation of the regression line is 71.8189.4856 += xy . 
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Figure 3.3 Calibration curve of ketoprofen 
 
3.1.2.7 Sample solution stability 
In order to design a chromatographic system for the analysis of an active component of a 
pharmaceutical product it is essential to have a good knowledge of susceptibility of the drug 
to degradation and its degradation pathway, assay interference by possible degradants or 
synthesis precursors and assay interference by chemicals employed in sample preparation and 
excipients present in the formulation (198).  The aim of a stability test is to detect any 
degradation of the solute of interest during the entire period of sample collection, processing, 
storing, preparing and analysis (214).  The stability of a 10 µg/ml solution of ketoprofen was 
evaluated under two storage conditions over a period of five days.  The results were 
expressed as percent peak area relative to initial (recovery).  Although a recovery of 100% is 
most desirable, in practice solute recoveries higher than 70% with a variation of 15% are 
accepted (214). 
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Figure 3.4 Curves of ketoprofen aqueous solution (10 μg/ml) stability stored in the dark at 4°C and on 
exposure to light at 25°C analysed by hplc 
 
Figure 3.4 shows that the sample solutions were stable when stored in the dark at 4°C but 
were found to be photolabile in the presence of light.  Ketoprofen was less stable on exposure 
to light at 25°C with a degradation of 81.9% on the second day.  All samples were stored in 
vials wrapped with aluminium foil and kept in the fridge.  Bempong et al. (190) reported that 
there were no significant changes in the chromatograms obtained with ketoprofen subjected 
to oxidative, heat, acid or base stress, when compared to the chromatograms obtained with 
the non-stressed samples. 
 
3.1.2.8 Conclusion 
This report presents development and validation of a simple isocratic hplc procedure suitable 
for the analysis of ketoprofen in solution.  The current hplc procedure separated the 
excipients and potential degradant peaks from the ketoprofen peak and has been 
demonstrated to be sufficiently accurate, specific, precise and stability indicating. 
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3.2 DEVELOPMENT AND VALIDATION OF AN ULTRAVIOLET 
SPECTROPHOTOMETRIC METHOD FOR THE DETERMINATION OF 
KETOPROFEN 
 
3.2.1 Method development 
3.2.1.1 Introduction 
The technique of ultraviolet-visible spectroscopy is one of the most frequently employed in 
pharmaceutical analysis.  It involves the measurement of the amount of ultraviolet-visible 
(190 - 600 nm) radiation absorbed by a substance in solution.  Instruments which measure the 
ratio, or a function of the ratio, of the intensity of two beams of radiation in the ultraviolet-
visible region are called ultraviolet-visible spectrophotometers.  Absorption of radiation in 
both the ultraviolet and visible regions of the electromagnetic spectrum occurs when the 
energy of the radiation matches that required to induce in the molecule an electronic 
transition and its associated vibrational and rotational transitions.  It is therefore convenient to 
consider the techniques of ultraviolet spectrophotometry and visible spectrophotometry 
together (216). 
 
The use of ultraviolet spectrophotometry as an analytical procedure has become less popular 
due to the advent of more sophisticated techniques such as chromatographic separation 
techniques resulting in limited literature been available for the determination of ketoprofen in 
pharmaceutical formulations.  Nevertheless there are some publications that have used 
ultraviolet spectrophotometry in the analysis of ketoprofen (144, 183, 184, 187).  An attempt 
was made to develop and validate an ultraviolet absorption spectrophotometric method for 
the determination of ketoprofen in transdermal formulations and compare the outcomes to 
those obtained from hplc. 
 
3.2.1.2 Principles of ultraviolet-visible absorption spectroscopy 
3.2.1.2.1 Beer-Lambert law 
When a beam of radiation is passed through a transparent cuvette containing a solution of an 
absorbing substance, reduction of the intensity of the radiation may occur (216).  The 
reduction is due in part to reflections at the surfaces and to scattering by any suspended 
particles present but in clear liquids is primarily accounted for by the absorption of radiation 
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by the liquid (220).  The Beer-Lambert law states that successive increments in the number of 
identical absorbing molecules in the path of a beam of monochromatic radiation absorb equal 
fractions of the radiation traversing them.  Equation 3.1 expresses the mathematical 
relationship between the absorbance A  of a 1 g/1000 ml solution, the incident radiation oI , 
the transmitted radiation TI , the absorptivity a , the pathlength of the cuvette  b  and the 
concentration of the solute c . 
 
abc
I
IA
T
o == log  (3.1) 
 
The absorptivity is a characteristic of a particular combination of solute and solvent for a 
given wavelength.  The name and value of a  depend on the units of concentration. When c  
is in moles per litre, the constant is called the molar absorptivity and has the symbol ε  
expressed in equation 3.2. 
  
bcA ε=  (3.2) 
 
It must be noted that absorptivity is a property of a substance (an intensive property), while 
absorbance is a property of a particular sample (an extensive property) and will therefore vary 
with the concentration and dimensions of the container.  The absorbance A  or the 
absorptivity a  is useful as a measure of the degree of absorption of radiation.  The molar 
absorptivity ε  is preferable if it is desired to compare quantitatively the absorption of various 
substances of known molecular mass (220).  Another form of the Beer-Lambert 
proportionality constant is the specific absorbance as outlined in the British Pharmacopoeia 
(226), which is the absorbance of a specified concentration in a cuvette of specified 
pathlength.  The most common form in pharmaceutical analysis is the A (1%, 1 cm), which is 
the absorbance of a 1 g/100 ml (1% m/v) solution in a 1 cm cuvette (216). 
 
The Beer-Lambert law indicates that the absorptivity is a constant independent of 
concentration, length of path and intensity of incident radiation.  The law provides no hint of 
the effect of temperature, the nature of the solvent or the wavelength.  For much practical 
work temperature effects may be disregarded, especially when the absorption of an unknown 
is directly compared with a standard at the same temperature.  The effect of changing the 
solvent on the absorption of a given solute cannot be predicted in any general way.  The 
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analyst is frequently limited to a particular solvent or class of solvents in which the material 
is soluble, so that the question may not arise.  A further restriction applies particularly to 
work in the ultraviolet range, where many common solvents absorb radiation.  Even at 
constant temperature and in a specified solvent, it is sometimes found that the absorptivity 
may not be constant.  If the absorbance A  is plotted against concentration, a straight line 
through the origin should result, according to the prediction of equation 3.1.  Deviations from 
the law are designated positive or negative, according to whether the observed curve is 
concave upward or downward (220).  Deviation from Beer-Lambert law may be observed in 
graphs of absorbance versus concentration (Beer’s Law plot) or of absorbance versus 
pathlength (Lambert’s Law plots).  These deviations may be primarily due to two reasons 
namely the use of non-monochromatic radiation or chemical effects.  A requirement for 
adherence to the Beer-Lambert law is that the radiation incident on the sample is 
monochromatic.  In normal circumstances, radiation of spectral bandwidth less than one-tenth 
the natural bandwidth of the substance, gives linear Beer’s Law and Lambert’s Law graphs if 
stray light is absent.  If, however, the radiation incident on the sample is insufficiently 
monochromatic due to the presence of stray light or the use of a wide slitwidth and if the 
absorptivity of the substance at these extraneous wavelengths is less than that at the nominal 
wavelength of measurement, the measured absorbance will be less than the true absorbance 
and negative deviation from linearity, particularly at high absorbances, will be observed in 
Beer’s Law and Lambert’s Law plots.  Conversely, if the absorptivity at the extraneous 
wavelengths is greater than that at the wavelength of measurement, then a positive deviation 
will be observed.  Deviation from the Beer-Lambert Law may also occur if the substance 
undergoes chemical changes (e.g., dissociation, association, polymerization, complex 
formation) as a result of the variation of concentration (216) and the law only holds for very 
dilute solutions.  Once a curve corresponding to equation 3.1 is established for the material 
under specified conditions, it may be used as a calibration curve.  The concentration of an 
unknown may then be read off from the curve as soon as its absorbance is found by 
observation (220). 
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3.2.1.3 Experimental 
3.2.1.3.1 Reagents 
All reagents used were of analytical grade.  Ketoprofen (K1751) was donated by Sigma-
Aldrich (Atlasville, South Africa).  Sodium hydrogen pellets and potassium dihydrogen 
orthophosphate were obtained from MERCK (Wadeville, South Africa). 
 
3.2.1.3.2 Instrumentation 
The ultraviolet spectrophotometric analysis was performed on a double beam (GBC UV-
Visible 916) spectrophotometer from GBC Scientific Equipment Pty Ltd (Victoria, Australia) 
equipped with a computer station with the appropriate software.  It was equipped with a 
deuterium lamp as the radiation source for measurements in the ultraviolet region.  Samples 
were held in identical 10 mm quartz cuvettes.  The slit width was set at 2 nm with an 
integration time of 1 s. 
 
3.2.1.3.3 Preparation of stock solutions 
Stock solutions of ketoprofen were prepared by accurately weighing approximately 10 mg 
into an A-grade 100 ml volumetric flask and made up to volume with 0.2 M phosphate buffer 
at pH 6.8.  Standards ranging in concentration from 0.5 - 15.0 µg/ml were prepared by serial 
dilution of this stock solution using A-grade glassware. 
 
3.2.1.4 Optimization of spectrophotometric conditions 
3.2.1.4.1 Solvent 
The choice of solvent is governed by the solubility of the absorbing substance and by the 
absorption of the solvent at the analytical wavelength.  Although water is the ideal solvent as 
it is transparent at all wavelengths in the visible and ultraviolet regions above 180 nm, it 
cannot be used as a solvent for the simple reason that ketoprofen is insoluble in water.  
Organic solvents on the other hand are restricted to measurements at wavelengths where the 
solvents are reasonably transparent.  The choice of solvent was based on the receptor fluid 
from the in vitro experiments of the hplc analytical procedure.  A 0.2 M phosphate buffer 
solution at pH 6.8 was chosen as the solvent.  This solvent showed the cut-off wavelength at 
approximately 200 nm making it ideal for the analysis of ketoprofen.  The blank solvent 
without active agent served as a reference in the uv analytical measurements. 
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3.2.1.4.2 Ultraviolet detection 
The absorption maximum of ketoprofen was measured at 255 nm as shown in Figure 2.7 in 
the chosen solvent.  This wavelength was used in the analysis of ketoprofen. 
 
3.2.1.4.3 Concentration of solute 
The intensity of radiation transmitted by an absorbing solution will show small random 
fluctuations due to small variations in the radiation source intensity, detector and amplifier 
noise.  Consequently, every absorbance value will have a small random error associated with 
it.  For modern instruments equipped with a phototube detector, it may be shown that the 
relative error is at a minimum when absorbance is 0.869.  The optimum accuracy and 
precision are therefore obtained when the absorbance is around 0.9.  However, in practice 
absorbances in the range 0.3 to 1.5 are sufficiently reliable and the concentration of the solute 
should be adjusted to give an absorbance within this range (216).  Sample solutions of higher 
concentrations were diluted where necessary with solvent to produce absorbance readings of 
less than 1. 
 
3.2.1.4.4 Spectrophotometric conditions 
The optimal spectrophotometric conditions established during the method development are 
summarised below in Table 3.9. 
 
Table 3.9 Optimal spectrophotometric conditions applied 
Parameter Settings employed 
Measurement mode Absorbance 
Solvent 0.2 M phosphate buffer at pH 6.8 
Wavelength 255 nm 
Integration time 1.0 s 
Slit width 2.0 nm 
Beam mode Double beam 
 
3.2.1.5 Conclusion 
The effects of altering system variables on the detection of ketoprofen were established in 
these preliminary investigations.  By optimising the choice of the solvent, detection 
wavelength and concentration of the solute, an ultraviolet spectrophotometric method was 
developed. 
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3.2.2 Method validation 
The conditions outlined below have been previously addressed in sections 3.1.2.2 - 3.1.2.7. 
 
3.2.2.1 Accuracy and bias 
 
Table 3.10 Accuracy test results on blinded samples of ketoprofen by uv analysis 
Concentration 
(μg/ml) 
Mean experimental 
concentration 
(μg/ml) 
Standard 
deviation 
RSD 
(%) 
Recovery 
(%) 
Bias 
(%) 
0.81 0.80 0.01 0.91 98.72 1.28 
7.07 7.09 0.01 0.18 100.26 -0.26 
12.12 11.91 0.15 1.27 98.23 1.77 
 
The accuracy results shown in Table 3.10 were within the limits indicating that the analytical 
method was accurate for the determination of ketoprofen. 
 
3.2.2.2 Precision 
3.2.2.2.1 Repeatability 
 
Table 3.11 Inter-day (repeatability) assessment on five concentrations of ketoprofen by uv analysis 
Concentration 
(μg/ml) 
Mean absorbance 
)5( =n  
Standard 
deviation 
% RSD Absorptivity 
1.01 0.06565 0.00003 0.05 65.00 
2.02 0.13554 0.00019 0.14 67.10 
5.05 0.33338 0.00004 0.01 66.02 
10.10 0.66864 0.00012 0.02 66.20 
15.15 0.99767 0.00014 0.01 65.85 
 
The inter-day assay results shown in Table 3.11 were within the limits indicating that there 
was minimum variation of the analytical method with respect to the analyst and the 
equipment for the determination of ketoprofen. 
 
3.2.2.2.2 Intermediate precision (ruggedness) 
Intermediate precision was determined in this laboratory on three different days with respect 
to the analyst and the equipment.  Five replicates of the five standards analysed below were 
injected over a three day period and collected as the intra-day data. 
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Table 3.12 Intra-day assessment of five concentrations of ketoprofen by uv analysis 
Concentration 
(μg/ml) 
Mean 
absorbance 
)5( =n  
Standard 
deviation 
% RSD Absorptivity 
1.01 0.06512 0.00248 3.80 64.48 
2.02 0.13904 0.00620 4.46 68.83 
5.05 0.33260 0.00310 0.93 65.86 
10.10 0.67383 0.00510 0.76 66.72 
15.15 1.01511 0.01511 1.49 67.00 
 
The intra-day assay results shown in Table 3.12 produced percent RSD values less than 5.0% 
which were acceptable based on literature (206 - 210). 
 
3.2.2.2.3 Reproducibility 
This was not assessed. 
 
3.2.2.3 Limit of detection and limit of quantitation 
The LOQ and LOD for ketoprofen were found to be 0.9 μg/ml and 0.3 μg/ml respectively.  
 
3.2.2.4 Linearity and range 
Calibration curves were constructed in the range of concentrations of 0.5 - 15.0 μg/ml for 
ketoprofen.  The Beer-Lambert law is obeyed over these concentration ranges.  The linear 
regression equation obtained was 0025.060657.0 += xy , with a correlation co-efficient of 
0.9999 for ketoprofen. 
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Figure 3.5 Calibration curve of ketoprofen by uv analysis 
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3.2.2.5 Sample solution stability 
The stability of ketoprofen sample solutions were evaluated by observing for changes in the 
absorbance readings at the analytical wavelength under two storage conditions over a five 
day period.  The results were expressed as percent absorbance relative to initial (recovery). 
 
1 2 3 4 5
90
100
110
120
Dark, 4°C
Exposed, 25°C
Time (Days)
Pe
rc
en
t o
f d
ru
g 
re
m
ai
ni
ng
 
Figure 3.6 Curves of ketoprofen aqueous solution (10 μg/ml) stored in the dark at 4°C and on 
exposure to light at 25°C analysed by uv 
 
Figure 3.6 showed that the solution was stable when stored in the dark at 4°C.  There was less 
than 5% variation confirming the hplc results.  The exposed solutions at 25°C indicated 
higher absorbance readings which could be due to degration products absorbing at 255 nm. 
 
3.1.2.6 Conclusion 
The proposed uv method allows a rapid and economical quantitation of ketoprofen without 
any time consuming sample preparation.  Moreover, the spectrophotometric methods involve 
simple instrumentation compared with other instrumental techniques. 
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CHAPTER FOUR 
THE IN VITRO RELEASE OF KETOPROFEN 
 
4.1 IN VITRO DISSOLUTION METHODOLOGY 
 
4.1.1 Introduction 
The evaluation of in vitro release of actives from semisolid preparations has received much 
attention in recent years.  Release is a function of several physicochemical characteristics 
within the semisolid, so that constancy of release from one batch to another implies that the 
manufacturing process is the same (115).  A bioavailability study of a topical formulation 
begins with the in vitro investigation of the drug release from the formulation under 
evaluation (106).  Historically, although in vitro release rate testing from semisolids could 
potentially provide valuable information about product performance, it is not an industry 
wide quality control test requirement as compared to the utility of in vitro dissolution testing 
of oral dosage forms (105).  To change this situation the extension of in vitro dissolution 
methodology to semisolid dosage forms has been the subject of substantial effort and debate.  
Similar to the dissolution testing of oral dosage forms, a simple, reliable and reproducible 
release rate method can guide formulation development, help to monitor batch-to-batch 
quality and stability and control the manufacturing process.  It is particularly useful for 
detecting the effect of product changes including drug substance, excipients and 
manufacturing processes (105, 107, 112, 113).  The measurement of in vitro release from 
semisolids attempts to measure changes in important physical properties that may be related 
to topical bioavailability.  However, measurement conditions do not usually mimic 
physiological reality.  In particular, the in vitro release methodology does not include a 
membrane resembling the SC of the skin, an essential determinant of skin penetration 
characteristics (116).  Therefore, in vitro release is not a surrogate for in vivo bioequivalency 
testing, but is intended to compare a product following scale-up or post approval 
manufacturing changes (105).  In vitro release testing cannot also, on first principles, be 
considered as a test for establishing the bioequivalence of a product relative to an innovator 
formulation, however such testing does appear to have value in the following instances: 
i. in formulation design and optimization, 
ii. for determining the likelihood that changes in composition and/or processing of a 
formulation might impact on its function and  
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iii. for qualifying a new manufacturing method or site (235). 
 
4.1.2 In vitro release testing 
Release testing can, in principle, reveal much about the physical attributes (solubility, 
microscopic viscosity, emulsion state, particle size) of a semisolid dosage form (235).  In 
vitro release is one of several standard methods which can be used to characterise 
performance characteristics of a topical dosage form, i.e., semisolids such as creams, gels and 
ointments.  Important changes in the characteristics of a drug product formula or the 
thermodynamic properties of the drug it contains will be seen as a difference in drug release 
(108). 
 
Recommendations on in vitro methodologies have been collated as guidelines by regulatory 
bodies.  The FDA Scale-Up And Post Approval Changes (SUPAC-SS) and the International 
Pharmaceutical Federation in collaboration with the American Association of Pharmaceutical 
Sciences (FIP/AAPS) have guidelines requiring the performance of release testing from 
semisolid dosage forms after formulation changes (108, 109).  In particular, in vitro 
dissolution of pre- and post-change formulations must be compared whenever changes are 
made to the composition of the product, manufacturing equipment, or process (105, 235).  
Although the FDA SUPAC-SS guidance includes general methodology descriptions of 
diffusion systems, it does not specify a particular test methodology because no compendial 
apparatus, procedures or requirement for in vitro release testing of semisolids topical dosage 
forms have been described in relevant Pharmacopoeias to date (105, 109, 110, 114).  An in 
vitro release study design recommended by FDA SUPAC-SS is employed in this laboratory. 
 
4.1.2.1 Diffusion cell system 
The modified Franz diffusion cells and the European Pharmacopoeia diffusion cells were 
employed in the comparative diffusion study on ketoprofen containing topical formulations.  
These cells have been described in section 1.4.2.  The Franz diffusion cells are more 
frequently employed in the measurement of in vitro release from semisolid formulations than 
the European Pharmacopoeia diffusion cells (105, 223). 
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4.1.2.2 Synthetic membrane 
Synthetic membranes selected for use in in vitro diffusion experiments should usually be 
commercially available, have little capacity to bind to the drug, have little tendency to 
interact with the releasing medium and offer the least possible diffusional resistance (113, 
235).  Commercially available synthetic membranes have the added benefit of ensuring 
batch-to-batch homogeneity and uniformity, a property that is lacking with biological 
membranes.  Silatos™ silicone sheeting REF 7458 from Atos Medical (Hőrby, Sweden) with 
a 0.12 mm thickness was used in both types of diffusion cell systems.  Its relatively inert, 
lipophilic nature makes it an ideal environment for partitioning and permeation of drugs 
while its aporosity provides some rate-limiting function to this process.  Pieces of the 
membrane were cut to fit the aperture through which diffusion occurs in both the Franz 
diffusion cell and the European Pharmacopoeia diffusion cell. 
 
4.1.2.3 Receptor medium 
A receiving medium that is similar to the physiological condition of the skin is indicated, 
including the practical consideration to choose a receiving medium that allows sufficient 
amounts of active ingredient released within a reasonable time period to ensure accurate 
analysis.  To achieve sink conditions, the receptor medium must have a high capacity to 
dissolve or carry away the drug in question.  This is accomplished by keeping the 
thermodynamic activity of the drug in the receiver medium at a small fraction of that initially 
found in the semisolid.  It is desirable to minimise the capacity of the receptor medium to 
elute ingredients from the semisolid matrix other than the drug.  A receptor medium is chosen 
which is compatible with the membrane and formulation (235).  The thermodynamic activity 
of the drug in the receptor medium should not exceed 10% of its thermodynamic activity in 
the donor medium so as to maintain a favourable driving force for permeation and assure 
reasonable and efficient collection of the permeant (236).  The choice of the appropriate 
receptor medium was primarily based on the physicochemical properties of ketoprofen.  
Ketoprofen is practically insoluble in water but soluble in alcoholic media.  A previous study 
in this laboratory (100) indicated that alcoholic solutions produced excess bubble formations 
on the under surface of the membrane using the Franz diffusion cells which reduced the 
surface area available for diffusion, therefore phosphate buffers were chosen.  An attempt 
was made to evaluate the effect of molarity and pH on the release rate of ketoprofen.   
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The in vitro diffusion was performed in modified Franz diffusion cells using Silatos™ silicone 
sheeting membrane with 100 mg of 2.5% m/m ketoprofen gel (Fastum®, South Africa) in the 
donor compartment.  The cells were maintained at 32 ± 0.5°C and the samples were analysed 
for ketoprofen at 2, 4, 8, 24, 48 and 72 hours by the hplc method described in the previous 
chapter.  The diffusion profile is illustrated in Figure 4.1. 
 
Generally there was an effect of the molarity and pH of the receptor medium on the release of 
ketoprofen.  The highest release profile was observed with 0.5 M phosphate buffer and this 
could be attributed to its high buffering capacity.  These buffers were not considered further 
because most of the drug had been released within 24 hours and moreover 0.5 M was 
considered too high a concentration which could reduce the life span of the hplc analytical 
column.  The 0.2 M phosphate buffer was chosen for further development as it is easier to 
prepare in small quantities and the diffusion profiles were smooth with gradual drug release 
over the diffusion run time.  It is also important to appreciate that the pH of an aqueous 
buffered receptor solution may markedly affect the apparent flux of a permeating weakly 
ionisable compound (111).  The pH value of 6.8 for all three concentrations produced higher 
diffusion profiles than pH 7.2.  Although some studies have reported (236) a pH value of 7.2 
as the standard receptor medium pH value, this laboratory chose to use pH 6.8 because the 
skin is reported to have a slightly acidic pH (105, 224). 
 
The buffer solution was prepared by accurately weighing 136.09 g of potassium dihydrogen 
orthophosphate into a 5 l A-grade volumetric flask and made up to volume with hplc grade 
water.  The pH was then adjusted to 6.8 using sodium hydroxide pellets.  The solution was 
filtered through a 0.44 μm hvlp filter from Millipore (Massachusetts, USA) and degassed 
under vacuum with an Eyela Aspirator A-2S from Tokyo Rikakikai Co., Ltd (Tokyo, Japan) 
before use.  The receptor medium indicated for use with the Franz diffusion cells was 
degassed 10 minutes prior to filling because of the greater possibility of the formation of air 
bubbles under the membrane. 
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Figure 4.1 Effect of molarity and pH on the diffusion profile of ketoprofen 
 
The temperature of the receptor medium can also affect the release profile of ketoprofen from 
the formulations.  Higher temperatures produce faster release of the active from topical 
formulations although excessively high temperatures that would melt the formulation or 
otherwise cause significant physical changes should be avoided (116).  Figure 4.2 illustrates 
the effect of receptor medium temperature on the in vitro release of ketoprofen from a 
proprietary formulation.  Although the receptor temperature is generally set to 32 ± 0.5°C to 
approximate skin surface temperature (116, 223) some studies have indicated the use of 37 ± 
0.5°C.  An attempt was made to evaluate the difference in the diffusion profiles at 32 ± 0.5°C 
and 37 ± 0.5°C using the European Pharmacopoeia diffusion cells with approximately 500 
mg of 2.5% m/m ketoprofen gel (Fastum®, South Africa) in each reservoir.  Although there is 
no significant difference in the diffusion profiles in Figure 4.2, it can be noted that at 37 ± 
0.5°C ketoprofen is released much faster compared to that at 32 ± 0.5°C.  The temperature of 
the water bath in the USP dissolution apparatus was maintained at 32 ± 0.5°C for all 
European Pharmacopoeia diffusion experiments.  However, it was observed with the Franz 
diffusion apparatus that the temperature had to be set at 37 ± 0.5°C to produce a temperature 
reading of the formulation in the donor compartment of 32 ± 0.5°C.  This suggests that there 
is some inevitable heat loss through the plastic tubes that connect the Franz diffusion cells in 
series.  The open end of the donor chamber of the Franz diffusion cell was covered with 
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PARAFILM ‘M’® American National Can™ (Chicago, USA), an impermeable film, and then 
with aluminium foil to exclude the evaporation of volatile components of the formulations 
and to maintain constant temperature readings. 
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Figure 4.2 Effect of temperature on the diffusion profile of ketoprofen 
 
4.1.2.4 Sample applications 
Thick applications are applied to the test membrane and the diffusion cell system is capped or 
completely submerged in the receptor medium to prevent volatile substances from 
evaporating (235).  The effect of mass of the sample application was investigated in modified 
Franz diffusion cells using Silatos™ silicone sheeting membrane with 50 mg, 100 mg and 
200 mg of 2.5% m/m ketoprofen gel (Fastum®, South Africa) in the donor compartment. 
 
Figure 4.3 illustrates the effect of mass on the in vitro release of ketoprofen from a 
proprietary product.  The 200 mg diffusion profile was significantly different from the 50 mg 
and 100 mg profiles.  200 mg was considered too excessive as such amounts could lead to 
saturation kinetics.  Although the diffusion profiles of 50 mg and 100 mg were not 
significantly different, 100 mg was chosen over 50 mg because it was easier to measure from 
the bulk formulation. 
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Figure 4.3 Effect of mass on the diffusion profile of ketoprofen 
 
Approximately 100 mg of the ketoprofen containing topical formulation was uniformly 
placed on the membrane within the donor compartment of the Franz diffusion cells.  The 
compartment was kept occluded to prevent solvent evaporation and any significant 
compositional changes.  The amount of topical formulation per unit membrane area available 
to the diffusant in the donor chamber of the Franz diffusion cell was calculated to be 60.63 
mg/cm2.  From this, the corresponding sample application was calculated for the European 
Pharmacopoeia diffusion cell.  Approximately 500 mg of the ketoprofen containing topical 
formulation was uniformly placed within the reservoir of each cell and the membrane placed 
over it ensuring the absence of air bubbles between the formulation and the membrane.  
Direct comparisons of the diffusion profiles obtained from both the Franz diffusion cells and 
the European Pharmacopoeia diffusion cells were possible because the mass of the topical 
formulation to the unit surface area available was identical. 
 
4.1.2.5 Number of samples 
A minimum of six samples is recommended to determine the release rate (profile) of a topical 
formulation (108).  The recommended number of six samples was based on the imperial 
system and therefore had six sample stations.  The imperial numerical system has been 
replaced by the metric numerical system and five samples taken at each sampling time were 
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deemed to be sufficient to give a diffusion profile from which the kinetics of the diffusion 
process could be calculated (100). 
 
4.1.2.6 Sampling time 
Samples of receptor fluid were taken at 2, 4, 8, 24, 48 and 72 hours.  These multiple sampling 
times were chosen over an appropriate time period to generate an adequate diffusion profile 
and to determine the drug release rate.  The Franz diffusion cells were completely emptied at 
each sampling time and refilled with fresh degassed receptor fluid.  Aliquots of 5 ml were 
taken from the European Pharmacopoeia diffusion cells at each sampling time before analysis 
using both the hplc and the uv spectrophotometric method developed in chapter three.  The 
total percentage of receptor fluid removed for sample analysis was 3% and considered 
insignificant to disrupt sink conditions. 
 
4.1.2.7 Sample analysis 
Samples withdrawn from the receptor chambers of both the Franz diffusion cell and the 
European Pharmacopoeia diffusion cell were analysed by validated hplc and uv 
spectrophotometric procedures as outlined in chapter three.  Samples from the Franz cell 
diffusion apparatus for uv analysis were diluted to obtain absorbance readings in the range of 
0.2 - 0.8.  Five ml of these samples were diluted to 25 ml with solvent in an A-grade 
volumetric flask.  The data obtained from both diffusion cell experiments were manipulated 
using a designed Microsoft® Office Excel 2003 spreadsheet (appendix I). 
  
4.1.2.8 Diffusion profile comparison 
Comparing the in vitro diffusion profiles provides the formulator with critical information 
necessary to screen formulations during product development, evaluate stability and optimise 
dosage forms.  Curve comparisons produce the means to evaluate the effect that changing a 
process variable has upon dissolution and are useful as a quality assurance tool to measure 
batch-to-batch uniformity (225).  The diffusion profiles of the three proprietary ketoprofen-
containing gel products from three different manufacturing sites and a number of 
extemporaneously prepared gel formulations were compared.  The diffusion profiles for each 
formulation were obtained using both the Franz diffusion cells and the European 
Pharmacopoeia diffusion cells with hplc and uv analysis and plotted to the model of Higuchi 
(101).  For each diffusion cell, drug release as a function of square root of time was 
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determined.  The drug release profile was best fitted by least squares linear regression using 
the time points over the square root time period of 72 hours.  The mean ± SD of the slope of 
ketoprofen release from five cells for each formulation was determined.  The rate of drug 
released and extent of drug released in each of the cells was statistically evaluated for 
significance between formulations by the ANOVA test using GraphPad PRISM® version 4.00 
from GraphPad Software Inc. (California, USA).  A statistical significant difference was 
accepted at p < 0.05. 
 90 
CHAPTER FIVE 
FORMULATIONS OF PROPRIETARY AND EXTEMPORANEOUS TOPICAL 
KETOPROFEN GEL PREPARATIONS USING CARBOPOL® POLYMERS AND 
CO-POLYMERS 
 
5.1 DERMATOLOGICAL FORMULATIONS 
 
5.1.1 Introduction 
Dermatological prescriptions are among those most frequently compounded.  Many 
pharmacists who seldom compound are often asked to prepare ointments and creams.  
Generally, this may include something as relatively basic as the addition of an active drug to 
a topical vehicle.  However, many dermatological products are much more complex, 
reflecting at the same time the experience and requests of the physician, the disorders 
experienced by the patient and the ability and facilities of the compounding pharmacist (130).   
 
Over the past few decades there have been many advances in the understanding of the 
physicochemical properties of both formulation systems and their ingredients.  These have 
led to the ability to develop physically, chemically and biologically stable products.  There 
has also been a significant increase in our knowledge of the properties of the skin and the 
processes that control skin permeation.  It has been established that the permeation of 
compounds across intact skin is controlled fundamentally by the SC and it is the chemical 
composition and morphology of this layer that usually determines the rate and extent of 
absorption.  Similarly, section 1.2.5 shows how to modify this barrier by chemical or physical 
means and thereby alter the rate of diffusion of many permeating molecules.  A basic 
deficiency, however, in the application of our understanding of the barrier properties of the 
skin to dermatological and transdermal therapy, is that this knowledge has largely been 
generated by investigations on normal skin, rather than pathological skin.  The relevance of 
such information to diseased skin, for which permeation characteristics are probably 
significantly altered, has yet to be fully established.  In modern-day pharmaceutical practice, 
therapeutic compounds are applied to the skin for dermatological (within the skin), local 
(regional) and for transdermal (systemic) delivery.  However, whatever the target site or 
organ, it is usually a prerequisite that the drug crosses the outermost layer of the skin (93). 
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5.1.2 Formulation of dermatological products 
The selection of formulation type for dermatological products is usually influenced by the 
nature of the skin lesion and the opinion of the medical practitioner.  To this day a practising 
dermatologist would prefer to apply a wet formulation (ranging from simple tap-water to 
complex emulsion formulations with or without drug) to a wet lesion and a dry formulation 
(e.g., petrolatum) to a dry lesion.  Solutions and powders lack staying power (retention time) 
on the skin and can afford only transient relief.  In modern-day pharmaceutical practice, 
semisolid formulations are the preferred vehicles for dermatological therapy because they 
remain in situ and deliver the drug over extended time periods (93).  The term vehicle is very 
common for a complex system and implies a differentiation between active and inactive 
principles, whereby the active principle is embedded into a matrix, the vehicle.  With the aid 
of the vehicle the active principle is delivered to the application site or target organ, where 
the desired effect is achieved (126).  In most cases, the developed formulation will be an 
ointment, emulsion or gel. 
 
5.1.2.1 Ointments 
Ointments are greasy, semisolid preparations which are often anhydrous and which contain 
the medicament either dissolved or dispersed in the vehicle (127).  There are four types of 
ointment bases namely hydrocarbon base, absorption base, water removable base and water-
soluble base.  Only the hydrocarbon bases are completely anhydrous.  A typical formulation 
contains fluid hydrocarbons (minerals oils and liquid paraffins) mixed with a longer alkyl 
chain, higher-melting point, hydrocarbons (white and yellow paraffin and petroleum jelly).  
The difference between the white and yellow paraffin is simply that the yellow paraffin has 
been bleached.  Although the non-medicated anhydrous ointments are extremely useful as 
emollients, their value as topical drug delivery systems is limited by the relative insolubility 
of many drugs in hydrocarbon oils.  It is possible to increase drug solubility within a 
formulation by incorporation of hydrocarbon-miscible solvents (section 1.2.5.1.1), such as 
isopropyl myristate or propylene glycol, into the ointment.  Although increasing the solubility 
of a drug within a formulation may often decrease the release rate, it does not necessarily 
decrease the therapeutic effect.  The preparation of ointment formulations may appear to be a 
simple matter of heating all of the constituents to a temperature higher than the melting point 
of all of the excipients and then cooling with constant mixing.  The reality, however, is that 
the process is somewhat more complex and requires careful control over various parameters, 
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particularly the cooling rate.  Rapid cooling creates stiffer formulations in which there are 
numerous small crystallites, whereas a slow-cooling rate results in the formulation of fewer, 
but larger, crystallites and a more fluid product (93).  
 
5.1.2.2 Gels 
Gels have a variety of applications in the administration of medications orally, topically, 
intranasally, vaginally and rectally.  Some gel systems are transparent and others are 
translucent, since the ingredients involved may not be completely dispersed or they may form 
aggregates which disperse light.  Gels are semisolid systems consisting of suspensions made 
up of small inorganic particles or large organic molecules interpenetrated by a liquid (128).  
The common characteristic of all gels is that they contain continuous structures that provide 
solid-like properties (93).  Where the gel mass consists of a network of small, discrete 
particles, the gel is classified as a two-phase system.  In these two-phase systems, if the 
particle size of the dispersed phase is large, the product is referred to as a magma.  Single-
phase gels consist of organic macromolecules uniformly distributed throughout a liquid in 
such a manner that no apparent boundaries exist between the dispersed macromolecules and 
the liquid.  Single-phase gels may be made from synthetic macromolecules or from natural 
gums (mucilages).  The continuous phase is usually aqueous, but it can also be alcoholic or 
oleaginous.  Gels exhibit a number of different characteristics, including imbibition, swelling, 
syneresis and thixotropy (128, 129). 
 
Table 5.1 General classification and description of gels (128) 
Class Description Examples 
Inorganic Usually two-phase systems Aluminium hydroxide gel, bentonite magma  
Organic Usually single-phase systems Carbopol®, tragacanth 
Hydrogels Contains water Silica, bentonite, pectin, sodium alginate, 
methylcellulose, alumina 
Organogels Hydrocarbon type Petrolatum, mineral oil/polyethylene gel, Plastibase 
 Animal/vegetable fats Lard, cocoa butter 
 Soap-base greases Aluminium stearate with heavy mineral-oil gel 
 Hydrophilic organogels Carbowax bases (PEG ointment) 
Hydrogels Organic hydrogels Pectin paste, tragacanth jelly 
 Natural and synthetic gums Methylcellulose, sodium carboxymethylcellulose, 
Pluronic® F-127 
 Inorganic hydrogels Bentonite gel (10% to 25%), Veegum® 
 
There are a variety of semi-synthetic celluloses in use as thickeners in gel formulations.  
These include methylcellulose, carboxymethylcellulose, hydroxyethylcellulose, 
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hydroxypropylcellulose and hydroxypropylmethylcellulose (93, 126).  Branched-chain 
polysaccharide gums, such as tragacanth, pectin, carrageenan and agar, are of naturally 
occurring plant origin, therefore they can have widely varying physical properties, depending 
on their source.  By far the most extensively employed gelling agents in the pharmaceutical 
and cosmetic industries are the carboxyvinyl polymers known as carbomers (93). 
 
5.1.2.3 Emulsions 
The most common emulsions used in dermatological therapy are creams.  These are two-
phase preparations in which one phase (the dispersed or internal phase) is finely dispersed in 
the other (the continuous or external phase).  The dispersed phase can have either a 
hydrophobic base (oil-in-water creams, o/w), or be aqueous based (water-in-oil creams, w/o).  
Whether a cream is o/w or w/o depends on the properties of the system used to stabilize the 
interface between the phases.  Emulsions have two incompatible phases in close conjunction 
and therefore the physical stability of creams is always tenuous, although it may be 
maximized by the judicious selection of an appropriate emulsion-stabilizing system.  In most 
pharmaceutical emulsions, the stabilizing systems comprise either surfactants (ionic or non-
ionic), polymers (non-ionic polymers, polyelectrolytes, or biopolymers), or mixtures of these.  
The most commonly used surfactant systems are sodium alkyl sulphates (anionic), alkyl 
ammonium halides (cationic) and polyoxyethylene alkyl ethers or polysorbates (non-ionic).  
These are often used alone or in conjunction with non-ionic polymeric substances, such as 
polyvinyl alcohol or poloxamer block co-polymers or polyelectrolytes, such as polyacrylic-
polymethacrylic acids (93).  Modern formulations, which are called emulsifier free, are 
composed of polymers, water and oil.  Several cosmetic and pharmaceutical preparations 
have been developed containing sodium polyacrylate dispersed in the oil phase as the main 
emulsifier or co-emulsifier for topical application.  These formulations have very high skin 
compatibility as they are free of surfactant or with low emulsifier content.  The o/w 
emulsions have a velvet-like and soft touch skin feeling, which does not display any tackiness 
compared to traditional thickeners and are suitable to realise light gel/cream textures (126). 
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5.2 EXCIPIENTS 
 
5.2.1 Gelling agents 
The in-house gelling agents used in the extemporaneous manufacture of gels are Carbopol® 
polymers and co-polymers.  The generic (i.e., non-proprietary) name adopted by USP-NF for 
various Carbopol® polymers is carbomer.  Carbopol® polymers are synthetic high molecular 
weight polymers of acrylic acid cross-linked with either allylsucrose or allylethers of 
pentaerythritol whereas Carbopol® co-polymers are synthetic high molecular weight 
polymers of acrylic acid with small amounts of long chain alkyl acrylate co-monomers cross-
linked with allylpentaerythritol.  All these polymers have the same acrylic acid backbone 
(227, 229).  These polymers contain between 56.0 - 68.0% of carboxylic acid (COOH) 
groups, calculated on the dry basis (238).  They are fluffy, white, mildly acidic flocculated 
powders averaging 2 to 7 microns in diameter.  Each primary particle can be viewed as a 
network structure of linear polymer chains interconnected by cross-links.  These linear 
polymers are soluble in a polar solvent, such as water.  Carbopol® polymers, along with 
Pemulen® polymeric emulsifiers are all cross-linked.  They swell in water up to 1000 times 
their original volume (and ten times their original diameter) to form a gel when exposed to a 
pH environment between 4.0 - 6.0.  Since the pKa of these polymers is 6.0 ± 0.5, the 
carboxylate groups on the polymer backbone ionize, resulting in repulsion between the 
negative charges, which adds to the swelling of the polymer.  Cross-linked polymers do not 
dissolve in water.  The glass transition temperature of Carbopol® polymer is 105°C in powder 
form.  However, the glass transition temperature drops dramatically as the polymer comes 
into contact with water.  The polymer chains starts gyrating and the radius of gyration 
becomes larger.  Macroscopically, this phenomenon manifests itself as swelling (228). 
 
Carbopol® polymers and co-polymers are used mainly in liquid or semisolid pharmaceutical 
formulations as suspending or viscosity increasing agents.  Formulations include creams, gels 
and ointments.  Carbopol® polymers are also employed as emulsifying agents in the 
preparation of o/w emulsions for external use and are also employed in cosmetics (238). 
 
In the dry state, a carbomer molecule is tightly coiled, but when dispersed in water the 
molecule begins to hydrate and partially uncoil, exposing free acidic moieties.  To attain 
maximum thickening effect the carbomer molecule must be fully uncoiled and this can be 
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achieved by one of two mechanisms.  The most common method is to convert the acidic 
molecule to a salt, by the addition of an appropriate neutralizing agent.  For formulations 
containing aqueous or polar solvents, carbomer gellation can be induced by the addition of 
simple inorganic bases such as sodium or potassium hydroxide.  Less polar or non-polar 
solvent systems can be neutralised with amines such as triethanolamine or diethanolamine.  
Neutralization ionises the carbomer molecule, generating negative charges along the polymer 
backbone, and the resultant electrostatic repulsion creates an extended three-dimensional 
structure.  It is important to add a sufficient quantity of the neutralising agent to commence 
gellation.  Insufficient or excess amounts of the neutralising agent will result in viscosity or 
thixotropic changes (93).  The use of a strong base such as sodium hydroxide is not 
recommended since there is a greater risk of overshooting the desired pH range thus causing 
loss of the gel integral network. 
 
A number of different Carbopol® polymer grades are commercially available which vary in 
molecular weight, degree of cross-linking and polymer structure and therefore they may not 
have identical properties with respect to their use for specific pharmaceutical purposes, e.g., 
as controlled-release agents, bioadhesives, topical gels, thickening agents and emulsifying 
agents.  Carbopol® polymers should not be interchanged unless performance equivalency has 
been ascertained (227).  Four different types of Carbopol® polymers namely 974 PNF, 980 
NF, 981 NF and Ultrez™ 10 NF with one co-polymer namely Pemulen® polymeric 
emulsifier, Pemulen® TR1 NF, were used in this laboratory. 
 
Carbopol® 974 PNF polymer was introduced specifically for use in oral and mucoadhesive 
contact applications such as controlled release tablets, oral suspensions and bioadhesives.  In 
addition Carbopol® 974 PNF provides thickening, suspending and emulsification properties 
to high viscosity systems for topical applications (227). 
 
Carbopol® 980 NF polymer forms clear hydroalcoholic gels.  This polymer is the key to 
obtaining clear gels.  Carbopol® 980 NF polymer is also the most efficient thickener of all the 
Carbopol® polymers and has extremely slow flow properties suitable for spray-on 
applications (227). 
 
Carbopol® 981 NF polymer provides permanent emulsions and suspensions with low 
viscosities.  Gels produced with this polymer have excellent clarity.  In ionic systems, this 
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polymer performs better than most of the other Carbopol® polymers.  Carbopol® 981 NF 
polymer produces higher viscosities than Carbopol® 980 NF at concentrations below 0.1% in 
water systems and at concentrations below 1.5% in solvent systems (227). 
 
Carbopol® Ultrez™ 10 NF polymer is a new member of the Carbopol® family.  It is a 
dispersable polymer that offers a wide range of performance properties and can be used in a 
variety of personal care applications (231).  The unique dispersion performance of Carbopol® 
Ultrez™ 10 NF polymer allows it to wet quickly, yet hydrate slowly.  This property helps 
minimise lumping, which can be troublesome when turbulent mixing is not available during 
dispersion (227).   
 
Pemulen® TR1 NF is a versatile primary polymeric emulsifier which can emulsify up to 30% 
oil by weight, within a pH range of 4.0 - 5.5 and up to 20% oil over the pH range of 3.0 - 
11.0.  ‘Primary’ indicates that it is an emulsion former, not an emulsion stabiliser, as many of 
the Carbopol® polymers are.  Pemulen® TR1 NF can enable formulation of permanent 
emulsions, even at elevated temperatures without the use of irritating surfactants.  In addition, 
the hydrophobic phase of emulsions formed with Pemulen® polymeric emulsifiers do not re-
wet in the presence of water as traditional surfactants-based emulsions do.  Instead, 
emulsions based on Pemulen® polymers deposit an occlusive layer on the skin delivering the 
topical medication in the form of low irritancy lotions and creams with elegant skin feel.  
Pemulen® TR1 NF can also be used for high clarity topical gels with hydrophobic or highly 
ionic components (227).  While Pemulen® TR1 NF thickens the water, Carbopol® polymers 
should be used with Pemulen® TR1 NF to provide greater thickening properties where higher 
viscosity emulsions are required.  Pemulen® polymeric emulsifiers can actually form o/w 
emulsions.  The lipophilic portion adsorbs at the oil-water interface and the hydrophilic 
portion swells in the water forming a gel network around oil droplets to provide exceptional 
emulsion stability to a broad range of oils (230).  Pemulen® polymeric emulsifiers have been 
designed to act both as primary emulsifiers and viscosity increasing agents (126). 
 
It is worth noting that other grades of Carbopol® polymers and co-polymers that can be used 
in the preparation of topical formulations, namely 934 NF, 934 PNF, 940 NF, 941 NF, 971 
PNF, 71G NF, 1342 NF and Pemulen® TR2 NF, are available but were not used in this study. 
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5.2.2 Triethanolamine 
Triethanolamine, also chemically known as triethylolamine, trihydroxytriethylamine or 
tris(hydroxyethyl)amine is widely used in topical pharmaceutical formulations primarily in 
the formation of emulsions.  It is a clear, colourless to pale yellow-coloured viscous liquid 
having a slight ammoniacal odour.  In this study triethanolamine is used as a weak 
neutralizing agent to commence the gelling process by converting the free acidic hydrogens 
into amine salts.  Triethanolamine may turn brown on exposure to air and light and thus 
should be stored in an airtight container, protected from light, in a cool, dry, place (256). 
 
5.2.3 Propylene glycol 
Propylene glycol, chemically known as 1,2-propanediol, is widely used as a solvent 
extractant and preservative in a variety of parenteral and non-parenteral pharmaceutical 
formulations.  It is a clear, colourless, viscous, practically odourless liquid with a sweet acrid 
taste resembling glycerine.  Propylene glycol can also be used as an antimicrobial 
preservative, disinfectant, humectant, plasticizer and water-miscible co-solvent.  Propylene 
glycol is chemically stable when mixed with ethanol 95% v/v or water.  Propylene glycol is 
hygroscopic and should be stored in an airtight container, protected from light, in a cool, dry, 
place (257).  For the purposes of this research propylene glycol was mainly employed as a 
water-miscible co-solvent to aid in the dissolution of ketoprofen during the manufacture and 
as a chemical penetration enhancer. 
 
5.2.4 Ethanol 
Ethanol is a colourless, clear, volatile, flammable liquid (277) and employed in the 
manufacture of topical formulation primarily as a solvent.  However, although alcohols are 
useful to increase solubility of non-polar drugs, their use as co-solvents with hydrophilic 
polymers is often limited. 
 
5.2.5 Transcutol® HP 
Transcutol® HP is highly purified diethylene glycol monoethyl ether.  It is a hydroscopic 
liquid that is freely miscible with both polar and non-polar solvents (53).  Transcutol® HP has 
unique solubilizing properties.  It has the ability to solubilize both hydrophilic and 
hydrophobic materials.  Transcutol® HP was traditionally used as an industrial solvent.  Since 
then it has been used in a wide variety of pharmaceutical and personal care products.  
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Transcutol® HP can be incorporated into all types of topical emulsions (creams and lotions), 
solutions, gels and ointments.  Transcutol® HP has been recognised as a potential transdermal 
permeation enhancer due to its non-toxicity, biocompatibility with skin and excellent 
solubilizing properties (53).  Recent studies (51) have shown that Transcutol® HP 
significantly increases the percutaneous penetration of various active substances particularly 
if used in combination with suitable co-solvents.  In this study, propylene glycol and ethanol 
were selected for a possible synergistic enhancer effect on account of their satisfactory 
solvent power for ketoprofen. 
 
Table 5.2 Common excipients employed and their sources 
Excipients Manufacturer 
Active principal ingredient  
 Ketoprofen Sigma-Aldrich (Atlasville, SOUTH AFRICA) 
Carbopol® polymers  
 Carbopol® 974 PNF Noveon Inc. (Cleveland, USA) 
 Carbopol® 980 NF Noveon Inc. (Cleveland, USA) 
 Carbopol® 981 NF Noveon Inc. (Cleveland, USA) 
 Carbopol® Ultrez™ 10 NF Noveon Inc. (Cleveland, USA) 
Carbopol® co-polymer  
 Pemulen® TR1 NF Noveon Inc. (Cleveland, USA) 
Neutralizing agent  
 Triethanolamine Aspen Pharmacare (Port Elizabeth, SOUTH AFRICA) 
Co-solvent/solubilizing agent  
 Ethanol MERCK (Wadeville, SOUTH AFRICA) 
 Transcutol® HP Gattefossé (Saint-Priest, FRANCE) 
 Propylene glycol MERCK (Wadeville, SOUTH AFRICA) 
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5.3 EXPERIMENTAL 
 
5.3.1 Proposed design 
The aim of this study was to statistically assess (p < 0.05, ANOVA) the in vitro release rate 
of ketoprofen from three proprietary products from three different countries and also from a 
series of extemporaneously prepared hydroalcoholic topical gel formulations using 
Carbopol® polymers and co-polymers as the gelling agents.  The investigation was further 
extended to assess the in vitro release of ketoprofen from these hydroalcoholic gels as a 
function of variables such as pH, different grades of Carbopol® polymers, drug/polymer ratio 
and drug/CPE ratio. 
 
5.3.2 Preliminary studies 
Initial studies pertaining to the manufacture of extemporaneous Carbopol® gel formulations 
containing an NSAID were sourced from Macedo et al. (232).  Low concentrations of 
Carbopol® polymers i.e., 0.5% m/m, 0.75% m/m and 1.0% m/m resulted in formulations 
which did not gel.  Very poor release was observed from all preliminary formulations mainly 
due to the amount of triethanolamine required in the preparation of these gels although 
justifiable due to the type of the Carbopol® polymer, Carbopol® 934 NF, initially used.  The 
amount of the organic base was too high and it is possible that salts of ketoprofen were 
formed in gel formulations which could not easily partition across the lipophilic silicone 
membrane.  Another possible explanation was that the pH of the gel formulations was too 
high mainly because of the large amount of organic base, triethanolamine, added.  The next 
step was to identify how much organic base was needed to effectively induce the gelling 
mechanism without having a significant effect on the release of ketoprofen. 
 
5.3.3 Preparation of extemporaneous topical gel formulations 
The gelling agent used in the preparation of the formulations was taken from the range of 
different grades of the Carbopol® polymers and co-polymers as indicated above.  The 
alcoholic and/or co-solvent mixture comprised varying amounts of propylene glycol, ethanol 
and Transcutol® HP.  The gels were prepared with different grades of Carbopol® polymers, 
with varying amount of the polymers.  Extemporaneous topical gels containing different 
amounts of ketoprofen and excipients were also prepared.  The required amount of 
ketoprofen was dissolved in the alcoholic and/or co-solvent mixtures in a 100 ml beaker 
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containing a magnetic bar placed on a LABCON MSH 10 magnetic stirrer/hot plate from 
LABMARK (Maraisburg, South Africa).  The open end of the beaker was covered with 
PARAFILM ‘M’® from American National Can™ (Chicago, USA) to minimise the 
evaporation of volatile components of the alcoholic and/or co-solvent mixture.  The required 
amount of Carbopol® polymer was slowly dispersed in the ketoprofen/co-solvent mixture 
with vigorous mixing at 1800 rpm.  The beaker was covered with aluminium foil and left 
mixing for approximately 60 minutes.  The mixture was also homogenised with an Ultra-
turrax® from Janke & Kunkel (Essex, UK) for 5 minutes at low speed.  After complete 
addition of the polymer and mixing, the gels were spontaneously formed with the addition of 
triethanolamine in a 1:1.5 ratio of polymer to base unless otherwise indicated.  Gels with 
partially wetted polymer lumps were discarded.  The composition of each extemporaneously 
prepared gel is shown in Tables 5.3 and 5.4.  
 
5.3.4 Physical characterization of extemporaneous topical gel formulations 
5.3.4.1 Drug content 
Approximately 800 mg of extemporaneous topical gel, equivalent to 20 mg of ketoprofen 
unless otherwise indicated, from each batch was weighed into a 50 ml Quickfit® Erlenmeyer 
flask on a Sartorius 1474 MP8-2 top load balance from Zeiss West Germany Optical 
Instruments (Pty) Ltd. (Port Elizabeth, South Africa).  Approximately 40 ml of mobile phase 
for hplc analysis or receptor phase for uv analysis was added to the gel and shaken vigorously 
until the gel dissolved.  The gel-liquid solution was then transferred to an A-grade 100 ml 
volumetric flask.  The procedure was repeated with either more mobile phase or receptor 
phase until the volume of the mixture was made up to the mark.  An aliquot of 2.5 ml of the 
solution was accurately transferred with a pipette to an A-grade 50 ml volumetric flask and 
made up to volume with either mobile phase or receptor phase.  The solution was filtered 
through a 0.45 μm hydrophilic pvdf membrane from Millipore® Millex-HV, Millipore 
Corporation (Bedford, MA, USA) prior to both hplc and uv analysis.  Individual 
concentrations were calculated from a standard calibration curve and the average values 
calculated for each batch. 
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Table 5.3 Summary of formulae used in the extemporaneous manufacture of ketoprofen gels KET001 - KET010 
EXCIPIENTS KET001 KET002 KET003 KET004 KET005 KET006 KET007 KET008 KET009 KET010 
Ketoprofen 2.50 2.50 2.50 2.50 2.50 2.50 2.50 2.50 2.50 2.50 
Carbopol® 974 PNF    1.50       
Carbopol® 980 NF     1.50   1.00 1.00 1.00 
Carbopol® 981 PNF      1.50     
Carbopol® Ultrez™ 10 NF 1.00 1.50 2.00        
Pemulen® TR1 NF       1.50 0.10 0.30 0.50 
Triethanolamine 1.50 2.25 3.00 2.25 2.25 2.25 2.25 1.65 1.95 2.25 
Ethanol 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 
Transcutol® HP           
Propylene glycol 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 20.00 
Distilled water ad 100 100 100 100 100 100 100 100 100 100 
 
 
Table 5.4 Summary of formulae used in the extemporaneous manufacture of ketoprofen gels KET011 - KET020 
EXCIPIENTS KET011 KET012 KET013 KET014 KET015 KET016 KET017 KET018 KET019 KET020 
Ketoprofen 2.50 2.50 2.50 2.50 1.50 5.50 2.50 2.50 2.50 2.50 
Carbopol® 974 PNF           
Carbopol® 980 NF 1.00          
Carbopol® 981 PNF           
Carbopol® Ultrez™ 10 NF   1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 
Pemulen® TR1 NF 1.00 1.00         
Triethanolamine 3.00 1.15 4.26 3.00 2.25 2.25 2.25 2.25 2.25 2.25 
Ethanol 20.00 20.00 20.00 20.00 20.00 20.00  20.00 40.00  
Transcutol® HP       20.00 20.00  40.00 
Propylene glycol 20.00 20.00 20.00 20.00 20.00 20.00 20.00    
Distilled water ad 100 100 100 100 100 100 100 100 100 100 
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5.3.4.2 pH 
The pH of each extemporaneous topical gel formulation was measured with a Crison GLP 21 
pH-meter from Crison Instruments (Lasec, South Africa).  About 20 g of the gel was 
subjected to pH measurement within 24 hours of manufacture.  An average pH reading of 
three readings was recorded. 
 
5.3.4.3 Viscosity 
This was not assessed. 
 
5.3.4.4 In vitro dissolution studies 
The in vitro dissolution methodology employed in this laboratory to assess the rate of drug 
release from the extemporaneous topical gel formulations as well as the proprietary products 
has been outlined in chapter four.  A summary of experimental conditions and settings are 
listed in Table 5.5 below.  The use of a finite dose technique was chosen for its similarity to 
the clinical use of topical formulations (183).  The diffusion profiles for each formulation are 
reported in appendix II. 
 
Table 5.5 Summary of in vitro experimental conditions 
Receptor medium 0.2 M phosphate buffer at pH 6.8 
Temperature 32 ± 0.5°C 
Run time 72 hours 
Agitation 100 rpm 
Franz diffusion volume 9 ml 
European Pharmacopoeia diffusion volume 1000 ml 
Sample application  
 Franz diffusion cell 100 mg 
 European Pharmacopoeia diffusion cell 500 mg 
Membrane Silatos™ silicone sheeting REF 7458 
Analytical procedure Hplc and uv spectrophotometric analysis 
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5.4 DIFFUSION PROFILES AND RELEASE KINETIC DATA OF 
PROPRIETARY KETOPROFEN CONTAINING TOPICAL GEL 
PREPARATIONS FROM THREE COUNTRIES 
 
5.4.1 Introduction 
There has been growing interest in percutaneous administration of NSAIDs for the treatment 
of local conditions (163, 172).  NSAIDs are one of the most widely used groups of agents 
both on prescription and over the counter for their analgesic, anti-inflammatory and 
antipyretic properties (170).  The rationale behind using NSAIDs in topical formulations is to 
achieve a high local concentration of the active ingredient at the affected site, with as low a 
plasma concentration as possible in order to minimise systemic adverse effects.  The short 
distance from the site of application (the skin) to the target (the joint) and the avoidance of 
the enterohepatic cycle is an attractive concept (169).   
 
Studies to evaluate the clinical efficacy and safety of various topical NSAIDs compared to 
oral NSAIDs have been reported (162, 169, 170) but little research (234) has been conducted 
to evaluate the efficacy of topical NSAIDs from different manufacturers containing the same 
concentration of medicament.  This gives rise to a potential problem when researchers 
conduct clinical trials using a particular brand of a proprietary product and publish results 
with the assumption that the results will be similar to other proprietary products which 
contain the same medicinal agent in the same concentration.  Another drawback in such 
research studies is that some authors fail to indicate the name of the proprietary product used 
in a study (106, 163) which makes it difficult to undertake inter-laboratory comparisons.  
Proprietary products may contain different vehicle types and numerous studies have reported 
(218, 233, 239 - 242, 248, 260, 262, 264 - 267) on the influence of the vehicle composition 
on the in vitro and in vivo release of various medicaments. 
 
Proprietary products usually undergo stringent processes and have to pass various tests as set 
out by the relevant regulatory body before they can be put on the market for use by the 
general public.  It would be expected that a proprietary product purchased in one country 
would be as efficacious as another proprietary product purchased in another country.  Studies 
have shown that formulations manufactured in different parts of the world have different 
efficacies and this maybe attributed to a number of reasons.  One reason is the climatic 
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conditions under which the formulations are manufactured and subjected to during storage.  
Although formulations are usually prepared in temperature controlled laboratories, sometimes 
differences with respect to formulation viscosity, pH and drug release kinetics do occur.  
Another problem is how the formulation is transported to the distribution sites or to other 
countries.  Most pharmaceutical products are manufactured in temperate climates and 
transported for use in tropical third world countries.  High temperatures in tropical countries 
can affect the efficacy of a formulation (100). 
 
Three different proprietary products each containing 2.5% m/m ketoprofen from South 
Africa, United Kingdom and France were used in this study.  The proprietary products from 
the United Kingdom and France were transported to South Africa in the hand luggage on a 
commercial flight while the South African product was purchased from a local pharmacy.  
The aim of this study was to investigate any possible differences with respect to the kinetics 
and release pattern of three proprietary products from three different countries. 
 
5.4.2 Results 
5.4.2.1 Composition of proprietary products 
All three proprietary products indicated a 2.5% m/m ketoprofen content and were 
manufactured containing the same type of excipients but no concentrations were indicated on 
the label.  However the South African manufacturers did not state on the product what type of 
excipients were used but indicated that the product contained p-hydroxybenzoic acid esters 
0.1% m/m as preservatives. 
 
Table 5.6 Detailed compositions of proprietary products as indicated on package 
Proprietary product Manufactured Excipients End use date 
Fastum® Gel South Africa Not stated 
p-hydroxybenzoic acid esters 
October 2008 
Ketum® Gel France Carbomer 940 
Ethanol 
Lavender oil 
Diethanolamine 
Purified water 
December 2006 
Oruvail® Gel United Kingdom Carboxypolymethylene 940 
Triethanolamine 
Lavender oil 
Ethanol 
Purified water 
January 2006 
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The presence of the preservatives was evident during the hplc analytical procedure which 
showed two additional peaks (A and B, section 3.1.2.4, Figure 3.2) next to the principal 
ketoprofen peak.  The chromatograms for the other products only contained the principal 
peak.  All three products were packaged in tubes.  The products were also well within their 
end use date suggesting that neither the excipients nor the active principal had undergone 
changes which could have an effect on the results.  It was also interesting to note that the 
South African product and the French product were both registered under the same license 
and the British product was registered under a separate license.  Similar results from both the 
South African and the French product were to be expected.  The composition of each of the 
proprietary products is listed in Table 5.6. 
 
5.4.2.2 Drug content and pH readings 
An assay procedure and pH determination as outlined in sections 5.3.4.1 and 5.3.4.2 
respectively confirmed that each proprietary product contained approximately 2.5% m/m 
ketoprofen and the pH readings ranged from 5.44 to 5.61.  The drug content and pH readings 
are reported in Table 5.7.  There was no statistical significant difference (p > 0.05, ANOVA) 
in the drug content and pH reading among the proprietary products. 
 
Table 5.7 Drug content uniformity and pH values of proprietary products 
Proprietary 
product 
Actual percentage 
(% m/m) ( 5=n ) 
Percentage RSD Percentage deviation pH 
Fastum® Gel 2.46 0.24 1.60 5.44 
Ketum® Gel 2.45 0.29 2.00 5.51 
Oruvail® Gel 2.45 0.26 2.00 5.61 
 
It was observed that the drug content of the proprietary products was less than the indicated 
value of 2.5% m/m on the products.  This finding was in agreement with a previous study 
(100) in this laboratory which showed that the actual drug content of proprietary topical 
ibuprofen products was less than that indicated on the products.  Although this finding may 
not be statistically significantly different (p > 0.05, ANOVA) from the indicated amount, it 
may further compound the lack of efficacy of the topical formulation when other formulation 
factors are taken into consideration.  Less than 2.5% m/m ketoprofen drug content can be 
mainly attributed to manufacturing processes.  The manufacturing process may allow for loss 
of drug and should be investigated.  Studies have reported (233) minimum interaction of 
ketoprofen with the Carbopol® polymer by differential scanning calorimetry and so the loss 
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of ketoprofen cannot be attributed to the gelling agent.  The pH of the formulation is 
normally achieved by the addition of a weak base, usually diethanolamine or triethanolamine, 
which consequently effects the gelling process.  The pH readings shown in Table 5.7 play an 
important role with respect to drug permeation.  The reported pKa of ketoprofen (section 
2.1.6) is 4.60 and by application of the Henderson-Hasselbach equation about 12.60%, 
10.95% and 8.90% of the unionised form of ketoprofen for Fastum® Gel, Ketum® Gel and 
Oruvail® Gel respectively is present in the neutral undissociated form.  From the pH data in 
Table 5.7, it can be inferred that Oruvail® Gel should produce the lowest diffusion profile 
whilst Fastum® Gel should produce the highest.  The neutral undissociated form of 
ketoprofen is more likely to cross the synthetic lipophilic membrane during the diffusion run 
than the ionised molecules of ketoprofen. 
 
5.4.2.3 In vitro release of ketoprofen 
The in vitro release profiles of the different proprietary products measured through a 
synthetic membrane using the Franz diffusion cell are illustrated below.  Figures 5.1 and 5.2 
illustrate the cumulative amount of ketoprofen released plotted against t  and 2/1t  
respectively. 
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Figure 5.1 Diffusion profiles of proprietary products )5( =n  
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Fastum® Gel and Ketum® Gel produced very similar diffusion profiles and thus as expected 
there was no statistically significant difference (p > 0.05, ANOVA) between the two 
proprietary products.  The incorporation of the preservatives in Fastum® Gel did not appear to 
affect the release rate of ketoprofen from that proprietary product.  Oruvail® Gel produced a 
very low diffusion profile despite the fact that this proprietary product contained the same 
type of excipients and similar results with respect to drug content and pH reading.  There was 
a statistically significant difference (p < 0.05, ANOVA) between Oruvail® Gel and the other 
two proprietary products.   
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Figure 5.2 Higuchi plots of proprietary products )5( =n  
 
The mean in vitro ketoprofen release across a synthetic silicone membrane increased with the 
square root of time for all proprietary products.  At the end of the 72 hour run, Oruvail® Gel 
produced a cumulative amount of 40% less compared to Ketum® Gel and Fastum® Gel.  
Fastum® Gel and Ketum® Gel produced similar initial fluxes of 59.72 ± 58.99 μg/cm2/h and 
66.56 ± 66.40 μg/cm2/h respectively although the initial flux produced by Ketum® Gel was 
slightly higher.  Oruvail® Gel produced an initial flux of 12.43 ± 12.63 μg/cm2/h which is 
80% less than that obtained from both Ketum® Gel and Fastum® Gel.  The individual fluxes 
are presented in appendix III.  At the end of the experiment, the gel matrix was still intact, 
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indicating that the process by which the drug was present in the receptor phase was diffusion 
controlled. 
 
The linear regression analysis performed on the square root data is shown in the Figure 5.2.  
The regression lines produced by both Ketum® Gel and Fastum® Gel are almost identical 
with the line produced by Oruvail® Gel being statistically significantly different (p < 0.05, 
ANOVA). 
 
Table 5.8 summaries the kinetic data obtained from the Higuchi plots of each proprietary 
product.  The linear regression correlation co-efficient )( 2r  obtained was greater than 0.91 
and the slope of each regression line displayed a significant deviation from zero  
(p < 0.05, ANOVA) indicating all three proprietary products conformed to the Higuchi 
principle. 
 
Table 5.8 In vitro ketoprofen release kinetic data of proprietary products 
Proprietary 
product 
Apparent release constant 
(μg/cm2/h½) 
Lag time 
(minutes) 
2r  
Fastum® (SA) 112.0 ± 5.111 3.91 0.9357 
Ketum® (FR) 109.6 ± 2.538 1.10 0.9826 
Oruvail® (UK) 45.63 ± 2.433 28.89 0.9142 
 
The highest apparent flux over 72 hours of 112.0 ± 5.111 μg/cm2/h½ was achieved with 
Fastum® Gel, with Ketum® Gel producing an apparent flux of 109.6 ± 2.538 μg/cm2/h½ and 
the lowest apparent flux of 45.63 ± 2.433 μg/cm2/h½  was obtained with Oruvail® Gel.  
Although the highest apparent flux was obtained with Fastum® Gel over a 72 hour period, 
Ketum® Gel had a shorter lag time compared to Fastum® Gel, implying that it would take 
Ketum® Gel approximately 3 minutes more to achieve the desired pharmacological action 
compared to Fastum® Gel.  Oruvail® Gel once again had a very long lag time close to half an 
hour. 
  
5.4.3 Discussion 
A number of studies have reported (100, 233, 234, 239 - 242, 248, 260, 262, 264 - 267) the 
effect of different vehicles on the release of a principal active ingredient in topical 
formulations.  There is however limited study on the effect of the same vehicle type on the 
release of the active ingredient.  This study has demonstrated that proprietary products 
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containing the same amount of drug and excipients can differ in the extent to which the drug 
is released.  The two products under the same manufacturing license produced differed 
significantly from the third product.  Fastum® Gel and Ketum® Gel proved to be much more 
efficient than Oruvail® Gel at each time interval measured even though all three proprietary 
products contained the same vehicle type. 
 
The results obtained from both Fastum® Gel and Ketum® Gel are very similar because they 
are both under the same licence implying that similar manufacturing processes may have 
been employed.  Although the results are almost identical they are not exactly the same and 
this is mainly attributed to difference in manufacturing processes between the two countries. 
 
The extremely low release profile of Oruvail® Gel could be attributed to a number of reasons.  
Although a viscosity assessment was not performed in this study, the Oruvail® Gel was 
subjectively thicker than the gel of the other two proprietary products.  The gelling process of 
Carbopol® polymers and the viscosity are indicative of how much triethanolamine is added 
and the type of Carbopol® polymer used.  The pH of the Oruvail® Gel was the highest and it 
may be that two phenomena are occurring.  Firstly, there is an increased viscosity of the 
formulation which invariably lengthens the lag time of ketoprofen release and secondly, 
ketoprofen is a weak acid with a pKa of 4.60 (section 2.1.6) and the pH of the formulation 
although acidic by virtue of having a pH value less than 7, is relatively basic to ketoprofen 
and thus this environment will make ketoprofen more favourable in the formulation and less 
likely to diffusive out.  The effect of pH of the formulation will be discussed later in section 
5.53. 
 
It was also interesting to note that less than 20% of ketoprofen present in the formulation is 
made available to diffuse out of the formulation into the receptor phase in the unionised form.  
Ionic molecules are not generally favoured to cross a silicone membrane, or the SC, and as a 
result approximately 80% of ketoprofen has not been used.  There are also a number of fates 
of active ingredients from topical formulations before they reach the site of action.  One 
noticeable fate is that drugs are also subjected to skin flora metabolism (36) which further 
reduces that amount of active drug that reaches the active site.  Generally there is low 
bioavailability of active ketoprofen in these formulations and this may explain why there are 
so few of these products on the market.  The use of Carbopol® polymers which require 
raising the pH to effect gelation is the main problem.  A possible suggestion is the use of 
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Carbopol® co-polymers which are viscosity increasers and may not need a large amount of 
base to effect gelation.  The results of this study will be discussed in section 5.5.3.  Research 
studies have been conducted (237) which have successfully employed other gelling agents 
such as Pluronic® F127 in the manufacture of topical preparations containing medicinal 
agents notably the NSAIDs with the added advantage of controlling the pH of the formulation 
which inevitable can improve the bioavailability of the drug into the skin.  However the costs 
of large scale manufacture of these topical products have made their use uncommon.  The use 
of soya-lecithin as another vehicle type for the transdermal delivery of ketoprofen has been 
conducted (191). 
  
5.4.4 Conclusion 
This data indicates that the simple denotation of ‘ketoprofen 2.5% m/m gel’ is inadequate as a 
means of distinguishing between similar formulations that might contain the same types of 
excipients or manufactured under the same licence.  This finding is very similar to a study 
demonstrated by Pershing et al. (255) which reports that drug release comparisons across all 
topical drug products between manufacturers can be different when the vehicle composition 
is not qualitatively and quantitatively the same and therefore cannot be assumed to be the 
same as a function of labelled strength.  This highlights the potential problems that may arise 
from the mistaken assumption that generic prescriptions and formulations are 
pharmaceutically and clinically equivalent and interchangeable (234). 
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5.5 DIFFUSION PROFILES AND RELEASE KINETIC DATA OF 
EXTEMPORANEOUS TOPICAL KETOPROFEN GEL PREPARATIONS 
USING CARBOPOL® POLYMERS AND CO-POLYMERS 
 
5.5.1 Introduction 
Gel preparations using Carbopol® polymers and co-polymers are classified as hydrogels 
(250).  Hydrogels are three-dimensional macromolecular networks that contain a large 
fraction of water within their structure, do not dissolve and are soft and pliable.  These 
properties are similar to natural tissue and therefore, hydrogels are particularly useful in 
biomedical and pharmaceutical applications (254).  The use of Carbopol® polymers and co-
polymers as vehicles for the in vitro and in vivo transdermal delivery of various medicinal 
agents has been extensively researched (51, 106, 148, 184, 232, 237, 239 - 253, 263) due to 
their ability to exhibit high viscosities at low concentrations.  Moreover, they are quite stable 
to heat with negligible batch-to-batch variability.  They are also unaffected by aging, do not 
support bacterial or fungal growth and are non-toxic and non-irritating (232).  Polyacrylic 
acid has been widely used as a bioadhesive agent in formulations to enhance bioavailability.  
It has been reported that the bioadhesiveness of polyacrylic acid gel is pH and ionic strength 
dependent (249). 
  
Section 5.4 reported different results from three proprietary products using the same vehicle 
composition and as a result this laboratory investigated the effect of altering a number of 
manufacturing variables on the in vitro release of ketoprofen from Carbopol® polymers and 
co-polymers and by so doing offer suggestions to improve topical bioavailability.  A number 
of new grades of these polymers have been synthesized which offer better dispersion profiles, 
optical clarity and improved stability.  Different grades of Carbopol® polymers and co-
polymers were sourced and used in this study.  
 
The aim of this investigation was to study the effect of varying solvent compositions, 
Carbopol® polymer type, Carbopol® polymer concentration, drug concentration and the 
incorporation of the co-polymer in the polymer matrix on the in vitro drug release from gels 
prepared using four different Carbopol® polymers and a Carbopol® co-polymer.  
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5.5.2 Results 
The composition of the formulations is shown in Tables 5.3 and 5.4.  All the gels formed 
were elegant and transparent with a few translucent gels mainly due to the evaporation of the 
volatile components during manufacture.  Some of the gels were not devoid of air bubbles.  
The air bubbles were incorporated during mixing after neutralisation had occurred.  KET017, 
KET018 and KET020 had an aromatic scent due to the incorporation of Transcutol® HP in 
the formula.  All the gels maintained their structural integrity after overnight storage prior to 
any other evaluation.  Preliminary studies showed that a minimum of 20% m/m alcoholic 
content in the formulation was required to dissolve ketoprofen in the hydrogel.  The alcoholic 
content upper limit for obtaining acceptable non-liquefied gel formulations was 40% m/m. 
 
Table 5.9 Drug content uniformity and pH values obtained for KET001 - KET020 
Formulation Drug content 
(% m/m) ( 5=n ) 
RSD 
(%) 
Deviation 
(%) 
pH 
KET001 2.49 0.21 0.40 5.46 
KET002 2.51 0.21 0.40 5.85 
KET003 2.51 0.20 0.40 5.91 
KET004 2.51 0.19 0.40 5.91 
KET005 2.52 0.22 0.80 5.73 
KET006 2.53 0.21 1.20 5.81 
KET007 2.54 0.23 0.80 5.81 
KET008 2.52 0.21 0.80 5.62 
KET009 2.51 0.22 0.40 5.64 
KET010 2.51 0.24 0.40 5.71 
KET011 2.52 0.21 0.80 5.41 
KET012 2.53 0.20 1.20 5.41 
KET013 2.50 0.19 0.00 7.21 
KET014 2.51 0.23 0.40 6.51 
KET015 1.51 0.21 0.00 6.40 
KET016 5.55 0.22 0.90 5.57 
KET017 2.51 0.24 0.40 5.76 
KET018 2.51 0.21 0.40 5.80 
KET019 2.51 0.19 0.40 5.94 
KET020 2.51 0.20 0.40 6.25 
 
The drug content uniformity and pH values of all the extemporaneous formulations prepared 
in this laboratory are reported in Table 5.9.  The assay values for all the formulations with the 
exception of KET015 and KET016 which were deliberately altered were within the limit of 
2.31 - 2.69% m/m as indicated in the 2002 edition of the British Pharmacopoeia (185).  The 
percentage deviation of all the extemporaneous formulations were less than those obtained 
from the proprietary products in Table 5.7.  The pH values were within limits of 5.41 - 6.25.  
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The pH of the vehicle of KET013 and KET014 was deliberately altered.  The pH value for 
KET015 was not deliberately altered.  The pH values indicated in Table 5.9 were very similar 
to those obtained from the proprietary products in Table 5.7.   
 
 Table 5.10 In vitro ketoprofen release kinetic data for KET001 - KET020 
Formulation Apparent release constant 
(μg/cm2/h½) 
Lag time 
(minutes) 
2r  
KET001 139.6 ± 5.109 6.78 0.9577 
KET002 95.75 ± 2.180 25.67 0.9832 
KET003 94.47 ± 3.225 34.56 0.9630 
KET004 104.4 ± 2.694 24.99 0.9785 
KET005 124.4 ± 4.364 25.17 0.9610 
KET006 133.3 ± 5.253 39.50 0.9513 
KET007 86.60 ± 3.744 24.06 0.9419 
KET008 116.6 ± 4.650 21.62 0.9501 
KET009 101.5 ± 2.944 38.73 0.9730 
KET010 96.80 ± 4.047 56.89 0.9455 
KET011 60.04 ± 5.217 65.90 0.8006 
KET012 136.1 ± 5.604 21.23 0.9470 
KET013 7.57 ± 0.7859 103.44 0.7380 
KET014 35.29 ± 3.014 62.06 0.8061 
KET015 43.96 ± 3.143 47.18 0.8556 
KET016 154.7 ± 9.051 39.70 0.8985 
KET017 75.56 ± 4.401 85.39 0.8993 
KET018 142.5 ± 8.035 59.23 0.9051 
KET019 98.83 ± 6.622 11.34 0.8710 
KET020 101.4 ± 6.352 115.43 0.8853 
 
Table 5.10 summaries the kinetic data obtained from the Higuchi plots for all the 
extemporaneous gel preparations.  In these preliminary studies, the mean in vitro ketoprofen 
release across a synthetic membrane increased with the square root of time for the gel 
preparations.  The linear regression correlation co-efficients range from 0.7380 - 0.9832.  
Although the linear regression correlation co-efficients expressed by the formulations were 
not all greater than 0.9, the slope of each regression line displayed a significant deviation 
from zero (p < 0.05, ANOVA) indicating conformation to the Higuchi principle.  KET013 
produced the lowest apparent flux of 7.578 ± 0.7859 μg/cm2/h½ whilst the highest apparent 
flux of 154.7 ± 9.051 μg/cm2/h½ was produced by KET016.  KET001 produced the shortest 
lag time of approximately 6 minutes and KET020 produced the longest lag time of 
approximately 2 hours.  No direct correlation was observed between the lag time and the 
apparent flux released.  KET020 produced the longest lag time of approximately 2 hours and 
a flux of 101.4 ± 6.352 μg/cm2/h½ and KET001 with the shortest lag time did not produce the 
maximum apparent flux. 
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5.5.2.1 Effect of different grades of Carbopol® polymers and co-polymer 
Five 2.5% m/m ketoprofen gels (KET002, KET004, KET005, KET006 and KET007) each 
containing a different grade (Carbopol® Ultrez™ 10 NF, Carbopol® 974 PNF, Carbopol® 980 
NF, Carbopol® 981 PNF and Pemulen® TR1 NF)  of Carbopol® polymer or co-polymer were 
prepared and evaluated. 
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Figure 5.3 Diffusion profiles showing the effect of different grades of Carbopol® polymers on the 
release of ketoprofen )5( =n  
 
The amount of ketoprofen released from the different grades of Carbopol® polymers or co-
polymer is shown in Figure 5.3 and 5.4.  It can be seen that the amount of drug released was 
lowest from KET007 and highest from KET006.  The rank order of the drug release from 
these formulations was KET006 > KET005 > KET004 > KET002 > KET007.  The 
differences between the released amounts of drug from the different grades were not 
statistically significant (p > 0.05, ANOVA).  The calculated apparent fluxes and the lag times 
for these formulations from Table 5.10 are graphically represented in Figure 5.5.  The pH 
values for these formulations were within the range of 5.70 - 5.95 and were not statistically 
significantly different (p > 0.05, ANOVA).  The minor changes in pH between the 
formulations did not have a significant effect on the release of drug. 
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Figure 5.4 Higuchi plots showing the effect of different grades of Carbopol® polymers )5( =n  
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Figure 5.5 Mean maximum fluxes and lag times obtained from the release kinetics of ketoprofen from 
different grades of Carbopol® polymers )5( =n  
    116 
Although KET006 produced the maximum apparent flux, it had the longest lag time.  There 
is an approximately a 1.5-fold increase in terms of drug release and the time it takes the drug 
to leave the formulation from KET006 in comparison to KET007.  Interestingly the amount 
of drug release from KET005 and KET006 was not statistically significantly different (p > 
0.05, ANOVA) but the time it takes for drug release from KET006 is approximately 1.6 times 
slower than KET005.  The lag times produced by KET002, KET004, KET005 and KET007 
were not statistically significantly different (p > 0.05, ANOVA). 
 
5.5.2.2 Effect of polymer concentration 
Three approximately 2.5% m/m ketoprofen gels (KET001, KET002 and KET003) each 
containing a different concentration (1.0% m/m, 1.5% m/m and 2.0% m/m) of Carbopol® 
Ultrez™ 10 NF polymer were prepared and evaluated.  Figure 5.6 and Figure 5.7 both show 
that the results can be divided into two groups. 
 
0 25 50 75
0
400
800
1200
KET001
KET002
KET003
Time (hours)
C
um
ul
at
iv
e 
am
ou
nt
 r
el
ea
se
d 
( μg
/c
m
2 )
 
Figure 5.6 Diffusion profiles showing the effect of different concentrations of Carbopol® Ultrez™ 10 
NF polymer on the release of ketoprofen )5( =n  
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A statistical significant difference (p < 0.05, ANOVA) between KET001, KET002 and 
KET003 with a rank order increase of KET001 > KET003 > KET002 was observed.  
KET001 produced an apparent flux approximately 1.5 times higher than KET002 and 
KET003.  The lag time produced by KET001 was approximately 4 times less than KET002 
and 5 times less than KET003. 
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Figure 5.7 Higuchi plots showing the effect of different concentrations of Carbopol® Ultrez™ 10 NF 
polymer )5( =n  
 
The pH of the gels produced was within 5.45 - 5.92.  Although the pH values were not 
significantly different (p > 0.05, ANOVA), there seemed to be a direct correlation between 
the pH value and the release of ketoprofen from these formulations.  The lowest pH value 
from KET001 produced the highest apparent flux of 139.6 ± 5.109 μg/cm2/h½ while the 
highest pH value from KET003 produced the lowest apparent flux of 94.47 ± 3.225 
μg/cm2/h½.  The amount of polymer used showed an inverse relationship to the apparent flux 
produced and a direct relationship to the lag time. 
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5.5.2.3 Effect of ketoprofen concentration 
Three 1.5% m/m Carbopol® Ultrez™ 10 NF polymer gels (KET015, KET002 and KET016) 
each containing a different concentration (1.5% m/m, 2.5% m/m and 5.5% m/m) of drug were 
prepared and evaluated.  The release rate of ketoprofen from these formulations as shown in 
Figures 5.8 and 5.9 showed concentration dependency.  There was a statistically significant 
difference (p < 0.05, ANOVA) between the formulations.   
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Figure 5.8 Diffusion profiles showing the effect of drug concentration on the release rate of 
ketoprofen )5( =n  
 
There was a good correlation between the concentration of ketoprofen and release rate for all 
the formulations however no correlation was observed between the concentration of 
ketoprofen and the lag times produced.  The rate of drug released, however, was not 
consistently proportional to the increase in drug concentration in the formulation.  For 
example, increasing the ketoprofen concentration 4-fold from 1.5% m/m to 5.5% m/m in the 
formulations produced a 3.5-fold increase in the rate of drug released.  The pH values of the 
formulations were within the range 5.56 - 6.40.  An inverse relationship between the drug 
concentration and the pH value of the formulation was observed.  KET015 with the drug 
concentration of 1.5% m/m ketoprofen produced the highest pH value of 6.40 while the 
lowest pH value of 5.57 was obtained from KET016 with a drug concentration of 5.5% m/m. 
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Figure 5.9 Higuchi plots showing the effect of drug concentration on the release rate of ketoprofen 
)5( =n  
 
5.5.2.4 Effect of vehicle pH 
The effects of vehicle pH (5.85, 7.21 and 6.51) were investigated for three formulations 
(KET002, KET013 and KET014) each containing 2.5% m/m ketoprofen in a Carbopol® 
Ultrez™ 10 NF polymer.  The change in pH was achieved by altering the amount of 
triethanolamine required to neutralise the polymer to bring about gelling.  There was a 
statistically significant difference (p < 0.05, ANOVA) between the release rates obtained 
from the different formulations.  The effect of pH was significant on the release of ketoprofen 
from the formulations.  It was apparent that as the pH was increased, the steady state flux 
falls substantially which was also accompanied by the expected large increase in the 
solubility of the drug in the formulation.  A plot of flux against the fraction of drug in the 
unionised (Figure 5.12) form revealed a direct linear dependence.  A pKa value of 4.60 for 
ketoprofen was used in these calculations (141, 145, 149).  An inverse correlation between 
the pH of the vehicle and the lag time was observed. 
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Figure 5.10 Diffusion profiles showing the effect of pH on the release rate of ketoprofen )5( =n  
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Figure 5.11 Higuchi plots showing the effect of pH on the release rate of ketoprofen )5( =n  
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Figure 5.12 Relationship between the apparent fluxes of the formulations to the amount of unionised 
drug present in each formulation )5( =n  
 
5.5.2.5 Effect of co-polymer concentration 
The effect of incorporating small amounts of Pemulen® TR1 NF into Carbopol® 980 NF 
formulations on the in vitro release of ketoprofen was investigated.  Four gels (KET008, 
KET009, KET010 and KET011) each containing 2.5% m/m ketoprofen, 1.0% m/m 
Carbopol® 980 NF and varying amounts (0.1% m/m, 0.3% m/m, 0.5% m/m and 1.0% m/m) 
of Pemulen® TR1 NF were prepared and evaluated.  Figures 5.13 and 5.14 illustrate the 
diffusion profiles obtained for these formulations.  Although no statistically significant 
difference (p > 0.05, ANOVA) among these profiles existed, the rank order increase of 
release of ketoprofen from these formulations is KET008 > KET009 > KET010 > KET011. 
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Figure 5.13 Diffusion profiles showing the effect of Pemulen® TR1 NF into Carbopol® 980 NF 
formulations on the release rate of ketoprofen )5( =n  
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Figure 5.14 Higuchi plots showing the effect of Pemulen® TR1 NF into Carbopol® 980 NF 
formulations on the release rate of ketoprofen )5( =n  
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Figure 5.15 Mean maximum fluxes and lag times obtained from the effect of Pemulen® TR1 NF 
incorporated in Carbopol® 980 NF formulations )5( =n  
 
Increasing the amount of the co-polymer in the formulations decreased the apparent flux from 
the formulations but increased the time it took for the drug to leave the formulation and 
diffuse into the receptor medium (Figure 5.15).   
 
The amount of flux produced and the lag time was not in direct proportion to increasing the 
amount of the co-polymer.  A 10-fold increase in Pemulen® TR1 NF produced a 2-fold 
decrease in apparent flux and a 2.3-fold increase in lag time whereas a 5-fold increase in 
Pemulen® TR1 NF produced a 1.2-fold decrease in apparent flux and an approximately 3-fold 
increase in lag time.  It was interesting to note that KET008 produced an identical profile to 
the proprietary product Fastum® Gel (Figure 5.16). 
  
Although there is no significant difference (p > 0.05, ANOVA) with respect to the apparent 
flux and the lag time of the drug produced, KET008 compared to the proprietary product, 
Fastum® Gel, produced a higher apparent flux of 116.6 ± 4.650 μg/cm2/h½ compared to that 
produced by Fastum® Gel of 112.0 ± 5.111 μg/cm2/h½ but more importantly, the lag time 
produced by KET008 was 5.5 times more than Fastum® Gel. There was no correlation 
between the vehicle pH of the formulations and the release pattern of ketoprofen. 
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Figure 5.16 Diffusion profiles comparing KET008 and Fastum® Gel )5( =n  
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Figure 5.17 Comparisons of apparent fluxes and lag times obtained from KET008 and Fastum® Gel 
)5( =n  
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5.5.2.6 Effect of solvent systems 
The effect of employing different solvents on the release rate and lag time of ketoprofen was 
investigated.  Transcutol® HP, ethanol and propylene glycol were the solvent systems 
studied.  Figures 5.18 and 5.19 illustrate the effect of the various solvent systems on the 
release rate of drug from the formulations.  The effect of Transcutol® HP was initially 
investigated.  Three gel formulations (KET017, KET018 and KET020) containing varying 
amounts of Transcutol® HP in the presence and absence of other solvent systems were 
prepared and evaluated.  KET017 and KET018 each contained 20.0% m/m Transcutol® HP 
with a composite solvent system of propylene glycol and ethanol respectively.  KET020 was 
formulated with 40.0% m/m Transcutol® HP.  The diffusion profiles are illustrated in Figures 
5.18 and 5.19.  Although no statistically significant difference (p > 0.05, ANOVA) was 
observed, the rank order increase is KET018 > KET020 > KET017.  Unusually long lag 
times were observed in these formulations as seen in Figure 5.20.  KET018 produced a lag 
time of approximately an hour and KET020 produced a lag time of almost 2 hours.  KET018 
containing ethanol produced better release kinetics compared to KET017 which contains 
propylene glycol.  A larger amount of Transcutol® HP produced a relatively large apparent 
flux but with an extremely long lag time. 
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Figure 5.18 Diffusion profiles showing the effect of solvent systems )5( =n  
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Figure 5.19 Higuchi plots showing the effect of solvent systems )5( =n  
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Figure 5.20 Mean apparent fluxes and lag times obtained from the Transcutol® HP formulations 
)5( =n  
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The effect of Transcutol® HP and ethanol as single solvent systems on the release rate of 
ketoprofen was also evaluated.  Two gel preparations (KET019 and KET020) both containing 
2.5% m/m ketoprofen in a 1.5% m/m Carbopol® Ultrez™ 10 NF polymer and 40.0% m/m 
ethanol or Transcutol® HP respectively were evaluated.  The diffusion profiles of KET019 
and KET020 are illustrated in Figures 5.18 and 5.19 above.  The initial flux from KET020 
was extremely low compared to KET019.  KET019 and KET020 both produced the same 
apparent flux but KET020 produced a 10.2-fold increase in lag time. 
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Figure 5.21 Mean apparent fluxes and lag times obtained from KET019 and KET020 )5( =n  
 
Co-solvents systems were also employed in the preparations of the gels to evaluate their 
effect on the release of ketoprofen.  Transcutol® HP/ethanol (KET018) and propylene 
glycol/ethanol (KET002) systems were used.  The diffusion profiles of these formulations are 
illustrated in Figures 5.18 and 5.19.  Although KET018 produced a 1.5-fold increase in 
apparent flux, it also produced a 2.3-fold increase in lag time.  Formulations containing 
Transcutol® HP produce large apparent fluxes but relatively long lag times. 
 
Transcutol® HP/propylene glycol (KET017) and ethanol/propylene glycol (KET002) systems 
were also compared.  The diffusion profiles of these formulations are illustrated in Figures 
5.18 and 5.19.  KET017 produced a smaller apparent flux compared to KET002, a finding 
contrary to the results obtained when KET002 and KET018 were compared.  In Figures 5.18 
and 5.19 KET017 produced the lowest diffusion profile.  From Figure 5.23 KET017 
produced a 1.3-fold decrease in apparent flux but produced a 3.3-fold increase in lag time.  
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The lag time of the Transcutol® HP containing formulation was higher and this finding was 
similar to that observed in Figure 5.22. 
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Figure 5.22 Mean apparent fluxes and lag times obtained from KET002 and KET018 )5( =n  
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Figure 5.23 Mean apparent fluxes and lag times obtained from KET002 and KET017 )5( =n  
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5.5.3 Discussion 
To develop effective topical formulations, it is important to determine the diffusion properties 
of drugs in the semisolid vehicles, especially when the release of drugs at the application site 
is likely to be rate-limited by the diffusion of drugs from those vehicles (245).  The drug must 
have some and preferably greater affinity for the membrane than for the vehicle, thereby 
maximising the thermodynamic leaving potential (260).  Although most topical formulations 
consist of simple components, the ability of a vehicle to release drugs at the local site is 
limited by numerous factors such as drug-vehicle, drug-skin and vehicle-skin interaction 
(245). 
 
In the preliminary studies, Carbopol® 934 NF was initially used as the test polymer for the 
manufacture of extemporaneous topical gels.  This polymer was unsuitable for the 
preparation of ketoprofen gels because the gel with optimum characteristics could only be 
formed at a pH range of 7.5 to 8.5 (258).  This pH range will make it impossible for any drug 
release to occur and therefore this polymer was not investigated any further.  Another finding 
during the preliminary studies was a decrease in consistency of the gel network with an 
increase in alcoholic content above 40% m/m.  This was probably due to competition for 
water molecules between the polymer and the alcohol which may lead to poor hydration and 
therefore reduced swelling of the polymer molecules so that they adopt a tighter more close-
coiled configuration.  Proniuk et al. (237) and Díez-Sales et al. (239) both found a similar 
decrease in gel integrity on increasing the alcoholic content.   
 
The choice of polymer for the manufacture of topical formulations should be one that 
produces the highest drug flux with the lowest lag time.  The effect of Carbopol® polymer 
type on the release of drug is illustrated in Figures 5.3 and 5.4.  Although no significant 
difference (p > 0.05, ANOVA) in drug release characteristics were observed for all five gels, 
some types of polymers were more efficient at releasing the drug than others.  Similar results 
were reported by Macedo et al. (232) and Edsman et al. (247) who worked with more than 
one Carbopol® polymer type and noticed differences in drug release rates.  Carbopol® 
polymers and co-polymers have the same acrylic acid backbone.  The main differences are 
related to the presence of co-monomer and cross-link density.  Minor adjustments in the 
cross-link density and co-monomer concentration can produce a large number of different 
polymers engineered to provide specific properties (228).  Therefore the differences observed 
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could be attributed to the differences in cross-link density as noted above.  Increasing the 
cross-link density of the polymer increases the tortuosity of the matrix through which the 
drug has to diffuse, thus decreasing drug release and increasing lag time (232). 
  
It is has been reported (251) that the main barrier to the release of drugs from aqueous 
Carbopol® polymer gels is a mechanical layer formed by the random network of polymer 
molecules, which binds and entraps surrounding water.  This aqueous phase in the polymer 
network may be the region responsible for diffusion of the drug from the gel.  A change in 
polymer concentration can affect the diffusional pathway and thus drug release.  Schantz et 
al. (259) showed that when diffusion of drugs occurs primarily through the aqueous channels 
in a gel, the diffusivity is an inverse function of polymer content.  Although statistical 
differences (p > 0.05, ANOVA) in Carbopol® polymer content were observed from Figure 
5.6, the apparent flux values of ketoprofen calculated in Table 5.10 did not decrease linearly 
with increased Carbopol® polymer concentration.  This finding was not in agreement with a 
study by Lu et al. (245).  These authors found that the effect of Carbopol® polymer content 
on diffusivity of methotrexate decreased linearly with increasing polymer content.  The 
observed decrease in apparent flux with increasing polymer concentration may be attributed 
to an increase in tortuosity of the formulations making it difficult for the drug to be released 
and therefore increasing the lag time. 
  
The effect of drug loading on release was evaluated and the results are illustrated in Figure 
5.8.  The increase in release rate with increasing concentration is due to the increasing 
thermodynamic activity of the drug which is related to its concentration in the base.  As 
pointed out in section 5.5.2.3 the release of ketoprofen from the polymer was not linearly 
related to the drug concentration.  This finding was not in agreement with El Gendy et al. 
(251) who found that the release of flurbiprofen from Carbopol® 934P and Pluronic® 407 
polymers was linearly related to the loading concentration in the base.  This may be due to 
the amount of drug that was used in the formulation of KET016.  The 5.5% m/m ketoprofen 
was not soluble in the alcoholic co-solvent mixture.  The initial drug release was mainly due 
to the drug molecules at the surface of the vehicle which were quickly released due to the 
slow molecular diffusion in the internal phase.  The diffusion profile obtained was a 
summation of both phenomena whereas with the other formulations the release was 
principally due to the diffusion from the core of the vehicle to the vehicle/membrane 
interface.  Gürol et al. (233) showed by differential scanning colorimetry, a strong hydrogen 
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bond formation between ketoprofen, Carbopol® polymer and triethanolamine at high 
concentrations of the drug.  This results in ketoprofen having high partition selectivity for the 
base and thus a lower than expected apparent flux was generated. 
 
The pH of the vehicle has been shown to be one of the major variables that could influence 
diffusion of drugs from semisolid vehicles (245).  Theoretically, the pH value of the vehicle, 
the drug solubility in the vehicle and the viscosity of the gel matrix are three important 
factors to consider in the evaluation of drug diffusion from a gel dosage form across the 
membrane or the skin (239, 240).  Therefore the pH values were adjusted to obtain values 
within limits of 5.00 - 6.00 unless where deliberately altered in KET013 and KET014 to 
investigate the effect of pH on ketoprofen release.  KET013 demonstrates a long lag time 
(approximately one half of an hour) before steady state diffusion is seen at a relatively low 
initial delivery rate of 0.78 µg/cm2/h.  This would suggest that chemical (dissolution and 
membrane partitioning) parameters are controlling the rate of delivery.  These delivery rates 
can be explained by examining Fick’s law of diffusion (section 1.3.2).  The flux is 
proportional to the partition co-efficient, the diffusion co-efficient and the donor 
concentration and inversely proportional to the thickness of the membrane.  In this study the 
intrinsic diffusion concentration, the membrane thickness and the donor concentration were 
constant.  Therefore in the absence of physical mechanisms, the rate of delivery will be 
dictated by the partition co-efficient between the donor formulation and the membrane (260).  
Numerous drugs are weak organic electrolytes (224) and therefore the ionization depends on 
the pH of the delivery medium.  Consideration of this pH, as well as of the drug dissociation 
constant (pKa), allow some degree of diffusion to be predicted (262).  The larger partition 
towards the donor formulation than to the membrane can be explained in terms of the 
percentage of ionised and unionised species present in the formulation in accordance with the 
pH-partition hypothesis.  An increase in formulation pH above the pKa of the drug 
significantly decreases the amount of unionised species available for diffusion.  The ionised 
species does not penetrate the membrane to any significant extent and when the drug is 
totally ionised the diffusion rate should be negligible, as is apparent in this case.   
 
The Carbopol® polymers and co-polymers are also affected by pH values.  The different 
grades of Carbopol® polymers have different effective pH ranges below and above which 
there is a loss of viscosity and between these two pH ranges, viscosity is optimum.  However, 
within the effective range, differences in viscosity of the gel formulation can still occur 
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depending on how much base is added.  The viscosity of a Carbopol® polymer based gel 
formulation begins to decrease after pH 9.0 and will continue to decrease if the pH is 
increased.  This is due to the dampening of the electrostatic repulsion caused by the presence 
of excess electrolytes.  It is possible to achieve high viscosity systems at pH values below 5.0 
and above 9.0, but the concentration of Carbopol® polymer must be increased (261).  The 
viscosity of the vehicle can hinder the diffusion of a drug across the membrane.  The removal 
of ketoprofen from the vehicle/membrane interface creates a drug depletion zone which is 
slowly replenished by further diffusion of ketoprofen from the core of the gel to the 
vehicle/membrane interface.  This diffusion is hindered by the viscosity of the vehicle, hence 
the decrease in ketoprofen delivery rate with time.   
 
Carbopol® polymers form transparent elegant hydrogels at concentrations as low as 0.5% 
m/m.  This concentration will however cease to hold when other excipients are present in the 
formulation.  The presence of ions decreases the efficiency of mucilages of Carbopol® 
polymers (258).  A formulation of ketoprofen gel requires 2.5% m/m of drug.  Another 
challenge is that ketoprofen is poorly soluble in water.  Less than 1 g is soluble in 10 l of 
water (section 2.1.5).  The manufacturing technology employed to circumvent this problem is 
the use of co-solvent systems to dissolve the drug so that a transparent elegant gel can be 
formulated.  However the use of alcohols as solvents in the manufacture of Carbopol® 
polymer based gels also reduce the viscosity of the formulation.  To circumvent these two 
challenges, Pemulen® TR1 NF co-polymers have been identified and can be added to the 
Carbopol® polymer vehicle.  Pemulen® TR1 NF co-polymers are indicated for use in the 
manufacture of transdermal and topical preparations as viscosity increasing agents.  They are 
used in conjunction with Carbopol® polymers where high viscosity vehicles are required.  
Concentrations as small as 0.1% m/m of Pemulen® TR1 NF co-polymers can produce 
significant differences in the viscosity of the formulations and ultimately the release profile 
of the drug.  This is evident in Figure 5.13.  With increasing concentration of the co-polymer 
there was a corresponding decrease in apparent flux with increasing lag times (Table 5.10).  
The difference is mainly due to increasing viscosity of the formulations.  It may also be that 
Pemulen® TR1 NF contains both hydrophobic and hydrophilic entities hence its ability to 
form emulsion systems.  Increasing the concentration of the co-polymer in the formulation 
increases the hydrophobic content and will result in a decrease in drug release.  Ketoprofen is 
a hydrophobic compound and will partition more in the formulation in the presence of 
increasing amounts of Pemulen® TR1 NF than in the vehicle/membrane interface.  Figures 
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5.13 and 5.14 both illustrate the efficacy of Pemulen® TR1 NF co-polymer in the 
manufacture of ketoprofen gels.  A 0.1% m/m Pemulen® TR1 NF co-polymer concentration 
produced a larger apparent flux and shorter lag time. 
  
As described above, due to the poor aqueous solubility of ketoprofen, alcoholic solvent or co-
solvent systems are needed to be able dissolve the drug in order to formulate an elegant 
transparent gel.  Co-solvents have been widely used as vehicles as well as penetration 
enhancers in topical formulations (240).  The effects of various solvent and co-solvent 
systems on the in vitro release of ketoprofen have been illustrated in Figures 5.18 - 5.23.  
Transcutol® HP, propylene glycol and ethanol were studied.  All three solvents have been 
actively researched for their role as penetration enhancers.  Transcutol® HP has been reported 
(51, 53, 262, 264, 266) to significantly increase the percutaneous penetration of various 
active substances particularly if used in combination with suitable co-solvents.  Mura et al. 
(51) studied the effect of propylene glycol as a co-solvent with Transcutol® HP and found 
that the combination significantly increases the flux of clonazepam.  Godwin et al. (53) 
reported that Transcutol® HP has been shown to increase the skin accumulation of topically 
applied compounds with a concomitant increase in transdermal permeation.  Studies on 
propylene glycol as the principal solvent system have shown (239, 266) an increase in drug 
flux with increasing amounts of propylene glycol however this was not the case with 
Velissaratou et al. (265).  They found that the release of chlorpheniramine maleate from 
ointment bases did not increase significantly when propylene glycol was incorporated.  Co-
solvent systems with isopropyl myristate (240), Transcutol® HP (51, 264), Azone (248), D-
limonene (248) and propylene glycol have all shown an increase in drug flux.  Studies on 
ethanol as a penetration enhancer have shown a modification of the SC as the principal 
mechanism.  Low concentrations affect only the lipid pathway, while the polar pathway is 
also affected at higher concentrations (25, 267).   
 
Ethanol, as a single solvent, was the most efficient system for the dissolution of the drug prior 
to the gelling process.  High flux values with short lag times were observed with ethanol 
when incorporated into the formulation as the only solvent.  This could be as a result of the 
extremely volatile nature of ethanol.  Ketoprofen is readily soluble in ethanol but ethanol 
volatises rapidly from the formulation when applied leaving behind a high concentration of 
drug which will be made available for diffusion.  This was in contrast to the findings of 
Suwanpidokkul et al. (267) who demonstrated that increasing the amount of ethanol was 
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associated with an increase in both flux values and lag times of zidovudine.  A co-solvent 
system of ethanol and Transcutol® HP produced a synergistic effect with respect to the 
amount of flux produced but an increase in lag time was noted.  Transcutol® HP has been 
indicated as a powerful solubilising agent (51) but is less volatile than ethanol.  The increase 
in lag time of KET018 in Figure 5.20 is due to the lower volatile nature of the co-solvent 
system thus it takes more time for the drug to diffuse from the core of the gel to the 
membrane.  This was evident in Figure 5.20 with the use of Transcutol® HP as a single 
solvent system.  Lafforgue et al. (264) also found reduced flux values of methyl nicotinate 
with Transcutol® HP, similar results were observed by Mayorga et al. (266).  Propylene 
glycol as a co-solvent failed to increase flux in ethanol or Transcutol® HP containing 
formulations to any significant extent.  The lag times produced were also increased.  These 
results were also observed by Mura et al. (51) and Arellano et al. (240).  Although propylene 
glycol produced an in vitro decrease in drug flux when used with a synthetic membrane, it 
has been reported (240) that there is an in vitro and in vivo increase in drug flux with human 
or animal skin.  This is because propylene glycol diffuses into the skin and enhances the 
partition of the drug into it, thus producing higher permeability co-efficients (239). 
 
5.5.4 Conclusion 
It is clear that many factors can influence the release of drug from a topical semisolid 
formulation.  Variables such as grade of polymer, polymer concentration, drug loading in 
donor chamber, vehicle pH and solvent systems can all influence the thermodynamic activity 
of the solute for the vehicle in question.  It is the combined effect of these factors that 
influence the release rate of the drug, the parameter most useful for screening of formulations 
during the early stages of product development. 
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5.6 COMPARISON OF DIFFUSION STUDIES OF KETOPROFEN BETWEEN 
THE FRANZ DIFFUSION CELL AND THE EUROPEAN PHARMACOPOEIA 
DIFFUSION CELL 
 
5.6.1 Introduction 
A number of different diffusion cells have been reported (110, 114 - 116, 270) in the 
literature for the measurement of drug release from topical formulations.  Some of these 
diffusion cells are commercially available and others are laboratory designed (268).  This 
diversity of apparatus has complicated the inter-laboratory comparisons of results and the 
extrapolation of data to the in vivo situation (268).  Chilcott et al. (269) studied the inter- and 
intra-laboratory variation in diffusion cell measurements from 18 laboratories and reported 
significantly different results on the in vitro release measurements of methyl paraben through 
a synthetic membrane.  Significantly different statistical results were also reported for similar 
diffusion cells from different laboratories. 
 
Nearly all the published work on the in vitro release of drugs from semisolids was reported 
using vertical Franz diffusion cells.  An alternative is the USP tablet dissolution apparatus 
modified to accommodate the European Pharmacopoeia diffusion cell.  Figures 1.8 and 1.9 in 
section 1.4.2 present schematic diagrams of the modified Franz diffusion cell and the 
European Pharmacopoeia diffusion cell.  In a recent study (100) in this laboratory the release 
of ibuprofen from various proprietary products through biological and synthetic membranes 
was greater from the European Pharmacopoeia diffusion cell than the vertical modified Franz 
diffusion cell, however the data was not corrected for membrane temperature which was 
different in the two diffusion systems.   
 
The purpose of this study was to compare the more commonly used modified Franz diffusion 
cell to the European Pharmacopoeia diffusion cell and note any significant differences (p < 
0.05, ANOVA) of in vitro release from semisolids while keeping the membrane temperature 
in both systems constant.  Three proprietary 2.5% m/m ketoprofen gel products and a number 
of extemporaneously manufactured gel formulations were evaluated using both diffusion 
cells and the results compared.  The use of a synthetic membrane in this study further 
minimises the variability associated with biological membranes. 
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5.6.2 Results 
The results presented in this study represent data obtained from hplc analysis.   
 
Table 5.11 In vitro release data comparison between Franz and European Pharmacopoeia diffusion 
cells 
 Franz diffusion cell European Pharmacopoeia diffusion 
cell 
 
Formulation 
Apparent 
release constant 
(μg/cm2/h1/2) 
Lag time 
(minutes) 
2r  Apparent 
release constant 
(μg/cm2/h1/2) 
Lag time 
(minutes) 
2r  
Fastum® Gel 112.0 ± 5.111 3.91 0.9357 154.4 ± 4.319 21.31 0.9748 
Ketum® Gel 109.6 ± 2.538 1.10 0.9826 158.6 ± 7.260 18.07 0.9353 
Oruvail® Gel 45.63 ± 2.433 28.89 0.9142 81.05 ± 3.859 97.23 0.9304 
KET001 139.6 ± 5.109 6.78 0.9577 157.3 ± 7.027 54.81 0.9382 
KET002 95.75 ± 2.180 25.67 0.9832 167.2 ± 5.682 44.69 0.9633 
KET003 94.47 ± 3.225 34.56 0.9630 108.8 ± 5.914 106.13 0.9111 
KET004 104.4 ± 2.694 24.99 0.9785 130.8 ± 6.046 63.28 0.9342 
KET005 124.4 ± 4.364 25.17 0.9610 154.4 ± 5.684 59.60 0.9572 
KET006 133.3 ± 5.253 39.50 0.9513 158.8 ± 6.083 48.21 0.9538 
KET007 86.60 ± 3.744 24.06 0.9419 166.1 ± 5.330 51.10 0.9671 
KET008 116.6 ± 4.650 21.62 0.9501 145.0 ± 6.179 46.86 0.9435 
KET009 101.5 ± 2.944 38.73 0.9730 169.5 ± 5.696 31.00 0.9641 
KET010 96.80 ± 4.047 56.89 0.9455 146.8 ± 5.021 52.99 0.9628 
KET011 60.04 ± 5.217 65.90 0.8006 118.9 ± 6.026 81.43 0.9219 
KET012 136.1 ± 5.604 21.23 0.9470 160.9 ± 10.33 68.31 0.8803 
KET013 7.57 ± 0.7859 103.44 0.7380 - - - 
KET014 35.29 ± 3.014 62.06 0.8061 83.09 ± 4.320 102.02 0.9181 
KET015 43.96 ± 3.143 47.18 0.8556 58.23 ± 3.557 112.78 0.8903 
KET016 154.7 ± 9.051 39.70 0.8985 179.0 ± 11.09 80.87 0.8876 
KET017 75.56 ± 4.401 85.39 0.8993 138.2 ± 6.902 103.28 0.9239 
KET018 142.5 ± 8.035 59.23 0.9051 213.8 ± 7.850 57.27 0.9574 
KET019 98.83 ± 6.622 11.34 0.8710 180.4 ± 6.881 20.56 0.9542 
KET020 101.4 ± 6.352 115.43 0.8853 160.2 ± 9.997 129.13 0.8861 
 
Table 5.11 summarizes the kinetic data obtained from the linear regression analysis 
performed at a 95% confidence interval for both the Franz diffusion cell and the European 
Pharmacopoeia diffusion cell.  For both cells the mean in vitro ketoprofen release across the 
synthetic membrane increased with the square root of time for all formulations.  The linear 
correlation co-efficient ranges from 0.7380 - 0.9832 for the Franz diffusion cell and 0.8803 - 
0.9748 for the European Pharmacopoeia diffusion cell.  Although the linear correlation co-
efficients expressed by some of the formulations in both diffusion cells were less than 0.9, the 
slope of each regression line displayed a significant deviation from zero (p < 0.05, ANOVA) 
indicating conformation to the Higuchi principle.  Higher flux values and longer lag times 
were observed with the European Pharmacopoeia diffusion cell for all formulations.  The 
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lowest flux value was produced by KET013 in the Franz diffusion cell but the concentrations 
were too small to be detected in the receptor fluid into which the European Pharmacopoeia 
diffusion cell had been submerged.  There was no correlation observed between the two 
diffusion cells with respect to lag time.  KET016 produced the highest flux value of 154.7 ± 
9.051 μg/cm2/h½ in the Franz diffusion cell while KET018 produced a flux value of 213.8 ± 
7.850 μg/cm2/h½ in the European Pharmacopoeia diffusion cell.  KET013 would probably 
have produced the lowest flux value in the European Pharmacopoeia diffusion cell if 
quantification was possible by a more sensitive analytical procedure. 
 
The individual diffusion profiles of the proprietary products and all the extemporaneous 
formulations are presented in appendix II.  Group representation of results from Franz 
diffusion cells and European Pharmacopoeia diffusion cells based on the experimental 
manipulation of formulations are illustrated below.  Figures 5.24 - 5.29 illustrate the 
comparison of the Franz diffusion cell and the European Pharmacopoeia diffusion cell for the 
in vitro release of ketoprofen from various formulations including the proprietary 
formulations.  The graphs show that the release of ketoprofen was somewhat higher in the 
case of the European Pharmacopoeia diffusion cells (p < 0.05, ANOVA). 
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Figure 5.24 Franz diffusion cell and European Pharmacopoeia diffusion cell comparison of the in 
vitro release of ketoprofen from proprietary formulations )5( =n  
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Figure 5.25 Effect of different grades of Carbopol® polymers on the release of ketoprofen from Franz 
diffusion cells and European Pharmacopoeia diffusion cells )5( =n  
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Figure 5.26 Effect of different concentration of Carbopol® Ultrez™ 10 NF polymer on the release of 
ketoprofen from Franz diffusion cells and European Pharmacopoeia diffusion cells )5( =n  
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Figure 5.27 Effect of drug concentration on the release of ketoprofen from Franz diffusion cells and 
European Pharmacopoeia diffusion cells )5( =n  
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Figure 5.28 Effect of pH on the release of ketoprofen from Franz diffusion cells and European 
Pharmacopoeia diffusion cells )5( =n  
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Figure 5.29 Effect of Pemulen® TR1 NF into Carbopol® 980 NF formulations on the release of 
ketoprofen from Franz diffusion cells and European Pharmacopoeia diffusion cells )5( =n  
 
5.6.3 Discussion 
The general setup of the diffusion apparatus was more tedious with the USP dissolution 
apparatus compared to the Franz apparatus.  Approximately 6 l of degassed receptor fluid 
was required for the USP dissolution apparatus whereas 500 ml was more than enough for a 
dissolution run time of 72 hours using the Franz diffusion cells.  The larger surface area of 
European Pharmacopoeia diffusion cell required more silicone membrane.  The loading of 
the gel formulation into the European Pharmacopoeia diffusion cell was much easier as 
compared to the Franz diffusion cell.  A direct weighing on a top loader analytical balance 
sufficed to transfer 500 mg of the gel into the donor chamber of the European Pharmacopoeia 
diffusion cell but a more tedious procedure was required for transferring 100 mg of gel into 
the donor chamber of the Franz diffusion cell.  It was easier to attain a more uniform spread 
of the gel in the European Pharmacopoeia diffusion cell compared to the Franz diffusion cell 
where obtaining a uniform layer was not always possible.  The manual manipulation of the 
receptor phase to avoid air bubbles during the dissolution run became very tedious in the 
Franz diffusion cells.  Since the Franz diffusion cells are made of glass they were more 
susceptible to breakages while the European Pharmacopoeia diffusion cells were made from 
teflon and not easily broken. 
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The observed differences in the diffusion rate observed with the European Pharmacopoeia 
diffusion cell in comparison to the Franz diffusion cell can be explained in terms of the 
design of the diffusion apparatus, experimental conditions and the intrinsic nature of the 
gelling agent.   
 
Although Keshary et al. (271) identified some shortfalls with respect to solution 
hydrodynamics, mixing efficiency and temperature control in the design of the original Franz 
diffusion cell, the modified Franz diffusion cell still leaves much to be desired in comparison 
to the European Pharmacopoeia diffusion cell.  A suggestion would be to further extend the 
water jacket circulating around the receptor chamber in the Franz diffusion cell to the donor 
chamber in order to maintain the same temperature in both chambers. 
 
The membrane temperature in both diffusion cells was adjusted in order to have the same 
temperature reading.  This was not a problem in the USP dissolution apparatus because when 
the European Pharmacopoeia diffusion cell is immersed in the receptor fluid, the temperature 
of the membrane will equilibrate with the temperature of the water bath.  This was somewhat 
of a challenge in the Franz diffusion apparatus.  An experiment conducted in this study, on 
the temperature of the membrane in the donor chamber of the Franz diffusion cells, 
confirmed that a membrane temperature of 32 ± 0.5°C was only possible when the 
temperature of the heating element was set to 37 ± 0.5°C.  Two problems were encountered 
as a result of this temperature manipulation.  There was a substantial amount of receptor fluid 
evaporation through the sampling port from the receptor chamber of the Franz diffusion cell 
and there was some heat loss from the plastic tubing connecting the pump to the Franz 
diffusion cells.  The evaporation from the receptor chamber meant that the lost fluids had to 
be replaced with fresh degassed receptor fluid which inevitably reduces the concentration of 
the permeant in the receptor chamber.  More serious though with regards to the evaporation 
of receptor fluid is the formation of air bubbles on the underside of the membrane which 
reduces diffusion.  The problem is exacerbated during the overnight run times when the Franz 
diffusion cell could not be manually tipped to remove the air bubbles even though the open 
end of the sampling ports were sealed.  The problem of air bubbles has been identified by a 
number of authors (110, 114, 118, 120) and still remains the major drawback to the use of the 
Franz diffusion cell. 
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The loss of receptor fluid containing diffused drug was inevitable during complete emptying 
of the Franz diffusion cell at sampling times.  This may have resulted in inaccurate drug 
quantification thus producing lower diffusion profiles as compared to those obtained from the 
European Pharmacopoeia diffusion cell.  The non-continuous process of the Franz diffusion 
cell may result in absolute sink conditions not being maintained during the entire diffusion 
run especially after 8 hours.  The concentration of the drug in the receptor fluid increases 
with time.  This increase decreases the concentration gradient of the drug between the donor 
chamber and the receptor chamber resulting in lower drug diffusion before the next sampling 
time.  In the case of the European Pharmacopoeia diffusion cell, absolute sink conditions 
were maintained at all times due to the large volume of the receptor phase and the continuous 
process which allowed for minimum drug loss during sampling times.  Reference to the 
diffusion profile of KET016 in appendix II shows that a nearly superimposable profile was 
observed until about 24 hours for both diffusion cells after which the rate of release from the 
Franz diffusion cell began to decrease.  Sink conditions were not maintained in the Franz 
diffusion cells after 24 hours. 
  
Another possible reason to explain the high release from the European Pharmacopoeia 
diffusion cell compared to the Franz diffusion cell is the nature of the gelling agent employed 
in the manufacture of the gels.  Carbopol® polymers, as with most other gelling agents, 
exhibit an intrinsic property known as thixotropy.  This is where the gel has the ability to 
exhibit gel-sol transitions when subjected to external conditions such as increase in shear rate 
or an increase in temperature (129).  In the European Pharmacopoeia diffusion cell, the 
temperature may be high enough for the gel to change into a slightly viscous liquid which 
will increase the kinetic energy of the drug within the formulation and therefore increase the 
rate of diffusion into the receptor fluid.  An increase in temperature is associated with an 
increase in kinetic energy and a decrease in activation energy.  This finding may not be the 
same for that obtained from the Franz diffusion cell.  Increasing the temperature in the Franz 
diffusion apparatus would lead to an inevitable temperature loss through the plastic tubing 
and thus the temperature of the donor chamber would not be high enough to change the 
physical state of the gel under evaluation.  Thixotropy would therefore not occur under such 
experimental conditions and fewer drug molecules will diffuse into the receptor phase. 
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5.6.4 Conclusion 
In product development, the large volume of the European Pharmacopoeia diffusion cell does 
not allow for the detection of very small quantities of diffused drug whereas it may be more 
than adequate to compare dissolution profiles of established finished products.  Conversely, 
the Franz diffusion cells will be the best diffusion cell to employ in the initial stages of 
product development because the small volume produces high concentrations of the diffused 
drug which can easily be quantified.  Formulations containing a large amount of drug may 
show reduced diffusion over long sampling times due to sink conditions not being 
maintained. 
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5.7 COMPARISON OF DIFFUSION STUDIES OF KETOPROFEN BETWEEN 
HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY AND 
ULTRAVIOLET SPECTROPHOTOMETRY 
 
5.7.1 Introduction 
A survey of the literature (148, 183, 184, 186, 187, 190, 192, 233, 272 - 276) has revealed 
several analytical procedures for the determination of ketoprofen in a number of formulations 
including topical gel preparations with hplc and uv spectrophotometric procedures the most 
commonly employed.  Most laboratories are equipped with a uv spectrophotometer primarily 
because it is simple and easy to use.  Major drawbacks associated with the use of a uv 
spectrophotometer are its inability to measure very dilute concentrations, differentiate 
between compounds absorbing at the same wavelength and its use with photolabile agents.  
The use of an hplc system, although more expensive and cumbersome to setup, is on the 
increase primarily because it overcomes the problems associated with the uv 
spectrophotometer and automated systems are available. 
 
A number of validated hplc analytical procedures for the determination of ketoprofen in the 
literature have been identified in section 3.1 but there seems to be little information on 
validated uv spectrophotometric procedures even though the uv spectrophotometer is the 
most common analytical apparatus used in laboratories.  This has resulted in some 
uncertainty when inter-laboratory comparisons are conducted and different authors present 
their results using different analytical methods.  Chilcott et al. (269) reported an international 
multicenter study on the in vitro release of methyl paraben with the choice of employing 
either an hplc or a uv spectrophotometric analytical procedure.  Although significantly 
different results were obtained with reference to the use of different diffusion cells, the results 
were not analysed for the effect of the choice of the analytical procedure employed in each 
laboratory. 
 
The purpose of this study was to compare the in vitro diffusion profiles obtained by utilising 
both the Franz diffusion cell and the European Pharmacopoeia diffusion cell under hplc and 
uv spectrophotometric analytical procedures.  Three proprietary 2.5% m/m ketoprofen gel 
products and a number of extemporaneously manufactured gel formulations were evaluated. 
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5.7.2 Results 
The flux values and lag times for all the formulations obtained from both the Franz diffusion 
cells and the European Pharmacopoeia diffusion cells using hplc and uv spectrophotometric 
analysis are reported in Tables 5.12 and 5.13.  The results were obtained from a linear 
regression of the data at a 95% confidence interval.  Generally higher flux values were 
obtained from both diffusion cells by the uv spectrophotometric analytical procedure 
although no significant differences (p > 0.05, ANOVA) were noted.  The regression co-
efficients obtained by uv analysis were generally somewhat higher than those obtained by 
hplc analysis.  No distinct relationship was noted with respect to the lag times although 
generally shorter times were observed by uv analysis compared to hplc analysis. 
 
Table 5.12 Comparison of analytic procedure using Franz diffusion cells 
 High-performance liquid 
chromatographic analysis 
Ultraviolet spectrophotometric analysis
 
Formulation 
Apparent 
release constant 
(μg/cm2/h1/2) 
Lag time 
(minutes) 
2r  Apparent 
release constant 
(μg/cm2/h1/2) 
Lag time 
(minutes) 
2r  
Fastum® Gel 112.0 ± 5.111 3.91 0.9357 126.3 ± 5.238 0.57 0.9463 
Ketum® Gel 109.6 ± 2.538 1.10 0.9826 113.5 ± 2.862 3.16 0.9794 
Oruvail® Gel 45.63 ± 2.433 28.89 0.9142 43.32 ± 2.437 39.83 0.9054 
KET001 139.6 ± 5.109 6.78 0.9577 152.1 ± 5.020 5.72 0.9653 
KET002 95.75 ± 2.180 25.67 0.9832 88.39 ± 3.506 34.84 0.9506 
KET003 94.47 ± 3.225 34.56 0.9630 100.7 ± 3.465 28.79 0.9624 
KET004 104.4 ± 2.694 24.99 0.9785 109.6 ± 2.815 25.76 0.9787 
KET005 124.4 ± 4.364 25.17 0.9610 117.7 ± 3.911 20.53 0.9648 
KET006 133.3 ± 5.253 39.50 0.9513 153.3 ± 5.009 15.45 0.9660 
KET007 86.60 ± 3.744 24.06 0.9419 100.2 ± 3.868 3.33 0.9531 
KET008 116.6 ± 4.650 21.62 0.9501 136.0 ± 4.950 10.13 0.9581 
KET009 101.5 ± 2.944 38.73 0.9730 105.5 ± 3.369 30.86 0.9674 
KET010 96.80 ± 4.047 56.89 0.9455 100.5 ± 4.113 56.79 0.9476 
KET011 60.04 ± 5.217 65.90 0.8006 65.02 ± 5.234 63.41 0.8238 
KET012 136.1 ± 5.604 21.23 0.9470 105.9 ± 6.158 59.57 0.8996 
KET013 7.57 ± 0.7859 103.44 0.7380 12.01 ± 1.033 21.58 0.8038 
KET014 35.29 ± 3.014 62.06 0.8061 41.57 ± 3.390 34.69 0.8201 
KET015 43.96 ± 3.143 47.18 0.8556 46.54 ± 2.705 39.51 0.8997 
KET016 154.7 ± 9.051 39.70 0.8985 145.8 ± 8.682 33.04 0.8953 
KET017 75.56 ± 4.401 85.39 0.8993 80.76 ± 4.641 82.13 0.9017 
KET018 142.5 ± 8.035 59.23 0.9051 149.8 ± 8.208 59.03 0.9098 
KET019 98.83 ± 6.622 11.34 0.8710 103.6 ± 6.482 10.04 0.8856 
KET020 101.4 ± 6.352 115.43 0.8853 93.85 ± 6.670 142.67 0.8571 
 
No data was recorded for KET013 in Table 5.13 because the amount of ketoprofen in the 
receptor fluid was too small to be accurately quantified. 
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Table 5.13 Comparison of analytical procedure using European Pharmacopoeia diffusion cells 
 High-performance liquid 
chromatographic analysis 
Ultraviolet spectrophotometric analysis
 
Formulation 
Apparent 
release constant 
(μg/cm2/h1/2) 
Lag time 
(minutes) 
2r  Apparent 
release constant 
(μg/cm2/h1/2) 
Lag time 
(minutes) 
2r  
Fastum® Gel 154.4 ± 4.319 21.31 0.9748 174.0 ± 3.958 7.31 0.9832 
Ketum® Gel 158.6 ± 7.260 18.07 0.9353 168.7 ± 7.892 10.70 0.9326 
Oruvail® Gel 81.05 ± 3.859 97.23 0.9304 88.36 ± 4.419 99.07 0.9238 
KET001 157.3 ± 7.027 54.81 0.9382 172.4 ± 6.500 25.90 0.9552 
KET002 167.2 ± 5.682 44.69 0.9633 187.5 ± 5.861 28.00 0.9688 
KET003 108.8 ± 5.914 106.13 0.9111 126.8 ± 5.960 55.22 0.9320 
KET004 130.8 ± 6.046 63.28 0.9342 154.0 ± 6.843 66.78 0.9388 
KET005 154.4 ± 5.684 59.60 0.9572 165.8 ± 5.495 12.29 0.9650 
KET006 158.8 ± 6.083 48.21 0.9538 185.8 ± 6.078 2.84 0.9659 
KET007 166.1 ± 5.330 51.10 0.9671 193.9 ± 5.183 17.75 0.9770 
KET008 145.0 ± 6.179 46.86 0.9435 162.9 ± 7.261 75.67 0.9385 
KET009 169.5 ± 5.696 31.00 0.9641 182.1 ± 6.848 59.82 0.9554 
KET010 146.8 ± 5.021 52.99 0.9628 173.9 ± 5.259 37.66 0.9707 
KET011 118.9 ± 6.026 81.43 0.9219 132.5 ± 6.462 48.60 0.9272 
KET012 160.9 ± 10.33 68.31 0.8803 158.6 ± 12.49 151.69 0.8300 
KET013 - - - - - - 
KET014 83.09 ± 4.320 102.02 0.9181 108.8 ± 5.947 100.09 0.9103 
KET015 58.23 ± 3.557 112.78 0.8903 77.52 ± 5.636 120.16 0.8515 
KET016 179.0 ± 11.09 80.87 0.8876 190.4 ± 11.21 44.53 0.8973 
KET017 138.2 ± 6.902 103.28 0.9239 153.5 ± 6.710 61.00 0.9407 
KET018 213.8 ± 7.850 57.27 0.9574 234.5 ± 7.300 40.06 0.9690 
KET019 180.4 ± 6.881 20.56 0.9542 200.7 ± 6.655 10.19 0.9650 
KET020 160.2 ± 9.997 129.13 0.8861 159.5 ± 10.61 146.02 0.8725 
 
Figures 5.30 - 5.41 illustrate the diffusion profiles of the proprietary formulations and the 
extemporaneous formulation using Franz diffusion cells and European Pharmacopoeia 
diffusion cells using hplc and uv spectrophotometric analysis.  The individual diffusion 
profiles of each formulation are presented in appendix II.  Although no statistically 
significant difference (p > 0.05, ANOVA) was obtained between the diffusion profiles using 
hplc and uv spectrophotometric analysis, there was generally a rank order increase with 
respect to data obtained using uv analysis in comparison to those obtained using hplc 
analysis.  The diffusion profiles produced by hplc analysis were generally smooth but some 
erratic profiles have been observed with uv analysis for KET012, KET014 and KET016 using 
European Pharmacopoeia diffusion cells.  The diffusion profiles using hplc and uv analysis 
were generally superimposable where the Franz diffusion cell was utilised but more erratic 
profiles were observed with the use of the European Pharmacopoeia diffusion cell indicating 
that the concentration of the drug may play an important factor.  KET016 displayed nearly 
superimposable diffusion profiles for both the Franz and European Pharmacopoeia diffusion 
cells. 
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Figure 5.30 In vitro Franz cell diffusion profiles of proprietary products using hplc and uv 
spectrophotometric analysis )5( =n  
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Figure 5.31 In vitro European Pharmacopoeia cell diffusion profiles of proprietary products using 
hplc and uv spectrophotometric analysis )5( =n  
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Figure 5.32 Effect of different grades of Carbopol® polymers on the release of ketoprofen using Franz 
diffusion cells with hplc and uv spectrophotometric analysis )5( =n  
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Figure 5.33 Effect of different grades of Carbopol® polymers on the release of ketoprofen using 
European Pharmacopoeia diffusion cells with hplc and uv spectrophotometric analysis )5( =n  
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Figure 5.34 Effect of different concentration of Carbopol® Ultrez™ 10 NF polymer on the release of 
ketoprofen using Franz diffusion cells with hplc and uv spectrophotometric analysis )5( =n  
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Figure 5.35 Effect of different concentration of Carbopol® Ultrez™ 10 NF polymer on the release of 
ketoprofen using European Pharmacopoeia diffusion cells with hplc and uv spectrophotometric 
analysis )5( =n  
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Figure 5.36 Effect of drug concentration on the release of ketoprofen using Franz diffusion cells with 
hplc and uv spectrophotometric analysis )5( =n  
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Figure 5.37 Effect of drug concentration on the release of ketoprofen using European Pharmacopoeia 
diffusion cells with hplc and uv spectrophotometric analysis )5( =n  
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Figure 5.38 Effect of pH on the release of ketoprofen using Franz diffusion cells with hplc and uv 
spectrophotometric analysis )5( =n  
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Figure 5.39 Effect of pH on the release of ketoprofen using European Pharmacopoeia diffusion cells 
with hplc and uv spectrophotometric analysis )5( =n  
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Figure 5.40 Effect of  incorporation of Pemulen® TR1 NF into Carbopol® 980 NF formulations on the 
release of ketoprofen using Franz diffusion cells with hplc and uv spectrophotometric analysis 
)5( =n  
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Figure 5.41 Effect of incorporation of Pemulen® TR1 NF into Carbopol® 980 NF formulations on the 
release of ketoprofen using European Pharmacopoeia diffusion cells with hplc and uv 
spectrophotometric analysis )5( =n  
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5.7.3 Discussion 
The larger and sometimes more erratic diffusion profiles observed more commonly using the 
European Pharmacopoeia diffusion cell on uv analysis can be explained by non-conformity to 
the Beer-Lambert Law as outlined in section 3.2.1.2.1.  The law holds for concentrations high 
enough to attain absorbance values in the region of 0.2 to 0.8.  The European Pharmacopoeia 
apparatus receptor fluid concentrations obtained from KET001, KET002, KET003, KET005, 
KET006, KET007, KET010, KET012, KET013, KET014 and KET015 were too low to be 
accurately quantified by the uv spectrophotometer.  This is because these formulations 
produced absorbance readings less than 0.2 which implied non-conformity with the Beer-
Lambert Law.  As a result erratic absorbance readings were obtained especially from the first 
8 hours of the diffusion run.  This was however not the case with the use of the Franz 
diffusion cells.  The relatively small volumes of the receptor chamber produced high 
concentrations of ketoprofen which had to be diluted to obtain absorbance values within the 
recommended range therefore producing diffusion profiles very similar to those obtained 
from hplc analysis. 
 
Another possible reason for the higher diffusion profiles obtained using uv analysis may be 
due to the photolability of ketoprofen.  Ketoprofen is photolabile and uv radiation converts 
ketoprofen into an excited state, and the energy can be dissipated as heat, light or be 
transferred to the surrounding molecules.  If the excitation energy cannot be lost then the 
molecule may rearrange and form decomposition products (272).  These decomposition 
products may also absorb in the same region as ketoprofen and may result in exaggerated 
absorbance values which would distort the diffusion profiles.  Although ketoprofen samples 
were stored in the dark at 4 ± 0.5°C, exposing the drug sample to uv light during 
spectrophotometric analysis could also result in the formation of decomposition products.  It 
was noted that a number of researchers (184, 187, 217, 219, 221, 222, 233, 274 - 276) who 
utilised uv analysis for the quantification of active pharmaceutical ingredients did not indicate 
the integration time.  This is very important as this is the time the drug sample is exposed to 
uv radiation.  An increased exposure may produce more decomposition products which may 
then produce elevated absorbance readings. 
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5.7.4 Conclusion 
During product development of topical formulations, hplc and uv analysis can be safely 
employed with the utilisation of the Franz diffusion cell.  The spectrophotometric method is 
however less sensitive in the initial stages of the diffusion experiment, especially where the 
European Pharmacopoeia diffusion cell is employed, due to its inability to accurately detect 
low concentrations.  Although the hplc system is a more expensive analytical apparatus, it is 
more sensitive to the detection of small concentrations which can provide vital information 
for the optimization of topical dermatological formulations.
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APPENDIX I 
DESIGNED SPREADSHEET
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DESIGNED SPREADSHEET 
 
Analyst  Filename  
Formulation  Batch ID  Run date  
Strength  Run No.  Number of repeats  
 
 
Analytical summary 
High-performance liquid chromatography Ultraviolet spectrophotometry 
Parameter Settings employed Parameter Settings employed 
Mobile phase 60% ACN:  40% 20 mM PB at pH 2.5 Measurement mode Absorbance 
Stationary phase Spherisorb S5 ODS2 4.0 mm x 250 mm Solvent 0.2 M PB at pH 6.8 
Receptor phase 0.2 M PB at pH 6.8 Wavelength 255 nm 
Flow rate 1.0 ml/min Integration time 1.0 s 
Detection wavelength 255 nm Slit width 2.0 nm 
Injection volume 20 µl Beam mode Double beam 
AUFS 0.2 Lamp change When necessary 
Date of analysis  Date of analysis  
 
 
Calibration data 
Concentration 
(µg/ml) 
Peak area/Absorbance 
(1) 
Peak area/Absorbance 
(2) 
Average Standard 
deviation 
   #DIV/0! #DIV/0! 
   #DIV/0! #DIV/0! 
   #DIV/0! #DIV/0! 
   #DIV/0! #DIV/0! 
   #DIV/0! #DIV/0! 
   #DIV/0! #DIV/0! 
   #DIV/0! #DIV/0! 
   #DIV/0! #DIV/0! 
Calibration date    
Equation of linear regression    
Correlation co-efficient    
 
 
 Diffusion cell chamber 
 1 2 3 4 5 
Surface area (cm2)      
Weighing      
 
 
Peak Area/Absorbance 
 Cell 1 Cell 2 Cell 3 Cell 4 Cell 5   
Time 
(hours) 
     Average Standard 
deviation 
0      #DIV/0! #DIV/0! 
2      #DIV/0! #DIV/0! 
4      #DIV/0! #DIV/0! 
8      #DIV/0! #DIV/0! 
24      #DIV/0! #DIV/0! 
48      #DIV/0! #DIV/0! 
72      #DIV/0! #DIV/0! 
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Volume recovered (ml) 
 Cell 1 Cell 2 Cell 3 Cell 4 Cell 5   
Time 
(hours) 
     Average Standard 
deviation 
0      #DIV/0! #DIV/0! 
2      #DIV/0! #DIV/0! 
4      #DIV/0! #DIV/0! 
8      #DIV/0! #DIV/0! 
24      #DIV/0! #DIV/0! 
48      #DIV/0! #DIV/0! 
72      #DIV/0! #DIV/0! 
 
Concentration (µg/ml) 
 Cell 1 Cell 2 Cell 3 Cell 4 Cell 5   
Time 
(hours) 
     Average Standard 
deviation 
0 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
2 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
4 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
8 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
24 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
48 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
72 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
 
 
Amount liberated (µg) 
 Cell 1 Cell 2 Cell 3 Cell 4 Cell 5   
Time 
(hours) 
     Average Standard 
deviation 
0 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
2 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
4 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
8 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
24 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
48 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
72 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
 
Amount liberated (µg/cm2) 
 Cell 1 Cell 2 Cell 3 Cell 4 Cell 5   
Time 
(hours) 
     Average Standard 
deviation 
0 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
2 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
4 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
8 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
24 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
48 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
72 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
 
Cumulative amount liberated (µg/cm2) 
 Cell 1 Cell 2 Cell 3 Cell 4 Cell 5   
Time 
(hours) 
     Average Standard 
deviation 
0 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
2 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
4 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
8 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
24 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
48 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
72 #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! #DIV/0! 
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Calibration Analysis
y = 0
R2 = #N/A
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An electronic version of this spreadsheet is included in the cd located at the back of the thesis. 
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BATCH PRODUCTION RECORD 
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BATCH PRODUCTION RECORD 
 
Formulator Adcock Ingram Limited, Private Bag X69, Bryanston, 2021, South Africa 
Product Fastum® gel Batch ID 76 Batch size 50 g 
Strength 2.5% m/m ketoprofen Date of issue 05/10/2004 Issued by RNO Tettey-Amlalo 
 
Materials Formulae Batch number Signatures 
 Percent m/m Actually added  Dispensed by Checked by 
Ketoprofen      
Carbopol® 940      
Triethanolamine      
Lavender oil      
Ethanol      
Purified water      
 
Manufacturing date 10/2002 Homogenising time  Primary packing Tube Storage 25°C 
Mixing time  Ambient temperature  Secondary packing Box Use by date 09/2007 
 
Production Equipment Manufacturer Model 
number 
Dissolution Equipment Manufacturer Model  
number 
Analytical balance Sartorius 2403 Franz diffusion cell RU 37058-8 
Top load balance Sartorius 1474 MP8-2 European Pharmacopoeia 
diffusion cell 
RU  
Magnetic stirrer Labcon MSH 10 Franz heating element Grant TM  
pH meter Crison GLP 21 USP dissolution apparatus Pharma Test PTWS H-425/D 
Ultra-turrax® Janke & Kunkel TP18-10 Membrane Silatos™ REF 7458 
 
Certificate of Analysis 
Test Result Limits Observation/Comment/Description 
pH 5.44 5.0 - 6.0 
Drug content   
1 HPLC analysis 2.46% m/m 2.31 - 2.69% m/m 
2 UV analysis 2.55% m/m 2.31 - 2.69% m/m 
A transparent gel with no air bubbles was noted.  The primary peak 
eluted at 4.00 mins with two other peaks eluting at 2.84 and 3.28 
mins during the hplc analytical procedure.  These peaks are 
suspected to be hydroxybenzoic acid esters which were present at 
0.1% m/m in the formulation. 
Dissolution Profile  
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Rhodes University 
Faculty of Pharmacy 
Transdermal Laboratory 
Grahamstown, South Africa  
 
BATCH PRODUCTION RECORD 
 
Formulator Menarini France, 1/7, rue du Jura, Silic 528, 94633 Rungis Cedex 
Product Ketum® gel Batch ID 04 22 Batch size 60 g 
Strength 2.5% m/m ketoprofen Date of issue 15/10/2004 Issued by RNO Tettey-Amlalo 
 
Materials Formulae Batch number Signatures 
 Percent m/m Actually added  Dispensed by Checked by 
Ketoprofen      
Carbopol® 940      
Diethanolamine      
Lavender oil      
Ethanol      
Purified water      
 
Manufacturing date  Homogenising time  Primary packing Tube Storage 25°C 
Mixing time  Ambient temperature  Secondary packing Box Use by date 12/2006 
 
Production Equipment Manufacturer Model 
number 
Dissolution Equipment Manufacturer Model  
number 
Analytical balance Sartorius 2403 Franz diffusion cell RU 37058-8 
Top load balance Sartorius 1474 MP8-2 European Pharmacopoeia 
diffusion cell 
RU  
Magnetic stirrer Labcon MSH 10 Franz heating element Grant TM  
pH meter Crison GLP 21 USP dissolution apparatus Pharma Test PTWS H-425/D 
Ultra-turrax® Janke & Kunkel TP18-10 Membrane Silatos™ REF 7458 
 
Certificate of Analysis 
Test Result Limits Observation/Comment/Description 
pH 5.51 5.0 - 6.0 
Drug content   
1 HPLC analysis 2.45% m/m 2.31 - 2.69% m/m 
2 UV analysis 2.59% m/m 2.31 - 2.69% m/m 
A transparent gel was noted and there were no air bubbles present.  
The primary peak eluted at 4.00 mins which is similar to the 
retention time of a standard sample of ketoprofen.  There were no 
other peaks observed during the hplc analytical procedure. 
Dissolution Profile  
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Rhodes University 
Faculty of Pharmacy 
Transdermal Laboratory 
Grahamstown, South Africa  
 
BATCH PRODUCTION RECORD 
 
Formulator Rhone-Poulenc Rorer, 50 Kings Hill Avenue, Kings Hill, West Malling, Kent ME 19 4 AH, United Kingdom 
Product Oruvail® gel Batch ID 30104 Batch size 30 g 
Strength 2.5% m/m ketoprofen Date of issue 24/10/04 Issued by RNO Tettey-Amlalo 
 
Materials Formulae Batch number Signatures 
 Percent m/m Actually added  Dispensed by Checked by 
Ketoprofen      
Carbopol® 940      
Triethanolamine      
Lavender oil      
Ethanol      
Purified water      
 
Manufacturing date 03/2000 Homogenising time  Primary packing Tube Storage 25°C 
Mixing time  Ambient temperature  Secondary packing Box Use by date 01/2006 
 
Production Equipment Manufacturer Model 
number 
Dissolution Equipment Manufacturer Model  
number 
Analytical balance Sartorius 2403 Franz diffusion cell RU 37058-8 
Top load balance Sartorius 1474 MP8-2 European Pharmacopoeia 
diffusion cell 
RU  
Magnetic stirrer Labcon MSH 10 Franz heating element Grant TM  
pH meter Crison GLP 21 USP dissolution apparatus Pharma Test PTWS H-425/D 
Ultra-turrax® Janke & Kunkel TP18-10 Membrane Silatos™ REF 7458 
 
Certificate of Analysis 
Test Result Limits Observation/Comment/Description 
pH 5.56 5.0 - 6.0 
Drug content   
1 HPLC analysis 2.45% m/m 2.31 - 2.69% m/m 
2 UV analysis 2.59% m/m 2.31 - 2.69% m/m 
A clear transparent gel was noted although the gel seemed to be too 
viscous compared to Fastum® (SA) and Ketum® (FR).  There were 
no air bubbles observed.  The primary peak eluted at 4.00 and there 
were no other peaks observed during the hplc analytical procedure.  
Dissolution Profile  
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Rhodes University 
Faculty of Pharmacy 
Transdermal Laboratory 
Grahamstown, South Africa  
 
BATCH PRODUCTION RECORD 
 
Formulator Ralph Nii Okai Tettey-Amlalo 
Polymer Carbopol® Ultrez™ NF 10 Batch ID KET001 Batch size 50 g 
Strength 2.5% m/m ketoprofen Date of issue 17/02/2005 Issued by RNO Tettey-Amlalo 
 
Materials Formulae Batch number Signatures 
 Percent m/m Actually added  Dispensed by Checked by 
Ketoprofen 2.50 1.25 g 093K1522 RNO JMH 
Carbopol® Ultrez™ NF 10 1.00 0.50 g CC2NLZG148 RNO JMH 
Triethanolamine 1.50 0.75 g 1024801 RNO JMH 
Ethanol 20.00 12.50 ml L601707 RNO JMH 
Propylene glycol 20.00 10.00 g 1026325 RNO JMH 
Purified water 55.00 27.50 ml  RNO JMH 
 
Manufacturing date 17/02/05 Homogenising time - Primary packing Jar Storage 25°C 
Mixing time 60 mins Ambient temperature 27°C Secondary packing - Use by date 19/02/05 
 
Production Equipment Manufacturer Model 
number 
Dissolution Equipment Manufacturer Model  
number 
Analytical balance Sartorius 2403 Franz diffusion cell RU 37058-8 
Top load balance Sartorius 1474 MP8-2 European Pharmacopoeia 
diffusion cell 
RU  
Magnetic stirrer Labcon MSH 10 Franz heating element Grant TM  
pH meter Crison GLP 21 USP dissolution apparatus Pharma Test PTWS H-425/D 
Ultra-turrax® Janke & Kunkel TP18-10 Membrane Silatos™ REF 7458 
 
Certificate of Analysis 
Test Result Limits Observation/Comment/Description 
pH 5.46 5.0 - 6.0 
Drug content   
1 HPLC analysis 2.49% m/m 2.31 - 2.69% m/m 
2 UV analysis 2.61% m/m 2.31 - 2.69% m/m 
A slightly translucent gel was formed. Air bubbles were 
incorporated during the neutralisation stage. 
Dissolution Profile  
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Rhodes University 
Faculty of Pharmacy 
Transdermal Laboratory 
Grahamstown, South Africa  
 
BATCH PRODUCTION RECORD 
 
Formulator Ralph Nii Okai Tettey-Amlalo 
Polymer Carbopol® Ultrez™ 10 NF Batch ID KET002 Batch size 50 g 
Strength 2.5% m/m ketoprofen Date of issue 21/02/2005 Issued by RNO Tettey-Amlalo 
 
Materials Formulae Batch number Signatures 
 Percent m/m Actually added  Dispensed by Checked by 
Ketoprofen 2.50 1.25 g 093K1522 RNO JMH 
Carbopol® Ultrez™ 10 NF 1.50 0.75 g CC2NLZG148 RNO JMH 
Triethanolamine 2.25 1.13 g 1024801 RNO JMH 
Ethanol 20.00 12.50 ml L601707 RNO JMH 
Propylene glycol 20.00 10.00 g 1026325 RNO JMH 
Purified water 53.75 26.88 ml  RNO JMH 
 
Manufacturing date 21/02/05 Homogenising time - Primary packing Jar Storage 24°C 
Mixing time 60 mins Ambient temperature 27°C Secondary packing - Use by date 23/02/05 
 
Production Equipment Manufacturer Model 
number 
Dissolution Equipment Manufacturer Model  
number 
Analytical balance Sartorius 2403 Franz diffusion cell RU 37058-8 
Top load balance Sartorius 1474 MP8-2 European Pharmacopoeia 
diffusion cell 
RU  
Magnetic stirrer Labcon MSH 10 Franz heating element Grant TM  
pH meter Crison GLP 21 USP dissolution apparatus Pharma Test PTWS H-425/D 
Ultra-turrax® Janke & Kunkel TP18-10 Membrane Silatos™ REF 7458 
 
Certificate of Analysis 
Test Result Limits Observation/Comment/Description 
pH 5.85 5.0 - 6.0 
Drug content   
1 HPLC analysis 2.51% m/m 2.31 - 2.69% m/m 
2 UV analysis 2.63% m/m 2.31 - 2.69% m/m 
An elegant gel was formed. The gel was slightly viscous and not as 
runny as KET001. 
Dissolution Profile  
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Rhodes University 
Faculty of Pharmacy 
Transdermal Laboratory 
Grahamstown, South Africa  
 
BATCH PRODUCTION RECORD 
 
Formulator Ralph Nii Okai Tettey-Amlalo 
Polymer Carbopol® Ultrez™ 10 NF Batch ID KET003 Batch size 50 g 
Strength 2.5% m/m ketoprofen Date of issue 28/02/2005 Issued by RNO Tettey-Amlalo 
 
Materials Formulae Batch number Signatures 
 Percent m/m Actually added  Dispensed by Checked by 
Ketoprofen 2.50 1.25 g 093K1522 RNO JMH 
Carbopol® Ultrez™ 10 NF 2.00 1.00 g CC2NLZG148 RNO JMH 
Triethanolamine 3.00 1.50 g 1024801 RNO JMH 
Ethanol 20.00 12.50 ml L601707 RNO JMH 
Propylene glycol 20.00 10.00 g 1026325 RNO JMH 
Purified water 52.50 26.25 ml  RNO JMH 
 
Manufacturing date 28/02/05 Homogenising time - Primary packing Jar Storage 25°C 
Mixing time 60 mins Ambient temperature 27°C Secondary packing - Use by date 02/03/05 
 
Production Equipment Manufacturer Model 
number 
Dissolution Equipment Manufacturer Model  
number 
Analytical balance Sartorius 2403 Franz diffusion cell RU 37058-8 
Top load balance Sartorius 1474 MP8-2 European Pharmacopoeia 
diffusion cell 
RU  
Magnetic stirrer Labcon MSH 10 Franz heating element Grant TM  
pH meter Crison GLP 21 USP dissolution apparatus Pharma Test PTWS H-425/D 
Ultra-turrax® Janke & Kunkel TP18-10 Membrane Silatos™ REF 7458 
 
Certificate of Analysis 
Test Result Limits Observation/Comment/Description 
pH 5.91 5.0 - 6.0 
Drug content   
1 HPLC analysis 2.51% m/m 2.31 - 2.69% m/m 
2 UV analysis 2.62% m/m 2.31 - 2.69% m/m 
An elegant gel was formed. The gel was slightly viscous and not as 
runny as KET001 but similar to KET002. 
Dissolution Profile  
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Rhodes University 
Faculty of Pharmacy 
Transdermal Laboratory 
Grahamstown, South Africa  
 
BATCH PRODUCTION RECORD 
 
Formulator Ralph Nii Okai Tettey-Amlalo 
Polymer Carbopol® 974P NF Batch ID KET004 Batch size 50 g 
Strength 2.5% m/m ketoprofen Date of issue 08/03/2005 Issued by RNO Tettey-Amlalo 
 
Materials Formulae Batch number Signatures 
 Percent m/m Actually added  Dispensed by Checked by 
Ketoprofen 2.50 1.25 g 093K1522 RNO JMH 
Carbopol® 974 PNF 1.50 0.75 g CC47LAB329 RNO JMH 
Triethanolamine 2.25 1.13 g 1024801 RNO JMH 
Ethanol 20.00 12.50 ml L601707 RNO JMH 
Propylene glycol 20.00 10.00 g 1026325 RNO JMH 
Purified water 53.75 26.88 ml  RNO JMH 
 
Manufacturing date 08/03/05 Homogenising time - Primary packing Jar Storage 25°C 
Mixing time 60 mins Ambient temperature 29°C Secondary packing - Use by date 10/03/05 
 
Production Equipment Manufacturer Model 
number 
Dissolution Equipment Manufacturer Model  
number 
Analytical balance Sartorius 2403 Franz diffusion cell RU 37058-8 
Top load balance Sartorius 1474 MP8-2 European Pharmacopoeia 
diffusion cell 
RU  
Magnetic stirrer Labcon MSH 10 Franz heating element Grant TM  
pH meter Crison GLP 21 USP dissolution apparatus Pharma Test PTWS H-425/D 
Ultra-turrax® Janke & Kunkel TP18-10 Membrane Silatos™ REF 7458 
 
Certificate of Analysis 
Test Result Limits Observation/Comment/Description 
pH 5.91 5.0 - 6.0 
Drug content   
1 HPLC analysis 2.51% m/m 2.31 - 2.69% m/m 
2 UV analysis 2.56% m/m 2.31 - 2.69% m/m 
Gel formed, although slightly translucent. It was as elegant as 
KET003. 
Dissolution Profile  
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Rhodes University 
Faculty of Pharmacy 
Transdermal Laboratory 
Grahamstown, South Africa  
 
BATCH PRODUCTION RECORD 
 
Formulator Ralph Nii Okai Tettey-Amlalo 
Polymer Carbopol® 980 NF Batch ID KET005 Batch size 50 g 
Strength 2.5% m/m ketoprofen Date of issue 17/03/2005 Issued by RNO Tettey-Amlalo 
 
Materials Formulae Batch number Signatures 
 Percent m/m Actually added  Dispensed by Checked by 
Ketoprofen 2.50 1.25 g 093K1522 RNO JMH 
Carbopol® 980 NF 1.50 0.75 g CC216CC696 RNO JMH 
Triethanolamine 2.25 1.13 g 1024801 RNO JMH 
Ethanol 20.00 12.50 ml L601707 RNO JMH 
Propylene glycol 20.00 10.00 g 1026325 RNO JMH 
Purified water 53.75 26.88 ml  RNO JMH 
 
Manufacturing date 17/03/05 Homogenising time - Primary packing Jar Storage 26°C 
Mixing time 60 mins Ambient temperature 28°C Secondary packing - Use by date 19/03/05 
 
Production Equipment Manufacturer Model 
number 
Dissolution Equipment Manufacturer Model  
number 
Analytical balance Sartorius 2403 Franz diffusion cell RU 37058-8 
Top load balance Sartorius 1474 MP8-2 European Pharmacopoeia 
diffusion cell 
RU  
Magnetic stirrer Labcon MSH 10 Franz heating element Grant TM  
pH meter Crison GLP 21 USP dissolution apparatus Pharma Test PTWS H-425/D 
Ultra-turrax® Janke & Kunkel TP18-10 Membrane Silatos™ REF 7458 
 
Certificate of Analysis 
Test Result Limits Observation/Comment/Description 
pH 5.73 5.0 - 6.0 
Drug content   
1 HPLC analysis 2.52% m/m 2.31 - 2.69% m/m 
2 UV analysis 2.58% m/m 2.31 - 2.69% m/m 
Gel formed similar to KET004. Air bubbles were present. 
Dissolution Profile  
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Rhodes University 
Faculty of Pharmacy 
Transdermal Laboratory 
Grahamstown, South Africa  
 
BATCH PRODUCTION RECORD 
 
Formulator Ralph Nii Okai Tettey-Amlalo 
Polymer Carbopol® 981P NF Batch ID KET006 Batch size 50 g 
Strength 2.5% m/m ketoprofen Date of issue 14/04/2005 Issued by RNO Tettey-Amlalo 
 
Materials Formulae Batch number Signatures 
 Percent m/m Actually added  Dispensed by Checked by 
Ketoprofen 2.50 1.25 g 093K1522 RNO JMH 
Carbopol® 981 PNF 1.50 0.75 g CC485CD381 RNO JMH 
Triethanolamine 2.25 1.13 g 1024801 RNO JMH 
Ethanol 20.00 12.50 ml L601707 RNO JMH 
Propylene glycol 20.00 10.00 g 1026325 RNO JMH 
Purified water 53.75 26.88 ml  RNO JMH 
 
Manufacturing date 14/04/05 Homogenising time - Primary packing Jar Storage 20°C 
Mixing time 60 mins Ambient temperature 22°C Secondary packing - Use by date 16/04/05 
 
Production Equipment Manufacturer Model 
number 
Dissolution Equipment Manufacturer Model  
number 
Analytical balance Sartorius 2403 Franz diffusion cell RU 37058-8 
Top load balance Sartorius 1474 MP8-2 European Pharmacopoeia 
diffusion cell 
RU  
Magnetic stirrer Labcon MSH 10 Franz heating element Grant TM  
pH meter Crison GLP 21 USP dissolution apparatus Pharma Test PTWS H-425/D 
Ultra-turrax® Janke & Kunkel TP18-10 Membrane Silatos™ REF 7458 
 
Certificate of Analysis 
Test Result Limits Observation/Comment/Description 
pH 5.81 5.0 - 6.0 
Drug content   
1 HPLC analysis 2.53% m/m 2.31 - 2.69% m/m 
2 UV analysis 2.61% m/m 2.31 - 2.69% m/m 
Transparent elegant gel formed. Air bubbles incorporated during 
neutralization. 
Dissolution Profile  
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Rhodes University 
Faculty of Pharmacy 
Transdermal Laboratory 
Grahamstown, South Africa  
 
BATCH PRODUCTION RECORD 
 
Formulator Ralph Nii Okai Tettey-Amlalo 
Polymer Pemulen® TR1 NF Batch ID KET007 Batch size 50 g 
Strength 2.5% m/m ketoprofen Date of issue 20/04/2005 Issued by RNO Tettey-Amlalo 
 
Materials Formulae Batch number Signatures 
 Percent m/m Actually added  Dispensed by Checked by 
Ketoprofen 2.50 1.25 g 093K1522 RNO JMH 
Pemulen® TR1 NF 1.50 0.75 g CC3DACT860 RNO JMH 
Triethanolamine 2.25 1.13 g 1024801 RNO JMH 
Ethanol 20.00 12.50 ml L601707 RNO JMH 
Propylene glycol 20.00 10.00 g 1026325 RNO JMH 
Purified water 53.75 26.88 ml  RNO JMH 
 
Manufacturing date 20/04/05 Homogenising time - Primary packing Jar Storage 18°C 
Mixing time 60 mins Ambient temperature 22°C Secondary packing - Use by date 22/04/05 
 
Production Equipment Manufacturer Model 
number 
Dissolution Equipment Manufacturer Model  
number 
Analytical balance Sartorius 2403 Franz diffusion cell RU 37058-8 
Top load balance Sartorius 1474 MP8-2 European Pharmacopoeia 
diffusion cell 
RU  
Magnetic stirrer Labcon MSH 10 Franz heating element Grant TM  
pH meter Crison GLP 21 USP dissolution apparatus Pharma Test PTWS H-425/D 
Ultra-turrax® Janke & Kunkel TP18-10 Membrane Silatos™ REF 7458 
 
Certificate of Analysis 
Test Result Limits Observation/Comment/Description 
pH 5.81 5.0 - 6.0 
Drug content   
1 HPLC analysis 2.54% m/m 2.31 - 2.69% m/m 
2 UV analysis 2.61% m/m 2.31 - 2.69% m/m 
A very thick gel was formed. The mixture prior to neutralization 
was not homogenised as the mixture did not resemble an emulsion. 
Dissolution Profile  
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Rhodes University 
Faculty of Pharmacy 
Transdermal Laboratory 
Grahamstown, South Africa  
 
BATCH PRODUCTION RECORD 
 
Formulator Ralph Nii Okai Tettey-Amlalo 
Polymer Carbopol® 980 NF, Pemulen® TR1 NF Batch ID KET008 Batch size 50 g 
Strength 2.5% m/m ketoprofen Date of issue 26/04/2005 Issued by RNO Tettey-Amlalo 
 
Materials Formulae Batch number Signatures 
 Percent m/m Actually added  Dispensed by Checked by 
Ketoprofen 2.50 1.25 g 093K1522 RNO JMH 
Carbopol® 980 NF 1.00 0.50 g CC216CC696 RNO JMH 
Pemulen® TR1 NF 0.10 0.05 g CC3DACT860 RNO JMH 
Triethanolamine 1.65 0.83 g 1024801 RNO JMH 
Ethanol 20.00 12.50 ml L601707 RNO JMH 
Propylene glycol 20.00 10.00 g 1026325 RNO JMH 
Purified water 54.75 27.38 ml  RNO JMH 
 
Manufacturing date 26/04/05 Homogenising time 5 mins Primary packing Jar Storage 25°C 
Mixing time 60 mins Ambient temperature 27°C  Secondary packing - Use by date 28/04/05 
 
Production Equipment Manufacturer Model 
number 
Dissolution Equipment Manufacturer Model  
number 
Analytical balance Sartorius 2403 Franz diffusion cell RU 37058-8 
Top load balance Sartorius 1474 MP8-2 European Pharmacopoeia 
diffusion cell 
RU  
Magnetic stirrer Labcon MSH 10 Franz heating element Grant TM  
pH meter Crison GLP 21 USP dissolution apparatus Pharma Test PTWS H-425/D 
Ultra-turrax® Janke & Kunkel TP18-10 Membrane Silatos™ REF 7458 
 
Certificate of Analysis 
Test Result Limits Observation/Comment/Description 
pH 5.62 5.0 - 6.0 
Drug content   
1 HPLC analysis 2.52% m/m 2.31 - 2.69% m/m 
2 UV analysis 2.61% m/m 2.31 - 2.69% m/m 
On addition of Pemulen® the mixture turned milky. Surprisingly 
after neutralisation, the mixture assumed a transparent appearance. 
Dissolution Profile  
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Rhodes University 
Faculty of Pharmacy 
Transdermal Laboratory 
Grahamstown, South Africa  
 
BATCH PRODUCTION RECORD 
 
Formulator Ralph Nii Okai Tettey-Amlalo 
Polymer Carbopol® 980 NF, Pemulen® TR1 NF Batch ID KET009 Batch size 50 g 
Strength 2.5% m/m ketoprofen Date of issue 05/05/2005 Issued by RNO Tettey-Amlalo 
 
Materials Formulae Batch number Signatures 
 Percent m/m Actually added  Dispensed by Checked by 
Ketoprofen 2.50 1.25 g 093K1522 RNO JMH 
Carbopol® 980 NF 1.00 0.50 g CC216CC696 RNO JMH 
Pemulen® TR1 NF 0.30 0.15 g CC3DACT860 RNO JMH 
Triethanolamine 1.95 0.98 g 1024801 RNO JMH 
Ethanol 20.00 12.50 ml L601707 RNO JMH 
Propylene glycol 20.00 10.00 g 1026325 RNO JMH 
Purified water 54.25 27.13 ml  RNO JMH 
 
Manufacturing date 05/05/05 Homogenising time 5 mins Primary packing Jar Storage 23°C 
Mixing time 60 mins Ambient temperature 26°C Secondary packing - Use by date 07/05/05 
 
Production Equipment Manufacturer Model 
number 
Dissolution Equipment Manufacturer Model  
number 
Analytical balance Sartorius 2403 Franz diffusion cell RU 37058-8 
Top load balance Sartorius 1474 MP8-2 European Pharmacopoeia 
diffusion cell 
RU  
Magnetic stirrer Labcon MSH 10 Franz heating element Grant TM  
pH meter Crison GLP 21 USP dissolution apparatus Pharma Test PTWS H-425/D 
Ultra-turrax® Janke & Kunkel TP18-10 Membrane Silatos™ REF 7458 
 
Certificate of Analysis 
Test Result Limits Observation/Comment/Description 
pH 5.64 5.0 - 6.0 
Drug content   
1 HPLC analysis 2.51% m/m 2.31 - 2.69% m/m 
2 UV analysis 2.58% m/m 2.31 - 2.69% m/m 
Emulsion like mixture prior to neutralization.  
Dissolution Profile  
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Rhodes University 
Faculty of Pharmacy 
Transdermal Laboratory 
Grahamstown, South Africa  
 
BATCH PRODUCTION RECORD 
 
Formulator Ralph Nii Okai Tettey-Amlalo 
Polymer Carbopol® 980 NF, Pemulen® TR1 NF Batch ID KET010 Batch size 50 g 
Strength 2.5% m/m ketoprofen Date of issue 04/06/2005 Issued by RNO Tettey-Amlalo 
 
Materials Formulae Batch number Signatures 
 Percent m/m Actually added  Dispensed by Checked by 
Ketoprofen 2.50 1.25 g 093K1522 RNO JMH 
Carbopol® 980 NF 1.00 0.50 g CC216CC696 RNO JMH 
Pemulen® TR1 NF 0.50 0.25 g CC3DACT860 RNO JMH 
Triethanolamine 2.25 1.13 g 1024801 RNO JMH 
Ethanol 20.00 12.50 ml L601707 RNO JMH 
Propylene glycol 20.00 10.00 g 1026325 RNO JMH 
Purified water 53.75 26.88 ml  RNO JMH 
 
Manufacturing date 04/06/05 Homogenising time 5 mins Primary packing Jar Storage 18°C 
Mixing time 60 mins Ambient temperature 20°C Secondary packing - Use by date 06/06/05 
 
Production Equipment Manufacturer Model 
number 
Dissolution Equipment Manufacturer Model  
number 
Analytical balance Sartorius 2403 Franz diffusion cell RU 37058-8 
Top load balance Sartorius 1474 MP8-2 European Pharmacopoeia 
diffusion cell 
RU  
Magnetic stirrer Labcon MSH 10 Franz heating element Grant TM  
pH meter Crison GLP 21 USP dissolution apparatus Pharma Test PTWS H-425/D 
Ultra-turrax® Janke & Kunkel TP18-10 Membrane Silatos™ REF 7458 
 
Certificate of Analysis 
Test Result Limits Observation/Comment/Description 
pH 5.71 5.0 - 6.0 
Drug content   
1 HPLC analysis 2.51% m/m 2.31 - 2.69% m/m 
2 UV analysis 2.59% m/m 2.31 - 2.69% m/m 
Emulsion like mixture prior to neutralisation. 
Dissolution Profile  
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Rhodes University 
Faculty of Pharmacy 
Transdermal Laboratory 
Grahamstown, South Africa  
 
BATCH PRODUCTION RECORD 
 
Formulator Ralph Nii Okai Tettey-Amlalo 
Polymer Carbopol® 980 NF, Pemulen® TR1 NF Batch ID KET011 Batch size 50 g 
Strength 2.5% m/m ketoprofen Date of issue 09/06/2005 Issued by RNO Tettey-Amlalo 
 
Materials Formulae Batch number Signatures 
 Percent m/m Actually added  Dispensed by Checked by 
Ketoprofen 2.50 1.25 g 093K1522 RNO JMH 
Carbopol® 980 NF 1.00 0.50 g CC216CC696 RNO JMH 
Pemulen® TR1 NF 1.00 0.50 g CC3DACT860 RNO JMH 
Triethanolamine 3.00 1.50 g 1024801 RNO JMH 
Ethanol 20.00 12.50 ml L601707 RNO JMH 
Propylene glycol 20.00 10.00 g 1026325 RNO JMH 
Purified water 52.50 26.25 ml  RNO JMH 
 
Manufacturing date 09/06/05 Homogenising time 5 mins Primary packing Jar Storage 18°C 
Mixing time 60 mins Ambient temperature 21°C Secondary packing - Use by date 11/06/05 
 
Production Equipment Manufacturer Model 
number 
Dissolution Equipment Manufacturer Model  
number 
Analytical balance Sartorius 2403 Franz diffusion cell RU 37058-8 
Top load balance Sartorius 1474 MP8-2 European Pharmacopoeia 
diffusion cell 
RU  
Magnetic stirrer Labcon MSH 10 Franz heating element Grant TM  
pH meter Crison GLP 21 USP dissolution apparatus Pharma Test PTWS H-425/D 
Ultra-turrax® Janke & Kunkel TP18-10 Membrane Silatos™ REF 7458 
 
Certificate of Analysis 
Test Result Limits Observation/Comment/Description 
pH 5.41 5.0 - 6.0 
Drug content   
1 HPLC analysis 2.52% m/m 2.31 - 2.69% m/m 
2 UV analysis 2.58% m/m 2.31 - 2.69% m/m 
A very thick, sticky gel was formed.  There were small clumps of 
polymer present in the final product. 
Dissolution Profile  
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Rhodes University 
Faculty of Pharmacy 
Transdermal Laboratory 
Grahamstown, South Africa  
 
BATCH PRODUCTION RECORD 
 
Formulator Ralph Nii Okai Tettey-Amlalo 
Polymer Pemulen® TR1 NF Batch ID KET012 Batch size 50 g 
Strength 2.5% m/m ketoprofen Date of issue 13/06/2005 Issued by RNO Tettey-Amlalo 
 
Materials Formulae Batch number Signatures 
 Percent m/m Actually added  Dispensed by Checked by 
Ketoprofen 2.50 1.25 g 093K1522 RNO JMH 
Pemulen® TR1 NF 1.00 0.50 g CC3DACT860 RNO JMH 
Triethanolamine 1.15 0.58 g 1024801 RNO JMH 
Ethanol 20.00 12.50 ml L601707 RNO JMH 
Propylene glycol 20.00 10.00 g 1026325 RNO JMH 
Purified water 55.35 27.68 ml  RNO JMH 
 
Manufacturing date 13/06/05 Homogenising time 5 mins Primary packing Jar Storage 18°C 
Mixing time 60 mins Ambient temperature 24°C Secondary packing - Use by date 15/06/05 
 
Production Equipment Manufacturer Model 
number 
Dissolution Equipment Manufacturer Model  
number 
Analytical balance Sartorius 2403 Franz diffusion cell RU 37058-8 
Top load balance Sartorius 1474 MP8-2 European Pharmacopoeia 
diffusion cell 
RU  
Magnetic stirrer Labcon MSH 10 Franz heating element Grant TM  
pH meter Crison GLP 21 USP dissolution apparatus Pharma Test PTWS H-425/D 
Ultra-turrax® Janke & Kunkel TP18-10 Membrane Silatos™ REF 7458 
 
Certificate of Analysis 
Test Result Limits Observation/Comment/Description 
pH 5.41 5.0 - 6.0 
Drug content   
1 HPLC analysis 2.53% m/m 2.31 - 2.69% m/m 
2 UV analysis 2.61% m/m 2.31 - 2.69% m/m 
Mixture was emulsion like prior to neutralization. On neutralization, 
the mixture was very opaque and not translucent like the previous 
formulations with Pemulen®. 
Dissolution Profile  
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Rhodes University 
Faculty of Pharmacy 
Transdermal Laboratory 
Grahamstown, South Africa  
 
BATCH PRODUCTION RECORD 
 
Formulator Ralph Nii Okai Tettey-Amlalo 
Polymer Carbopol® Ultrez™ 10 NF Batch ID KET013 Batch size 50 g 
Strength 2.5% m/m ketoprofen Date of issue 28/06/2005 Issued by RNO Tettey-Amlalo 
 
Materials Formulae Batch number Signatures 
 Percent m/m Actually added  Dispensed by Checked by 
Ketoprofen 2.50 1.25 g 093K1522 RNO JMH 
Carbopol® Ultrez™ 10 NF 1.50 0.75 g CC2NLZG148 RNO JMH 
Triethanolamine 4.26 2.13 g 1024801 RNO JMH 
Ethanol 20.00 12.50 ml L601707 RNO JMH 
Propylene glycol 20.00 10.00 g 1026325 RNO JMH 
Purified water 51.76 25.88 ml  RNO JMH 
 
Manufacturing date 28/06/05 Homogenising time 5 mins Primary packing Jar Storage 18°C 
Mixing time 60 mins Ambient temperature 24.5°C Secondary packing - Use by date 01/07/05 
 
Production Equipment Manufacturer Model 
number 
Dissolution Equipment Manufacturer Model  
number 
Analytical balance Sartorius 2403 Franz diffusion cell RU 37058-8 
Top load balance Sartorius 1474 MP8-2 European Pharmacopoeia 
diffusion cell 
RU  
Magnetic stirrer Labcon MSH 10 Franz heating element Grant TM  
pH meter Crison GLP 21 USP dissolution apparatus Pharma Test PTWS H-425/D 
Ultra-turrax® Janke & Kunkel TP18-10 Membrane Silatos™ REF 7458 
 
Certificate of Analysis 
Test Result Limits Observation/Comment/Description 
pH 7.21 5.0 - 6.0 
Drug content   
1 HPLC analysis 2.50% m/m 2.31 - 2.69% m/m 
2 UV analysis 2.52% m/m 2.31 - 2.69% m/m 
An elegant gel was formed.   Presence of air bubbles on mixing. 
Dissolution Profile  
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Rhodes University 
Faculty of Pharmacy 
Transdermal Laboratory 
Grahamstown, South Africa  
 
BATCH PRODUCTION RECORD 
 
Formulator Ralph Nii Okai Tettey-Amlalo 
Polymer Carbopol® Ultrez™ 10 NF Batch ID KET014 Batch size 50 g 
Strength 2.5% m/m ketoprofen Date of issue 05/07/2005 Issued by RNO Tettey-Amlalo 
 
Materials Formulae Batch number Signatures 
 Percent m/m Actually added  Dispensed by Checked by 
Ketoprofen 2.50 1.25 g 093K1522 RNO JMH 
Carbopol® Ultrez™ 10 NF 1.50 0.75 g CC2NLZG148 RNO JMH 
Triethanolamine 3.00 1.50 g 1024801 RNO JMH 
Ethanol 20.00 12.50 ml L601707 RNO JMH 
Propylene glycol 20.00 10.00 g 1026325 RNO JMH 
Purified water 52.76 26.38 ml  RNO JMH 
 
Manufacturing date 05/07/05 Homogenising time 5 mins Primary packing Jar Storage 18°C 
Mixing time 60 mins Ambient temperature 25°C Secondary packing - Use by date 07/07/05 
 
Production Equipment Manufacturer Model 
number 
Dissolution Equipment Manufacturer Model  
number 
Analytical balance Sartorius 2403 Franz diffusion cell RU 37058-8 
Top load balance Sartorius 1474 MP8-2 European Pharmacopoeia 
diffusion cell 
RU  
Magnetic stirrer Labcon MSH 10 Franz heating element Grant TM  
pH meter Crison GLP 21 USP dissolution apparatus Pharma Test PTWS H-425/D 
Ultra-turrax® Janke & Kunkel TP18-10 Membrane Silatos™ REF 7458 
 
Certificate of Analysis 
Test Result Limits Observation/Comment/Description 
pH 6.51 5.0 - 6.0 
Drug content   
1 HPLC analysis 2.51% m/m 2.31 - 2.69% m/m 
2 UV analysis 2.52% m/m 2.31 - 2.69% m/m 
An elegant gel was formed.   Presence of air bubbles on mixing. The 
gel was thicker than KET013 and KET014. 
Dissolution Profile  
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Rhodes University 
Faculty of Pharmacy 
Transdermal Laboratory 
Grahamstown, South Africa  
 
BATCH PRODUCTION RECORD 
 
Formulator Ralph Nii Okai Tettey-Amlalo 
Polymer Carbopol® Ultrez™ 10 NF Batch ID KET015 Batch size 50 g 
Strength 1.5% m/m ketoprofen  Date of issue 18/06/05 Issued by RNO Tettey-Amlalo 
 
Materials Formulae Batch number Signatures 
 Percent m/m Actually added  Dispensed by Checked by 
Ketoprofen 1.50 0.75 g 093K1522 RNO JMH 
Carbopol® Ultrez™ 10 NF 1.50 0.75 g CC2NLZG148 RNO JMH 
Triethanolamine 2.25 1.13 g 1024801 RNO JMH 
Ethanol 20.00 12.50 ml L601707 RNO JMH 
Propylene glycol 20.00 10.00 g 1026325 RNO JMH 
Purified water 54.75 27.38 ml  RNO JMH 
 
Manufacturing date 18/06/05 Homogenising time 5 mins Primary packing Jar Storage 18°C 
Mixing time 60 mins Ambient temperature 25°C Secondary packing - Use by date 20/06/05 
 
Production Equipment Manufacturer Model 
number 
Dissolution Equipment Manufacturer Model  
number 
Analytical balance Sartorius 2403 Franz diffusion cell RU 37058-8 
Top load balance Sartorius 1474 MP8-2 European Pharmacopoeia 
diffusion cell 
RU  
Magnetic stirrer Labcon MSH 10 Franz heating element Grant TM  
pH meter Crison GLP 21 USP dissolution apparatus Pharma Test PTWS H-425/D 
Ultra-turrax® Janke & Kunkel TP18-10 Membrane Silatos™ REF 7458 
 
Certificate of Analysis 
Test Result Limits Observation/Comment/Description 
pH 6.40 5.0 - 6.0 
Drug content   
1 HPLC analysis 1.51% m/m 1.31 - 1.69% m/m 
2 UV analysis 1.52% m/m 1.31 - 1.69% m/m 
An elegant gel was formed.   Presence of air bubbles on mixing. 
Dissolution Profile  
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Rhodes University 
Faculty of Pharmacy 
Transdermal Laboratory 
Grahamstown, South Africa  
 
BATCH PRODUCTION RECORD 
 
Formulator Ralph Nii Okai Tettey-Amlalo 
Polymer Carbopol® Ultrez™ 10 NF Batch ID KET016 Batch size 50 g 
Strength 5.5% m/m ketoprofen Date of issue 04/08/2005 Issued by RNO Tettey-Amlalo 
 
Materials Formulae Batch number Signatures 
 Percent m/m Actually added  Dispensed by Checked by 
Ketoprofen 5.50 2.75 g 093K1522 RNO JMH 
Carbopol® Ultrez™ 10 NF 1.50 0.75 g CC2NLZG148 RNO JMH 
Triethanolamine 2.25 1.13 g 1024801 RNO JMH 
Ethanol 20.00 12.50 ml L601707 RNO JMH 
Propylene glycol 20.00 10.00 g 1026325 RNO JMH 
Purified water 50.75 25.38 ml  RNO JMH 
 
Manufacturing date 03/08/05 Homogenising time 5 mins Primary packing Jar Storage 18.5°C 
Mixing time 60 mins Ambient temperature 24°C Secondary packing - Use by date 06/08/05 
 
Production Equipment Manufacturer Model 
number 
Dissolution Equipment Manufacturer Model  
number 
Analytical balance Sartorius 2403 Franz diffusion cell RU 37058-8 
Top load balance Sartorius 1474 MP8-2 European Pharmacopoeia 
diffusion cell 
RU  
Magnetic stirrer Labcon MSH 10 Franz heating element Grant TM  
pH meter Crison GLP 21 USP dissolution apparatus Pharma Test PTWS H-425/D 
Ultra-turrax® Janke & Kunkel TP18-10 Membrane Silatos™ REF 7458 
 
Certificate of Analysis 
Test Result Limits Observation/Comment/Description 
pH 5.57 5.0 - 6.0 
Drug content   
1 HPLC analysis 5.55% m/m 5.31 - 5.69% m/m 
2 UV analysis 5.60% m/m 5.31 - 5.69% m/m 
The gel formed was not as elegant as the others.  The ketoprofen 
came out of solution and precipitated due to the amount 
incorporated. The gel was gritty and not attractive. 
Dissolution Profile  
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Rhodes University 
Faculty of Pharmacy 
Transdermal Laboratory 
Grahamstown, South Africa  
 
BATCH PRODUCTION RECORD 
 
Formulator Ralph Nii Okai Tettey-Amlalo 
Polymer Carbopol® Ultrez™ 10 NF Batch ID KET017 Batch size 50 g 
Strength 2.5% m/m ketoprofen Date of issue 11/08/2005 Issued by RNO Tettey-Amlalo 
 
Materials Formulae Batch number Signatures 
 Percent m/m Actually added  Dispensed by Checked by 
Ketoprofen 2.50 1.25 g 093K1522 RNO JMH 
Carbopol® Ultrez™ 10 NF 1.50 0.75 g CC2NLZG148 RNO JMH 
Triethanolamine 2.25 1.13 g 1024801 RNO JMH 
Transcutol® HP 20.00 10.00 g 0339024 RNO JMH 
Propylene glycol 20.00 10.00 g 1026325 RNO JMH 
Purified water 53.75 26.88 ml  RNO JMH 
 
Manufacturing date 11/08/05 Homogenising time 5 mins Primary packing Jar Storage 18°C 
Mixing time 60 mins Ambient temperature 25°C Secondary packing  - Use by date 13/08/05 
 
Production Equipment Manufacturer Model 
number 
Dissolution Equipment Manufacturer Model  
number 
Analytical balance Sartorius 2403 Franz diffusion cell RU 37058-8 
Top load balance Sartorius 1474 MP8-2 European Pharmacopoeia 
diffusion cell 
RU  
Magnetic stirrer Labcon MSH 10 Franz heating element Grant TM  
pH meter Crison GLP 21 USP dissolution apparatus Pharma Test PTWS H-425/D 
Ultra-turrax® Janke & Kunkel TP18-10 Membrane Silatos™ REF 7458 
 
Certificate of Analysis 
Test Result Limits Observation/Comment/Description 
pH 5.76 5.0 - 6.0 
Drug content   
1 HPLC analysis 2.51% m/m 2.31 - 2.69% m/m 
2 UV analysis 2.52% m/m 2.31 - 2.69% m/m 
An elegant sweet smelling gel was formed. Devoid of air bubbles. 
Dissolution Profile  
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Rhodes University 
Faculty of Pharmacy 
Transdermal Laboratory 
Grahamstown, South Africa  
 
BATCH PRODUCTION RECORD 
 
Formulator Ralph Nii Okai Tettey-Amlalo 
Polymer Carbopol® Ultrez™ 10 NF Batch ID KET018 Batch size 50 g 
Strength 2.5% m/m ketoprofen Date of issue 14/08/2005 Issued by RNO Tettey-Amlalo 
 
Materials Formulae Batch number Signatures 
 Percent m/m Actually added  Dispensed by Checked by 
Ketoprofen 2.50 1.25 g 093K1522 RNO JMH 
Carbopol® Ultrez™ 10 NF 1.50 0.75 g CC2NLZG148 RNO JMH 
Triethanolamine 2.25 1.13 g 1024801 RNO JMH 
Ethanol 20.00 12.50 ml L601707 RNO JMH 
Transcutol® HP 20.00 10.00 g 0339024 RNO JMH 
Purified water 53.75 26.88 ml  RNO JMH 
 
Manufacturing date 14/08/05 Homogenising time 5 mins Primary packing Jar Storage 18°C 
Mixing time 60 mins Ambient temperature 24°C Secondary packing - Use by date 16/08/05 
 
Production Equipment Manufacturer Model 
number 
Dissolution Equipment Manufacturer Model  
number 
Analytical balance Sartorius 2403 Franz diffusion cell RU 37058-8 
Top load balance Sartorius 1474 MP8-2 European Pharmacopoeia 
diffusion cell 
RU  
Magnetic stirrer Labcon MSH 10 Franz heating element Grant TM  
pH meter Crison GLP 21 USP dissolution apparatus Pharma Test PTWS H-425/D 
Ultra-turrax® Janke & Kunkel TP18-10 Membrane Silatos™ REF 7458 
 
Certificate of Analysis 
Test Result Limits Observation/Comment/Description 
pH 5.80 5.0 - 6.0 
Drug content   
1 HPLC analysis 2.51% m/m 2.31 - 2.69% m/m 
2 UV analysis 2.52% m/m 2.31 - 2.69% m/m 
An elegant sweet smelling gel was formed. Devoid of air bubbles. 
Dissolution Profile  
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Rhodes University 
Faculty of Pharmacy 
Transdermal Laboratory 
Grahamstown, South Africa  
 
BATCH PRODUCTION RECORD 
 
Formulator Ralph Nii Okai Tettey-Amlalo 
Polymer Carbopol® Ultrez™ 10 NF Batch ID KET019 Batch size 50 g 
Strength 2.5% m/m ketoprofen Date of issue 23/08/2005 Issued by RNO Tettey-Amlalo 
 
Materials Formulae Batch number Signatures 
 Percent m/m Actually added  Dispensed by Checked by 
Ketoprofen 2.50 1.25 g 093K1522 RNO JMH 
Carbopol® Ultrez™ 10 NF 1.50 0.75 g CC2NLZG148 RNO JMH 
Triethanolamine 2.25 1.13 g 1024801 RNO JMH 
Ethanol 40.00 25.00 ml L601707 RNO JMH 
Purified water 53.75 26.88 ml  RNO JMH 
 
Manufacturing date 22/08/05 Homogenising time 5 mins Primary packing Jar Storage 18°C 
Mixing time 60 mins Ambient temperature 24°C Secondary packing - Use by date 25/08/05 
 
Production Equipment Manufacturer Model 
number 
Dissolution Equipment Manufacturer Model  
number 
Analytical balance Sartorius 2403 Franz diffusion cell RU 37058-8 
Top load balance Sartorius 1474 MP8-2 European Pharmacopoeia 
diffusion cell 
RU  
Magnetic stirrer Labcon MSH 10 Franz heating element Grant TM  
pH meter Crison GLP 21 USP dissolution apparatus Pharma Test PTWS H-425/D 
Ultra-turrax® Janke & Kunkel TP18-10 Membrane Silatos™ REF 7458 
 
Certificate of Analysis 
Test Result Limits Observation/Comment/Description 
pH 5.94 5.0 - 6.0 
Drug content   
1 HPLC analysis 2.51% m/m 2.31 - 2.69% m/m 
2 UV analysis 2.53% m/m 2.31 - 2.69% m/m 
An elegant gel was formed. Devoid of air bubbles. 
Dissolution Profile  
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Rhodes University 
Faculty of Pharmacy 
Transdermal Laboratory 
Grahamstown, South Africa  
 
BATCH PRODUCTION RECORD 
 
Formulator Ralph Nii Okai Tettey-Amlalo 
Polymer Carbopol® Ultrez™ 10 NF Batch ID KET020 Batch size 50 g 
Strength 2.5% m/m ketoprofen Date of issue 29/08/2005 Issued by RNO Tettey-Amlalo 
 
Materials Formulae Batch number Signatures 
 Percent m/m Actually added  Dispensed by Checked by 
Ketoprofen 2.50 1.25 g 093K1522 RNO JMH 
Carbopol® Ultrez™ 10 NF 1.50 0.75 g CC2NLZG148 RNO JMH 
Triethanolamine 2.25 1.13 g 1024801 RNO JMH 
Transcutol® HP 40.00 20.00 g 0339024 RNO JMH 
Purified water 53.75 26.88 ml  RNO JMH 
 
Manufacturing date 29/08/05 Homogenising time 5 mins Primary packing Jar Storage 18°C 
Mixing time 60 mins Ambient temperature 25°C Secondary packing - Use by date 31/08/05 
 
Production Equipment Manufacturer Model 
number 
Dissolution Equipment Manufacturer Model  
number 
Analytical balance Sartorius 2403 Franz diffusion cell RU 37058-8 
Top load balance Sartorius 1474 MP8-2 European Pharmacopoeia 
diffusion cell 
RU  
Magnetic stirrer Labcon MSH 10 Franz heating element Grant TM  
pH meter Crison GLP 21 USP dissolution apparatus Pharma Test PTWS H-425/D 
Ultra-turrax® Janke & Kunkel TP18-10 Membrane Silatos™ REF 7458 
 
Certificate of Analysis 
Test Result Limits Observation/Comment/Description 
pH 6.25 5.0 - 6.0 
Drug content   
1 HPLC analysis 2.51% m/m 2.31 - 2.69% m/m 
2 UV analysis 2.52% m/m 2.31 - 2.69% m/m 
An elegant sweet smelling gel was formed devoid of air bubbles. 
Dissolution Profile  
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Rhodes University 
Faculty of Pharmacy 
Transdermal Laboratory 
Grahamstown, South Africa  
 
R A W  D A T A  
 
Summary of methodology 
Receptor medium 0.2 M phosphate buffer at pH 6.8 
Temperature 32 ± 0.5°C 
Run time 72 hours 
Agitation 100 rpm 
Franz diffusion volume 9 ml 
European diffusion volume 1000 ml 
Sample application  
 Franz diffusion cell 100 mg 
 European Pharmacopoeia diffusion cell 500 mg 
Membrane Silatos™ silicone sheeting 
Analytical procedure Hplc and uv spectrophotometric analysis 
 
Abbreviation 
ACUM Cumulative Amount Released (µg/cm2) 
SD Standard deviation 
 
Fastum® (SA) 
 Franz diffusion apparatus European diffusion apparatus 
Time HPLC UV HPLC UV 
(hours) ACUM SD ACUM SD ACUM SD ACUM SD 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 119.44 14.65 153.80 19.95 103.55 18.12 170.23 25.41 
4 181.20 25.42 234.27 32.48 186.23 27.19 261.68 27.63 
8 280.91 43.15 353.15 50.22 305.02 33.29 419.30 31.11 
24 505.30 78.73 596.65 86.11 614.23 69.60 750.21 77.23 
48 755.72 133.26 868.01 136.41 966.55 95.98 1128.34 109.70 
72 931.04 182.15 1061.86 185.07 1281.96 72.26 1467.49 70.92 
 
 
Ketum® (FR) 
 Franz diffusion apparatus European diffusion apparatus 
Time HPLC UV HPLC UV 
(hours) ACUM SD ACUM SD ACUM SD ACUM SD 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 98.46 26.14 114.61 24.14 88.07 23.05 136.46 26.30 
4 164.77 39.72 183.32 37.27 186.57 37.97 220.10 42.29 
8 262.93 52.96 287.83 57.09 336.63 84.03 365.59 85.55 
24 492.84 108.45 553.99 124.67 700.31 212.35 791.37 225.21 
48 647.41 162.86 740.29 186.13 1008.82 193.43 1103.02 217.95 
72 753.93 205.70 888.91 245.79 1283.49 129.19 1365.29 159.42 
 
 
Oruvail® (UK) 
 Franz diffusion apparatus European diffusion apparatus 
Time HPLC UV HPLC UV 
(hours) ACUM SD ACUM SD ACUM SD ACUM SD 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 29.11 5.73 24.87 4.91 0.00 2.03 5.48 11.66 
4 48.94 10.50 39.45 9.74 21.41 3.82 28.69 14.66 
8 80.37 19.42 64.52 18.14 68.09 6.80 58.44 10.48 
24 170.83 41.53 153.23 40.43 233.81 23.01 247.73 28.12 
48 283.28 57.64 263.73 55.36 449.58 42.54 489.52 41.93 
72 377.73 74.11 357.70 70.83 656.99 47.86 720.33 51.86 
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KET001 
 Franz diffusion apparatus European diffusion apparatus 
Time HPLC UV HPLC UV 
(hours) ACUM SD ACUM SD ACUM SD ACUM SD 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 91.50 21.78 105.21 21.30 34.57 6.20 103.00 6.28 
4 182.58 44.17 208.23 44.10 84.60 14.23 202.00 14.04 
8 344.81 77.56 383.91 74.56 194.13 31.63 277.00 31.61 
24 718.04 98.20 781.13 92.22 611.90 86.12 690.60 86.16 
48 962.91 101.65 1046.79 96.85 1005.09 141.08 1157.60 141.09 
72 1079.60 91.93 1186.52 91.81 1195.17 179.22 1355.80 179.07 
 
 
KET002 
 Franz diffusion apparatus European diffusion apparatus 
Time HPLC UV HPLC UV 
(hours) ACUM SD ACUM SD ACUM SD ACUM SD 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 36.19 4.07 48.07 3.16 56.66 7.75 106.34 15.45 
4 67.71 8.86 86.58 11.60 115.27 23.94 188.16 58.27 
8 127.41 18.68 151.09 21.01 255.21 46.73 336.36 70.34 
24 290.26 45.61 320.00 47.28 653.59 88.99 743.98 106.62 
48 498.25 83.45 535.74 83.98 1014.00 101.81 1202.42 121.63 
72 686.05 78.50 734.62 73.87 1335.25 94.14 1506.47 94.20 
 
 
KET003 
 Franz diffusion apparatus European diffusion apparatus 
Time HPLC UV HPLC UV 
(hours) ACUM SD ACUM SD ACUM SD ACUM SD 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 43.87 6.20 52.72 5.95 3.05 6.73 86.05 45.44 
4 87.99 12.43 105.76 13.86 24.89 13.75 89.88 32.70 
8 161.91 19.02 185.81 20.70 75.05 28.43 142.73 26.69 
24 360.56 38.81 392.87 46.87 280.58 80.45 379.73 70.86 
48 580.90 63.95 621.79 74.32 614.06 81.58 757.16 78.23 
72 769.79 77.55 826.97 90.16 878.67 52.69 1060.15 65.45 
 
 
KET004 
 Franz diffusion apparatus European diffusion apparatus 
Time HPLC UV HPLC UV 
(hours) ACUM SD ACUM SD ACUM SD ACUM SD 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 49.17 5.05 51.98 6.88 20.77 10.74 33.96 33.79 
4 99.22 9.30 104.13 11.01 65.17 21.02 70.26 22.60 
8 195.07 14.19 202.79 15.62 171.23 47.99 180.52 45.30 
24 467.65 31.75 484.19 32.13 449.60 95.81 521.53 100.68 
48 669.48 47.83 700.72 50.69 799.48 119.17 926.60 111.26 
72 820.35 46.92 863.74 49.80 1028.31 134.68 1220.17 138.80 
 
 
KET005 
 Franz diffusion apparatus European diffusion apparatus 
Time HPLC UV HPLC UV 
(hours) ACUM SD ACUM SD ACUM SD ACUM SD 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 60.08 9.31 70.49 12.27 30.90 10.49 174.95 33.54 
4 120.42 18.99 125.83 19.05 78.05 14.06 233.43 59.59 
8 235.54 33.41 226.83 28.54 188.19 28.22 308.85 103.79 
24 536.43 54.66 516.20 45.12 575.78 55.65 683.95 67.65 
48 812.29 90.65 778.94 79.06 954.17 88.25 1122.17 123.54 
72 974.88 130.07 925.91 120.55 1196.81 100.59 1355.94 108.75 
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KET006 
 Franz diffusion apparatus European diffusion apparatus 
Time HPLC UV HPLC UV 
(hours) ACUM SD ACUM SD ACUM SD ACUM SD 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 53.12 7.09 102.09 18.38 60.62 13.33 250.47 85.14 
4 109.96 16.43 200.86 10.58 106.08 21.28 327.64 59.29 
8 207.88 32.94 326.84 37.27 211.64 39.38 427.97 95.02 
24 516.04 81.09 650.97 89.83 597.59 96.00 813.58 132.15 
48 838.85 117.83 999.63 126.07 1000.23 128.28 1247.84 138.59 
72 1057.80 130.64 1246.78 143.89 1245.11 102.27 1583.55 130.33 
 
 
KET007 
 Franz diffusion apparatus European diffusion apparatus 
Time HPLC UV HPLC UV 
(hours) ACUM SD ACUM SD ACUM SD ACUM SD 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 50.54 8.98 100.22 19.47 47.22 10.65 168.74 42.81 
4 90.96 17.67 167.49 17.51 106.69 21.63 220.58 23.12 
8 165.11 25.69 257.17 31.81 225.73 39.98 365.53 76.80 
24 358.37 34.85 464.66 44.62 624.42 79.99 811.40 102.67 
48 553.77 86.82 675.25 98.02 1030.43 54.55 1277.19 93.68 
72 697.59 129.99 830.31 144.36 1304.19 47.05 1569.05 73.79 
 
 
KET008 
 Franz diffusion apparatus European diffusion apparatus 
Time HPLC UV HPLC UV 
(hours) ACUM SD ACUM SD ACUM SD ACUM SD 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 65.06 11.53 98.70 25.54 68.74 23.82 0.00 6.17 
4 126.52 20.59 189.57 32.92 89.81 25.33 62.99 24.91 
8 227.98 35.41 313.74 50.74 202.30 48.31 181.78 60.09 
24 496.32 68.70 611.26 82.27 543.63 105.60 565.41 117.77 
48 770.88 93.15 915.60 104.06 892.28 137.54 961.65 134.23 
72 920.37 156.19 1092.23 167.75 1157.32 125.49 1275.32 117.66 
 
 
KET009 
 Franz diffusion apparatus European diffusion apparatus 
Time HPLC UV HPLC UV 
(hours) ACUM SD ACUM SD ACUM SD ACUM SD 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 47.84 2.45 60.66 9.39 66.24 13.83 23.12 31.17 
4 86.52 6.92 107.52 26.09 147.66 20.00 92.84 26.77 
8 151.86 12.25 168.05 30.61 297.29 40.28 225.62 40.81 
24 387.62 14.48 413.90 27.61 728.10 92.65 696.23 77.45 
48 646.09 35.74 678.07 60.20 1085.89 121.72 1122.63 106.26 
72 805.20 51.06 844.38 79.73 1324.47 129.57 1403.56 128.65 
 
 
KET010 
 Franz diffusion apparatus European diffusion apparatus 
Time HPLC UV HPLC UV 
(hours) ACUM SD ACUM SD ACUM SD ACUM SD 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 30.95 8.80 33.46 2.92 54.69 1.64 101.83 16.67 
4 62.21 11.83 64.21 5.47 79.06 9.03 153.07 22.83 
8 122.12 16.62 127.48 12.49 206.58 33.44 263.38 23.17 
24 331.10 29.48 341.83 26.13 521.18 52.70 636.49 58.01 
48 590.83 69.12 611.77 69.39 906.95 79.86 1088.22 72.69 
72 774.00 97.61 805.34 95.65 1164.01 47.45 1410.67 51.47 
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KET011 
 Franz diffusion apparatus European diffusion apparatus 
Time HPLC UV HPLC UV 
(hours) ACUM SD ACUM SD ACUM SD ACUM SD 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 20.76 5.03 24.54 5.53 11.93 5.56 73.35 14.68 
4 37.92 9.60 43.83 10.50 45.31 11.44 90.79 18.14 
8 70.35 17.91 78.52 19.10 119.74 20.74 197.74 111.23 
24 184.61 60.77 196.73 62.12 373.47 71.09 433.66 97.81 
48 336.03 125.55 369.21 118.76 680.16 102.02 784.40 105.53 
72 504.73 173.49 546.40 172.25 957.91 135.91 1104.37 123.75 
 
 
KET012 
 Franz diffusion apparatus European diffusion apparatus 
Time HPLC UV HPLC UV 
(hours) ACUM SD ACUM SD ACUM SD ACUM SD 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 87.59 12.82 38.68 12.57 56.57 34.63 0.00 0.00 
4 154.68 23.40 56.56 24.70 99.77 34.44 0.00 0.00 
8 259.22 41.54 112.57 45.57 185.24 66.90 15.37 34.38 
24 563.87 84.03 375.46 88.39 465.15 162.11 277.25 134.87 
48 892.66 143.04 666.92 142.81 917.04 260.61 844.86 217.47 
72 1089.29 170.85 823.32 168.82 1347.58 200.22 1310.14 201.54 
 
 
KET013 
 Franz diffusion apparatus European diffusion apparatus 
Time HPLC UV HPLC UV 
(hours) ACUM SD ACUM SD ACUM SD ACUM SD 
0 0.00 0.00 0.00 0.00     
2 1.58 0.46 9.56 3.84     
4 2.61 0.76 16.54 6.91     
8 5.43 1.48 24.39 8.89     
24 17.99 4.61 41.38 12.97     
48 38.51 13.66 71.02 21.51     
72 65.50 28.11 105.62 36.96     
 
 
KET014 
 Franz diffusion apparatus European diffusion apparatus 
Time HPLC UV HPLC UV 
(hours) ACUM SD ACUM SD ACUM SD ACUM SD 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 12.53 5.03 23.59 7.84 1.21 3.64 255.40 119.11 
4 23.08 10.57 42.29 14.33 20.09 6.73 215.59 47.32 
8 44.87 21.07 72.22 30.01 64.81 15.35 226.10 72.31 
24 110.31 48.10 147.32 60.21 226.35 41.15 442.20 68.35 
48 198.62 75.44 245.59 88.25 461.50 57.71 716.36 73.06 
72 296.71 90.97 351.91 104.42 674.62 58.06 1004.90 102.05 
 
 
KET015 
 Franz diffusion apparatus European diffusion apparatus 
Time HPLC UV HPLC UV 
(hours) ACUM SD ACUM SD ACUM SD ACUM SD 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 14.71 5.01 23.66 3.14 0.00 1.07 216.27 119.46 
4 28.69 9.92 43.78 2.65 7.57 5.19 163.66 55.78 
8 74.73 46.39 74.81 11.65 38.06 11.13 173.05 54.89 
24 159.23 54.40 166.11 37.66 158.26 35.96 308.96 89.00 
48 253.70 76.48 271.40 65.62 318.91 61.08 495.77 50.80 
72 363.61 89.54 392.07 80.90 469.31 79.78 750.57 92.14 
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KET016 
 Franz diffusion apparatus European diffusion apparatus 
Time HPLC UV HPLC UV 
(hours) ACUM SD ACUM SD ACUM SD ACUM SD 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 91.09 15.09 94.94 12.97 52.93 13.40 158.98 46.86 
4 146.50 21.72 150.14 17.34 96.61 21.31 199.79 60.83 
8 235.81 35.19 239.65 33.13 178.30 35.44 241.10 41.03 
24 529.85 120.87 535.59 116.88 478.19 91.55 552.15 98.17 
48 932.48 234.93 861.41 246.19 961.85 178.01 1069.24 164.51 
72 1291.90 257.54 1234.17 243.26 1530.81 247.50 1687.03 237.02 
 
 
 KET017 
 Franz diffusion apparatus European diffusion apparatus 
Time HPLC UV HPLC UV 
(hours) ACUM SD ACUM SD ACUM SD ACUM SD 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 20.65 5.51 24.44 2.21 2.14 4.17 73.61 34.59 
4 35.18 5.76 39.69 3.53 28.03 11.51 94.68 45.93 
8 68.78 9.67 76.27 10.12 90.17 24.84 165.41 16.06 
24 200.53 32.29 217.70 37.17 391.47 89.47 484.06 92.01 
48 413.12 70.44 443.56 72.01 792.85 79.60 923.62 92.36 
72 637.57 84.55 681.91 91.36 1095.63 73.55 1250.62 77.35 
 
 
KET018 
 Franz diffusion apparatus European diffusion apparatus 
Time HPLC UV HPLC UV 
(hours) ACUM SD ACUM SD ACUM SD ACUM SD 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 31.12 9.75 34.51 9.62 48.62 11.50 106.26 10.41 
4 72.11 23.40 77.72 23.60 91.64 13.10 158.90 17.38 
8 174.90 48.40 180.95 54.34 248.37 35.51 342.46 36.91 
24 522.56 148.76 547.77 153.52 862.98 88.52 962.35 79.49 
48 893.75 201.50 941.99 201.88 1343.83 106.85 1492.07 128.72 
72 1099.57 199.09 1155.07 196.23 1620.25 114.85 1825.72 102.00 
 
 
KET019 
 Franz diffusion apparatus European diffusion apparatus 
Time HPLC UV HPLC UV 
(hours) ACUM SD ACUM SD ACUM SD ACUM SD 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 72.30 19.10 78.65 17.95 82.93 32.06 172.59 44.39 
4 134.86 36.22 145.58 34.19 185.36 61.70 267.40 67.02 
8 225.99 64.72 242.68 62.60 360.79 110.36 448.99 110.00 
24 435.38 135.74 457.86 134.89 832.21 164.34 909.70 169.76 
48 652.75 188.27 685.61 183.43 1195.60 137.12 1308.18 166.19 
72 803.03 200.14 844.92 195.61 1395.59 115.04 1644.93 120.36 
 
KET020 
 Franz diffusion apparatus European diffusion apparatus 
Time HPLC UV HPLC UV 
(hours) ACUM SD ACUM SD ACUM SD ACUM SD 
0 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
2 8.60 0.46 2.53 5.46 0.00 4.71 0.00 0.03 
4 17.90 2.11 -0.13 5.55 8.72 10.97 0.00 0.03 
8 48.58 11.78 12.34 8.47 51.11 24.29 10.21 26.27 
24 244.35 66.49 191.86 61.77 364.40 101.61 325.63 99.17 
48 564.48 105.50 507.41 105.70 919.33 156.81 895.11 135.09 
72 824.78 106.10 765.68 106.96 1268.45 134.70 1271.25 129.35 
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PODIUM AND POSTER PRESENTATIONS 
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PODIUM PRESENTATION AT CONFERENCES 
 
1. The effect of propylene glycol on the in vitro release of ibuprofen from 
extemporaneous cream formulations. 
RNO Tettey-Amlalo and JM Haigh. 
25th Annual Academy Pharmaceutical Congress, Grahamstown, South Africa, 2004. 
2. An investigation into the effect of Pemulen® TR1 NF on the in vitro release rate of 
ketoprofen from extemporaneous Carbopol® 980 NF formulations. 
RNO Tettey-Amlalo and JM Haigh. 
26th Annual Academy Pharmaceutical Congress, Port Elizabeth, South Africa, 2005. 
 
POSTER PRESENTATION AT CONFERENCES 
 
1. Comparison of the in vitro release of ketoprofen from extemporaneously prepared 
gels containing different concentrations of Carbopol® polymers. 
RNO Tettey-Amlalo and JM Haigh. 
65th International Congress of the International Pharmaceutical Federation, Cairo, 
Egypt, 2005. 
2. Comparative in vitro release of ketoprofen from commercial gel formulations through 
silicone membrane utilizing European Pharmacopoeia and Franz diffusion cells. 
RNO Tettey-Amlalo and JM Haigh. 
65th International Congress of the International Pharmaceutical Federation, Cairo, 
Egypt, 2005. 
3. Comparative in vitro release of ketoprofen and ibuprofen from commercially 
available topical gels from three countries. 
RNO Tettey-Amlalo, CH Purdon and JM Haigh. 
65th International Congress of the International Pharmaceutical Federation, Cairo, 
Egypt, 2005. 
4. An investigation into the in vitro release rate of ketoprofen utilising different grades 
of Carbopol® polymers in extemporaneous formulations. 
RNO Tettey-Amlalo and JM Haigh. 
26th Annual Academy Pharmaceutical Congress, Port Elizabeth, South Africa, 2005. 
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